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ABSTRACT
Prelamin A Influences a Program of Gene Expression
In Regulation of Cell Cycle Control
by
Christina Norton Bridges

The A-type lamins are intermediate filament proteins that constitute a major part of the
eukaryotic nuclear lamina—a tough, polymerized, mesh lining of the inner nuclear
membrane, providing shape and structural integrity to the nucleus. Lamin A (LA)
filaments also permeate the nucleoplasm, providing additional structural support, but
also scaffolding numerous tethered molecules to stabilize, organize, and facilitate
molecular interactions to accomplish critical functions of cellular metabolism. Over the
past 2 decades, much attention has been focused on roles of LA in maintenance of
nuclear structural integrity. Only since the late 1990s have scientists discovered the
devastating effects of LA gene (LMNA) mutations, as they have associated hundreds of
LMNA mutations to a large group of diseases, called laminopathies, with a broad
spectrum of phenotypes, ranging from skeletal, muscular, and neurological defects, to
defective lipid storage, to accelerated aging phenotypes in diseases called progerias.
Recent advances demonstrate LA regulatory functions include cell signaling, cell cycle
regulation, transcription, chromatin organization, viral egress, and DNA damage repair.
Amidst the flurry of fascinating research, only recently have researchers begun to focus
attention on the different isoforms that exist for LA, a precursor form among them. LA is
initially synthesized as Prelamin A (PreA), and undergoes a series of modifications that
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truncate the protein to produce “mature” LA. Existence of the precursor form, and its
complex maturation pathway, have puzzled researchers since their realization. With a
pattern of expression related to cell cycle phase, we hypothesized a role for PreA in cell
cycle control. To investigate, we have performed array studies to assess gene
expression effects at the levels of transcript expression, protein expression, and
phosphorylation modification status. Here, we present evidence for a PreA-mediated
program of cell cycle regulatory gene and protein expression modulation. Implicated
pathways include RB-E2F, p53, p27Kip1, FoxOs, p300, and the Cyclins, with additional
evidence indicating a role for the Pin1 prolyl isomerase in mediating PreA regulation of
the cell cycle.
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CHAPTER 1
INTRODUCTION
The Nuclear Lamins
The nuclear lamins are a Class V family of intermediate filament proteins that
form a thin, fibrous scaffold lining the inner nuclear membrane, thereby providing
structural rigidity to the nucleus1,2. Two primary types of lamina proteins exist: the Atype and B-type lamins. Three genes encode the 2 primary lamina proteins. The Atype lamins, Lamins A and C, are both encoded by the single Lamin A (LMNA) gene by
alternative splicing3-5. There are 2 Lamin B isoforms, B1 and B2, that are encoded by
the LMNB1 and LMNB2 genes, respectively6. The B-type lamins are ubiquitously
expressed in vertebrate cells from the earliest stages of development throughout
differentiation and have been described as “essential1,7,” whereas expression of A-type
lamins is associated with the advent of some level of cellular differentiation 8, and are
expressed in most, but not all differentiated cells9,10. Lmnb -/- mice die in early
developmental stages, demonstrating the null phenotype is lethal. Lmna -/- mice,
however, are able to survive at least several weeks after birth, though they demonstrate
some phenotypes of disorders experienced by humans with mutations in LMNA or in the
genes that code for proteins that process Lamin A (LA)11. Our studies focus on LA,
which has been shown to play a role in many cellular functions, the complexities of
which are continuously developing. Recent research has revealed important functions
in processes ranging broadly from maintenance of structural and mechanical integrity of
the nuclear membrane, to modulation of organismal aging and preservation of the
fidelity of the genome.
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Post-Translational Lamin Processing
LA is initially synthesized as a 74 kDa precursor, Prelamin A (PreA)12,13, which
undergoes an unusual maturation sequence in which 2 endoproteolytic cleavages occur
to yield a 72 kDa mature LA protein14 (Figure 1). The first cleavage is initiated by the
attachment of a farnesyl group (farnesylation) to the cysteine residue of a C-terminal
CaaX-motif (where “C” is a cysteine, “a” is an aliphatic amino acid and “X” is usually
serine, glutamine or methionine)15-17. Farnesylation of mammalian proteins is reported
to target the affected proteins to membranes18,19, through inducing specific proteinprotein interactions20, and is catalyzed by the enzyme farnesyltransferase (FTase)21,
which recognizes the C-terminal CaaX motif of its substrate proteins. FTase transfers
a farnesyl group from farnesyl pyrophosphate to the CaaX cysteine, forming a thioether
linkage. Once farnesylated, these proteins typically undergo 2 further C-terminal
modifications. Endoproteolytic removal of 3 C-terminal amino acids, this cleavage
(often referred to as “-aaXing”)16, can be carried out by the endoproteases
Zmpste2422,23 or Rce124. The –aaXing cleavage is followed by carboxyl methylation of
the newly created C-terminus, carried out by isoprenyl carboxyl methyl transferase
(ICMT)25. In a further processing step, LA undergoes a second endoproteolytic
cleavage to remove an additional 15 C-terminal amino acid residues (aa 647-661,
human sequence), including the farnesylated cysteine26,27. This second cleavage is
unique to LA in higher vertebrates, and is specifically carried out by Zmpste24 28.
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Figure 1. Maturation of Lamin A Protein by Proteolytic Posttranslational Processing.
The precursor protein undergoes successive modifications: by the enzyme FTase
(which attaches a farnesyl moiety), followed by Zmpste24- or Rce1-mediated cleavage
of the –SIM residues (-aaXing), after which ICMT methylates the carboxyl terminus,
signalling the 2nd proteolysis, by Zmpste24 (uniquely) between the tyrosine (Y) and
leucine (L) residues of the RSYLLG Zmpste24 recognition site, releasing the 2 kDa
farnesylated C-terminal fragment to yield mature LA (72 kDa).
The LA precursor isoform is reportedly toxic to the cell, and it accumulates in
several laminopathies29,30. Though previous work, including much from our own
laboratory [including 21,27,28,31], has provided insight into the processing pathway of PreA, as
described above, the functional significance of the pathway remains puzzling. Clearly,
the processing introduces differences compared to the other lamins: The B-type lamins
also have a CaaX motif, are farnesylated, and undergo the same initial aaX-peptide
cleavage processing as Lamin A (in which the 3 c-terminal amino acids are removed),
followed by carboxymethylation of the truncated protein. However, because the B
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lamins are not subjected to the second cleavage, they maintain the farnesyl
modification. By virtue of this permanently farnesylated state, Lamin B remains tightly
associated with the membrane even through mitosis, while the A-type lamins dissociate
during mitosis and reassemble32-34. Lamin C, which lacks the CaaX motif altogether,
and is thus never farnesylated, maintains only a loose association with the nuclear
membrane, primarily through polymerization with Lamin B and Lamin A 35. Existing in a
heteropolymeric tapestry together with each other, the different lamin isoforms
demonstrate some structural and functional overlap, yet their different structural
characteristics convey different functions from each other, as well.
The Laminopathies
Diseases resulting from mutations in the lamins, or in the genes that encode the
proteins responsible for lamin processing, are collectively termed “laminopathies.” At
least 12 distinct laminopathies have been described, comprising a surprisingly diverse
group of phenotypic disorders36,37,38, and most result from some of the >250 mutations
that have been identified within the LMNA gene39. These phenotypes range from
inability to properly accumulate and/or process lipids, as in the several different types of
lipodystrophies, including Dunnigan’s Partial Lipodystrophy (DPLD) and Familial Partial
Lipodystrophy (FPLD2), as well as musculoskeletal phenotypes associated with several
types of muscular dystrophies, such as Emery Dreyfus Muscular Dystrophy (EDMD)
and Limb-Girdle Muscular Dystrophy (LGMD1B), cardiac defects as found in Dilated
Cardiomyopathy (CMD1A), and neurological defects, as in Autosomal Recessive
Charcot-Marie-Tooth syndrome (CMT-AR). Additionally, mutations in LMNA, or in
genes coding for LA-processing proteins, cause a group of premature aging disorders,
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called progerias or progeroid diseases, including Hutchinson Gilford Progeria Syndrome
(HGPS), Atypical Werner Syndrome (A-WS), Restrictive Dermopathy (RD), and
Mandibuloacral Dysplasia (MAD)[reviewed in 38,40]. Phenotypic expression in the progerias
include several of the aforementioned phenotypes (perturbations of lipid metabolism,
cardiac and musculoskeletal defects, etc.), in addition to increased DNA damage
accumulation, early cellular senescence, and several other pathogenic phenotypes that
are typically associated with progressive aging, such as bone degeneration, alopecia,
and atherosclerosis41-46. HGPS is perhaps the most studied of these progerias and is
usually caused by a heterozygous LMNA point mutation in the third nucleotide of codon
608 that, while not changing the encoded amino acid, introduces a cryptic splice site
that removes 150 nucleotides from the mRNA transcript, resulting in a 50 residuetruncation of the protein product47-49. This mutation is frequently referred to as
“LAdel50,” and the mutant protein has become known as “progerin.” HGPS patients
typically die around a median age of 13 years due to atherosclerotic/cardiac-related
pathology17,41,47,48,50-55 [and a few of many HGPS/Progeria reviews: 17,22,29,31,40,42-44,46,55-78].
A 2-category classification system for laminopathies has been suggested 79,
grouping them by phenotypic similarity derived through hierarchical cluster analysis.
The first class of laminopathies includes those with skeletal muscle, cardiac and
neurological involvement, such as EDMD, LGMD1B, CMD1A, and CMT-AR. The
second class of laminopathies includes those with partial lipodystrophy, bone dysplasia,
and progeric involvements, such as FPLD2, MAD, HGPS, A-WRN, and RD.
Interestingly, mutations in the first class of laminopathies are found mainly in the LMNA
region upstream of the nuclear localization signal (NLS, located at residues 416–423),

27

while mutations downstream of the NLS appear to result in diseases in the second class
of laminopathies. The structure in Figure 2 schematically represents the domain/exon
arrangement of Lamin A80.

Processed, “Mature” LA

647
PreA

Adapted from Shumaker, et al., 2003

Figure 2. Structure and Domain Arrangement of Lamin A Protein. The Lamin A central
rod domain has 4 subdomains 1A, 1B, 2A, 2B (red); the nuclear localization signal
(NLS) is indicated by a grey box (residues 417-422); the immunoglobulin (Ig) fold is
represented by the molecular ribbon structure (at residues 436-544), and the C-terminal
CaaX sequence is represented by a green box (terminal residues 661-664). Exon
nucleotide base-pair lengths are demarcated by the blue rectangular bar, top.

The central α-helical rod domain region upstream of the NLS is essential for the
intra-molecular interactions in the nuclear lamina that contribute to structural integrity,
while the DNA-binding region, located downstream of the NLS, is more likely to be
involved in interactions involving chromatin remodeling complexes and transcription
factors81. Such a nonrandom association between the mutation position and organ
system involvement suggests a phenotype–genotype relationship79, suggestive of
different pathogenic mechanisms accounting for the 2 groups of laminopathies, either
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involving compromise of the nuclear structure and stability, or aberrance in the
chromatin organization that controls transcription79,82,83.
Lamin A Structural Functions
The central rod domain of the A type nuclear lamins, similar to the B-Lamins, is
approximately 45 kDa. When these intermediate filaments form polymers by homo- or
hetero-dimerizing longitudinally in 50–52-nm long 2-stranded a-helical coiled coils, the
coiled coils are flanked at each end by 2 globular heads corresponding to the C-terminal
tail domains of each individual filament protein2,5. Once PreA is fully processed to
mature LA (mLA), and no longer farnesylated, the obligatory membrane association is
apparently relaxed20,21, but multimeric polymerization with Lamin B assists in
maintenance of a meshwork of LA proteins on the internal surface of the nuclear
membrane. The LA polymers infiltrate the nucleoplasm84, thus providing nuclear
integrity and shape (Schematic, Figure 3)1.
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Figure 3. Lamin A at Nuclear Envelope and throughout Nucleoplasm. Peripheral
nuclear Lamin A and fibrous structural permeation of the nucleoplasm (red structures).
Various binding partners/lamina-associated moieties (ie. chromatin (blue), nuclear pore
complexes (crossing the membrane), proteins such as Rb or PCNA).

Nuclei of LA-deficient cells have fragile membranes, subject to mechanical
rupture, and microscopically presenting deformations such as blebbing and
invaginations7,80,85,86. Nuclear organization, stiffness, and shape-stability are reported to
rely primarily on A-type lamins87. Some have suggested the mechanisms of pathology
related to LA mutation derive simply from a compromised nuclear membrane structure,
such as aberrant placement and stability of nuclear pore complexes, alteration of
membrane transport of molecules, impaired access to receptors for membrane binding
proteins, general nuclear disorganization, and cell death due to rupture of the fragile
nucleus88,89.
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Lamin A Non-Structural Functions
In addition to providing nuclear integrity and shape, the Lamin A polymer mesh
permeating the nucleoplasm provides a scaffolding system upon which numerous
proteins rely for spatiotemporal organization of interactions and processes. In this role,
Lamin A has been demonstrated as critical to the functional control of many
transcriptional regulators and cellular processes that regulate cellular homeostasis.
This function is more widely accepted as the source of LA-dysfunction-related pathology
mechanisms that result in the most devastating phenotypic outcomes for affected
organisms. In addition to spatiotemporal organization of interacting molecules, binding
to LA has been shown to affect expression levels of many proteins. Typically, the
effects on expression are through stabilization of the bound protein, usually by
preventing ubiquitination and subsequent proteosomal degradation. These interactions
are defective even in many cases in which LMNA mutations do not alter the nuclear
envelope structure and fail to perturb the structural nucleoplasmic mesh. Therefore, LArelated dysfunction in such disorders could not be attributed merely to integrity of the
nuclear structure. Instead, control of cellular functions involving these molecules rely on
interactions with LA in a role independent of structural maintenance of the
nucleus[Reviews include 85,86,88-91].
Lamin A Functions in Cell Cycle Regulation
Many studies have examined contributions of the A-type lamins to regulation of
cell proliferation and tissue homeostasis[ reviewed 92,93]. The LA role in cell cycle regulation
incorporates both structural and nonstructural functions. For instance, as cells replicate
genetic material and divide in proliferation, the nuclear envelope must depolymerize and
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“dissolve” properly when needed, but then must repolymerize and reassemble with
precision of arrangement and timing to form viable daughter cells 32, providing
implications of a structural LA function in the process. At the same time, cell cycle
progression involves extremely tight regulation of the spatiotemporal control of the
interactions between a large number of different molecules, such as transcriptional
regulators and target proteins, thus involving nonstructural LA functions. Cells that are
committed to differentiate but still undergoing proliferation contain intra-nuclear
populations of A-type lamins that interact with the major lamin-associated protein
LAP2α92. This lamin-LAP2α complex has been shown to bind to and regulate the
localization and activity of a major cell cycle regulatory protein, the tumor suppressor
retinoblastoma protein (pRb)94. The harmonic expression of these components appears
be the keystone determining cellular decisions at the most fundamental points of
regulation of cell proliferation and differentiation95,96.
In cells that express the A/C lamins, LA is one of the most abundantly expressed
proteins in the cell, and it has been shown that small amounts of new LA are being
incorporated into the lamina on a constant basis13. LA proteins exhibit a fairly low rate
of turnover (though, even that rate is higher than for B-type lamins), which, coupled with
the steady low-level synthesis of new LA, leads to a gradual increase in the actual level
of protein expression in the cell. However, as cell size increases with cell growth,
mainly through G1 phase, the overall result is a relatively stable proportion of lamin
protein to cell size, maintained throughout the entire cell cycle35,97. Phosphorylation
induces dramatic depolymerization of the lamins in mitosis, effectively dissolving the
nuclear membrane. Studies have shown that much LA protein appears to be conserved
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in the process of cell division, as cytokinesis occurs fairly rapidly, and daughter cells are
able to regenerate much of their nuclear membranes from the pre-existing,
depolymerized, residual LA from the parent cell13,32,33,97,98. It is the reuse of existing LA
protein in daughter cells that contributes to the accumulation of progressively higher
levels of mutant protein with aging or successive cell culture passaging.
The endoproteolytic cleaving of PreA is such an efficient and rapidly executed
process84, the progenitor is largely undetectable in cycling cells. However, we and
others99,100 have noted PreA accumulation in senescent cells. We also detect PreA
accumulation under conditions of quiescence, such as with serum starvation or highdensity cell culture plating. Cells that express the A/C lamins are typically able to enter
quiescence under conditions of contact inhibition or mitogen deprivation, as from serum
starvation of cultured cells. Conversely, cells that do not express A/C lamins lack a
quiescent state7,8. Frequently, cell cycle-dependent changes in expression of a
particular protein, such as those detected for PreA, indicate some role in regulating the
cycle. While numerous studies provide demonstration of LA functions in cell cycle
control [reviewed in (among others): 63,68,86,88,94,101-103], less is known about the precursor isoform,
which is the specific isoform of the LA protein that seems to exhibit a cell cycledependent expression pattern.
Our hypothesis: accumulation of the PreA protein isoform is induced as part of
program of modulating gene expression and posttranslational modifications to an array
of regulators from several different cell cycle pathways, thereby coordinating these into
a network of interactions resulting in spatio-temporal regulation of the cell cycle, wherein
different isoforms of LA exert different effects on cell cycle control, regulation of mitotic
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progression, DNA repair checkpoint controls, chromatin organization, and influences on
the processes leading to and maintaining cell cycle exit.

Aims of This Study
This study aims to investigate the role of PreA as a cell cycle regulator, by
examining its expression patterns and the effects of its expression on, or interactions
with, other known mediators of control over mitotic cell cycle progression. Owing to the
aforementioned efficiency of the proteolytic processing of PreA, in order to assist in the
study of the effects of expression of the unprocessed, immature protein, we have
developed a stable cell line harboring an inducibly-expressed uncleavable mutant form
of PreA in which the site of the second cleavage is mutated (“L647R PreA”). Several
relationships between PreA and its interacting partners indicate this protein isoform
could have a distinct purpose of its own, independent of simply existing as a precursor
form of the mature LA (mLA). In all likelihood, PreA serves as an integral scaffolding
protein for many interactions, as does mLA, though perhaps each of the 2 isoforms, and
other isoforms, as well, are able to interact uniquely with distinct molecules in a
mechanism that helps to coordinate cellular operations in a cell cycle specific manner.
We ask 3 main questions. First, is accumulation of the PreA isoform is a byproduct of
cell cycle arrest or an induction factor for that arrest? Second, does expression of the
PreA isoform result in effects on cell cycle regulatory genes and proteins? Finally, do
cell cycle regulators have interactions with the C-terminal fragment of the PreA isoform,
that constitutes the difference between the LA isoforms, and therefore would imply
isoform-specific activity?
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Our current study evaluates some PreA-specific effects on cell cycle control by
comparing the differential effects on cell cycle related genes when exogenous PreA is
expressed versus conditions without exogenous expression of any LA isoform. We
examine PreA isoform-expression effects on direct and indirect interaction partners
already known to act in cell cycle regulatory roles. Among these are transcription factors
and coactivators, such as E2F, p300 and FOXO proteins; cyclins, such as cyclins D and
E; cyclin dependent kinase inhibitors (CKIs), such as p27Kip1 and p21Waf1; and tumor
supressors retinoblastoma (RB/pRB) and p53. We evaluate the overall profile of altered
cell cycle gene expression induced by exogenous PreA expression in the context of the
known cellular functions of the affected genes to begin to ascertain potential PreA
functional roles in regulation of the cell cycle. Additionally, we consider a motif analysis
of the c-terminal region of the full length LA protein, which constitutes the differentiating
peptide sequence between PreA and mature LA. We focus the motif analysis on the
kinase substrate sites and phosphorylation-mediated protein-binding sites and consider,
as well, these phosphorylation-related motifs in the context of sites for many of the
known binding proteins for this region. Finally, we examine the potentially LA-relevant
expression of Pin1, a peptidyl prolyl cis/trans isomerase, shown to play a key role in
control of mitosis and cell cycle progression.
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CHAPTER 2
MATERIALS AND METHODS
Materials
General Laboratory Chemicals, Buffers, and Reagents
100bp DNA Ladder, GibcoBRL Life technologies, USA
1Kb DNA Ladder, GibcoBRL Life technologies, USA
Agar, Bacto, BD Diagnostics, Sparks, MD, USA
Agarose, NuSieve, Lonza/Fisher Scientific, USA
Albumin bovine fraction, Sigma, USA
Ampicillin, MP Biomedical/Fisher Scientific
Bacto-peptone, Difco, BD Diagnostics, USA
Bacto-yeast extracts, Difco, BD Diagnostics, USA
Bis-Tris 4-12% Gradient Polyacrylamide Gels, NuPAGE, Invitrogen/Life
Technologies, USA
BondBreaker tris(2-carboxyethyl)phosphine (TCEP), Pierce/Thermofisher, USA
BSA (bovine serum albumin) Pierce/Thermofisher, USA

Calcium chloride dehydrate, Fisher Scientific, USA
Coomassie Blue G250, GelCode Blue Safe Protein Stain, Pierce/Thermofisher, USA

DNA Loading Solution, 6X, Sigma-Aldrich, USA
Dithiothreitol (DTT), Pierce/Thermofisher, Rockford, IL,USA
Doxycyclin, MP Biomedicals, USA

Dulbecco’s modified eagle medium (DMEM) with and without Phenol Red /with and
without Phosphate, Lonza/Fisher Scientific, USA
Dimethyl Sulfoxide (DMSO), Sigma-Aldrich, USA
ECL Hyperfilm GE Healthcare Amersham/Fisher Scientific, USA
Ethylenediaminetetraacetic acid (EDTA), ACROS Organics/Fisher Scientific, USA
Ethanol, Fisher BioReagents/Fisher Scientific, USA
Ethidium Bromide, Sigma-Aldrich, USA
Fetal bovine serum, Lonza/Fisher Scientific, USA /Gibco, USA
Fetal calf serum, Lonza/Fisher Scientific, USA /Gibco, USA
Formaldehyde 16%, Fisher BioReagents, Fisher Scientific, USA
G418 antibiotic, MP Biomedicals, USA

GenoStat, Millipore/Fisher Scientific, USA
Glycerin (Glycerol), Sigma-Aldrich, USA
HCl Fisher BioReagents, Fisher Scientific, USA
HygromycinB, MP Biomedicals, USA
Iodoacetamide, Sigma-Aldrich, USA
Isopropanol, Fisher BioReagents, Fisher Scientific, USA
Juglone, Santa Cruz Biotechnology, USA
Kanamycin, MP Biomedicals, USA
2/β- Mercaptoethanol (2-ME/BME), Sigma-Aldrich, USA
MES 20X Buffer concentrate, NuPAGE, Invitrogen/Life Sciences, USA
Methanol, Sigma-Aldrich, USA
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Milk powder, various, USA
MOPS 20X Buffer concentrate, NuPAGE Invitrogen/Life Sciences, USA
NP-40, Sigma, USA
Orthophosphate ([32]P-orthophosphate), New England Nuclear
PBS (phosphate-buffered saline), Lonza-Biowhittaker/Fisher Scientific, USA
Penicillin/Streptomycin, MP Biomedicals, USA
Propidium iodide (PI)+ RNase, BD Diagnostics, USA
Protease and Phosphatase Inhibitor Cocktail, Halt, Pierce/Thermofisher, USA
Protein A Magnetic Protein Separation/Immunoprecipitation Beads, Dynabeads,
Invitrogen/Life Sciences, USA
Protein A Agarose Beads, Invitrogen/Life Sciences, USA
Protein Molecular Weight Marker: Sharp Prestained, Invitrogen/Life Sciences, USA
Protein Molecular Weight Marker: Cruz Marker, Santa Cruz Biotechnology, USA
RheoSwitch® Ligand RSL1 (5 mM in DMSO), New England Biolabs (NEB), USA
Skatole/ BNPS Skatole (3-bromo-3-methyl-2-l(2-nitrophenyl)thiol-3H indole),
Sigma-Aldrich, USA
SDS (sodium dodecyl sulphate), Sigma, USA
Sodium acetate Sigma-Aldrich, USA
Sodium chloride Fisher BioReagents, Fisher Scientific, USA
[3H]-Thymidine, New England Nuclear, USA
Tris base, Fisher BioReagents, Fisher Scientific, USA
Triton X-100, Sigma-Aldrich, USA
Trypsin, Proteomics Grade, Bioreagent, Dimethylated, Sigma-Aldrich, USA
Trypsin/Versene-EDTA, Lonza-Biowhittaker/Fisher Scientific, USA
Tryptone, Difco, BD Diagnostics, USA
Tween 20, Sigma-Aldrich, USA
Yeast extracts, Difco, BD Diagnostics, USA
Enzymes, Kits
Enzymes for DNA Manipulation:
DNA restriction endouncleases, NEB, USA (NotI, SalI, AsisI, MluI)
DNA restriction endouncleases, Promega, USA (NotI, SalI)
DNAse I, Qiagen, USA
RNAse A Qiagen, USA
Shrimp Alkaline Phosphatase, TSAP, Promega, USA
T4 DNA Ligase Kit, Ligafast Rapid, Promega, USA
TaqGold® DNA Polymerase, PCR Buffer, and dNTPs, Applied Biosystems, USA
Commercial Kits:
BCA protein assay(Reducing Agent Compatible), Pierce/Thermofisher,
USABioRad
DC Detergent Compatible Protein Assay, BioRad, USA
Cell Cycle Control Pathway Antibody Array, Full Moon Biosystems, USA
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Magnetofect Polymag Transfection System, OzBiosciences, France
NE PER Nuclear/Cytoplasmic Extract Reagent Kit, Pierce/Thermofisher, USA
MicroBCA Protein Assay Reagent Kit, Pierce Chemical, Rockford, IL
SuperSignal West Pico ECL Western Blotting Detection Reagents Kit, Pierce/
Thermofisher, USA
SuperSignal West Dura ECL Western Blotting Detection Reagents Kit, Pierce/
Thermofisher, USA
GeneAmp PCR Reagent Kit, Applied Biosystems,USA
Plasmid Mini Plasmid DNA Extraction Kit, Qiagen, USA
Plasmid Miniprep Kit, Zymo, USA
Plasmid Midi Plasmid DNA Extraction Kit, Qiagen, USA
Plasmid Maxi Endo-free Kit Plasmid DNA Extraction Kit, Qiagen, USA
Qiaquick DNA Gel-Extraction Kit, Qiagen, USA
QuikChange® Lightning Site-Directed Mutagenesis Kit, Stratagene/Agilent
Technologies, USA
Rheoswitch Inducible Gene Expression Vector System, New England Biolabs,
Germany/USA
RNEasy Protect Cell Mini RNA Extraction Kit, Qiagen, USA
SA- β-Galactosidase Staining Assay Kit, Cell Signaling, USA
SABiosciences RNA Extraction Kit, SABiosciences/Qiagen, USA
SABiosciences RT2 Profiler Mouse Cell Cycle PCR Arrays, PAMM-020
SABiosciences/Qiagen, USA
RT² First-Stand cDNA Synthesis Kit, SABiosciences/Qiagen, USA
RT² qPCR SYBR Green Master Mixes, SABiosciences/Qiagen, USA
General Laboratory Supplies and Equipment
Microcentrifuge, Eppendorf MiniSpin, Eppendorf, USA
Tabletop Centrifuge, Sorvall, Thermofisher, USA
High Performance Centrifuge, Beckman J-14, Beckman, USA
Flow Cytometer, Accuri C6 Modular, BD, USA / Heidelberg, Germany
Gel Documentation & Imaging System, Alpha Innotech, USA
Hunter Thin Layer Electrophoresis (HTLE) Chromatography System, CBS Scientific,
USA
MiniGel Electrophoresis System, XCell Surelock MiniCell, Invitrogen/Life Sciences, USA
iBlot Dry Gel Blot Transfer System, Invitrogen/Life Technologies, USA
iBlot Transfer Stacks, Regular or Mini, PVDF or Nitrocellulose, Invitrogen/Life
Technologies, USA
Micropipettors, Gilson, Rainin Pipetman,
Needles (22, 26 Gauge)/Syringes, BD-Becton Dickinson, USA
Spectrophotometer, NanoDrop ND 1000, Thermofisher, USA
Sterile filter 0.22 μm, Millipore/Fisher Scientific, USA
Fluorescent Microscope ,Nikon, USA/Germany
pH Meter, Corning, USA
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Chemiluminescence Imaging System, Fujifilm LAS4000
Gel Imaging System, Alpha Innotech, USA
Thermocyclers (9700, 9720, 9600), Applied Biosystems
Genetic Analyzers/ “Sequencers” (3100, 3130), Applied Biosystems
Materials Used in Cloning/Subcloning and Bacterial Cell Culture
Bacterial Strains (E.coli):
XL1-Blue, Stratagene, USA
XL10-Gold, Stratagene, USA
Zymo Z-competent DH5-α, Zymo, USA
Media:
Normal Growth MediumLB (Luria Bertani) Medium (10 g/L tryptone, 5 g/L yeast extract,
5g/L NaCl, pH 7.2)
Antibiotic Selection MediaLB/Ampicillin Medium (50 μg/ml Ampicillin)
LB/ Kanamycin (25 μg/ml Kanamycin)

Plasmids and Oligonucleotides
Cloning vectors:
pCMV6-XL: TruORF Entry Vector, Expressed Zmpste24 protein in mammalian
cells, Origene, USA
pCMV6-AN-GFP: TruORF Destination Vector, Expressed Zmpste24
protein in mammalian cells, Origene, USA
pEGFP-C1: Expressed a green fluorescence fusion protein in mammalian
cells, Clontech, USA
pEGFP-C3: Expressed a green fluorescence fusion protein in mammalian
cells, used as a transfection control plasmid, Clontech, USA
pNEBR-R1 Rheoswitch regulator plasmid: Inducibly expressed regulatory
protein in mammalian cells, NEB, USA
pNEBR-X1 Hygro Rheoswitch expression plasmid: Inducibly expressed
protein in mammalian cells, under control of pNEBR-R1
Rheoswitch regulator plasmid, NEB, USA
Constructs Used in Experiments:
pCMV6-XL-Zmpste24, Origene, USA
pEGFP-C1-Myc-Lamin A (Gift from Francis Collins 65 to Michael Sinensky)
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pEGFP-C1-Myc-Lamin A-del50 (Gift from Francis Collins65 to Michael
Sinensky)
pEGFP-C1-Myc-Lamin A-L647R (generated by site-directed mutagenesis
from pEGFP-C1-Myc-LaminA)
pEGFP-C1-Myc-Lamin A stably in Tet-On HeLa cells (Gift from Robert D.
Goldman63 to Michael Sinensky and Antonio Rusinol)
pEGFP-C1-Myc-Progerin (Lamin A-del50) stably in Tet-On HeLa cells
(Gift from Robert D. Goldman63 to Michael Sinensky and Antonio
Rusinol)
pNEBR-X1-Hygro-EGFP-Myc-Lamin A (generated by subcloning EGFPMyc-Lamin A from pEGFP-C1-Myc-Lamin A into pNEBR-X1-Hygro)
pNEBR-X1-Hygro-EGFP-Myc-Lamin A-L647R (generated by subcloning
EGFP-Myc-Lamin A-L647R from pEGFP-C1-Myc-Lamin A-L647R
into pNEBR-X1-Hygro)
pNEBR-X1-Hygro-EGFP-Myc-Lamin A-del50 (generated by subcloning
EGFP-Myc-Lamin A-del50 from pEGFP-C1-Myc-Lamin A-del50
into pNEBR-X1-Hygro)
pNEBR-X1-Hygro-EGFP (generated by subcloning EGFP from pEGFP-C1
into pNEBR-X1-Hygro)
pGST-Pin1 (from Addgene, plasmid #19027, deposited by MB Yaffe104)
Oligonucleotides Used:
DNA Amplification PrimersInsert Amplification* from pEGFP-C1-Lamin A/ Lamin A del50
NotI-EGFP-Fwd 5’-ATCAGCGGCCGCATGGTGAGCAAG-3’
LA-Sal1-Rev 5’-GCGCGTCGACTGCAG AATT CTTAC ATGATG-3’
*also used as sequencing primers in confirmation of DNA isolated
from stably transfected cells
DNA Sequencing PrimersOrigene TruORF vector sequencing, for Zmpste24 construct
sequencing, provided with kit from manufacturer, sequence not
provided:
“VP1.5” Forward Sequencing Primer for Origene TruORF
vector sequencing; “XL39” Reverse Sequencing Primer for
Origene TruORF vector sequencing
pEGFP-C1-1465-1485 reverse sequencing primer for pEGFP-C1
constructs:
5’-gttcagggggaggtgtgggag-3’
RheoSwitch R-X1 Sequencing Primer for confirming constructs in
Rheoswitch pNEBR-X1 vector:
5´ (GGGTATATAATGGGGGC) 3´
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Mutagenesis PrimersMutagenesis of pEGFP-C1-Myc-Lamin A to generate pEGFP-C1-MycLamin A-L647R:
FWD Primer 5’-GACCCCGCTGAGTACAACCTG -3’
REV Primer 5’-AAAGAAAAATAACCCTTTGGTTTTTTTC-3’

Transfection Reagents
TransPass D1, NEB, Ipswich, MA, USA/Frankfurt, Germany
Polymag Magnetofection reagent, OzBiosciences, France
Mirus TransIT-3T3, Mirus Bio, USA

Antibodies
Primary Antibodies: The following primary antibodies were used either in
immunoblot analysis or as primary antibodies in immunoprecipitation.
Anti-GFP, Rabbit, ab290, Abcam, USA
Anti-PreA (In House, Rabbit IgG Anti-Serum)
Anti-Lamin A (H102), C-Term 563-664, Rabbit, #20680, Santa Cruz, USA
Anti-Lamin A/C (H-110), N-Term, Rabbit #20681, Santa Cruz, USA
Anti-Lamin A 4C11, Mouse, #4777, Cell Signaling, USA
Anti-Pin1 (H-123), Rabbit, sc-15340, Santa Cruz, USA
Anti-FoxO3a, rabbit, #9467, Cell Signaling, USA
Anti-p27 (M-197), Rabbit, #776, Santa Cruz, USA
Anti-Ki67, Rabbit, Cellomics/Thermofisher, USA
Anti-Tubulin, Abcam, USA
Anti-β-actin, Abcam, USA
Secondary Antibodies:
From Santa Cruz, USAGoat Anti-Rabbit IgG-HRP sc-# 2030,
Rabbit Anti-Mouse IgG-HRP, sc-#358914
From Cell Signaling Technology, USAGoat Anti-Rabbit-AlexaFluor®488 (Green) and -Alexa Fluor®555 (Red)
Rabbit Anti-Mouse-Alexa Fluor®488 (Green) and -Alexa Fluor®555 (Red)
From Molecular Probes, Invitrogen, USA
Rabbit Anti-Mouse-FITC(Green) and -Texas Red (Red)
Goat Anti-Rabbit-FITC and -Texas Red
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Mammalian Cell Culture
Mammalian Cell Lines:
WI-38 (Human lung adherent fibroblast cells growing as monolayer, 24 hr doubling
time, approx 40-50 psgs competent), CCL-75, ATCC, USA
BJ (Human foreskin fibroblast adherent monolayer cells, telomerase negative, 72
psgs competency), CRL-2522, ATCC, USA
HeLa (Human cervical epithelial adenocarcinoma fibroblast adherent monolayer cells)
CCL-2, ATCC, USA
3T3-L1 (Swiss mouse embryo fibroblast pre-adipocyte adherent monolayer cells,
capable of chemical induction of differentiation), CL-173, ATCC, USA
Inoculate 3 to 5 X 10(3) cells/cm2
NIH 3T3 (Swiss mouse embryo fibroblast adherent monolayer cells), CRL-1658, ATCC,
USA Inoculate 3 to 5 X 10(3) cells/cm2
NIH 3T3 (Rheoswitch, containing pNEBR-R1 regulator plasmid), NEB, USA
Mammalian Cell Culture Media, Reagents, Antibiotics:
Doxycyclin, MP Biomedicals, USA
Dulbecco’s modified eagle medium (DMEM) with and without Phenol Red /with
and without Phosphate, Lonza/Fisher Scientific, USA
Dimethyl Sulfoxide (DMSO) Sigma-Aldrich, USA
Fetal bovine serum, Lonza/Fisher Scientific, USA /Gibco, USA
Fetal calf serum, Lonza/Fisher Scientific, USA /Gibco, USA
G418 antibiotic , MP Biomedicals, USA

HygromycinB, MP Biomedicals, USA
PBS (phosphate-buffered saline), Lonza-Biowhittaker/ Fisher Scientific, USA
Penicillin/Streptomycin, MP Biomedicals, USA
Trypsin/Versene-EDTA, Lonza-Biowhittaker/ Fisher Scientific, USA
Buffers
Cell Lysis:
Standard Cell Lysis Buffer10 mM Tris-HCl, pH 7.0, 10 mM NaCl, 3 mM MgCl2, 0.4% Nonidet P-40
(NP-40)
Immunoprecipitation (IP) Lysis Buffer (Non Denaturing)20 mM Tris HCl pH 8; 137 mM NaCl; 10% glycerol; 1% NP-40 or Triton X100; 2 mM EDTA
RIPA buffer1% (v/v) NP40; 0.5%(w/v) Deoxycholate; 0.1%(w/v) SDS; 0.15 M NaCl
5mM EDTA; 50 mM Tris pH 8.0
Other Buffers:
TBE (5X)0.45 M Tris-Borate; 0.01 M EDTA pH8.3, autoclaved
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TBS (10X)0.2 M Tris base; 1.5 M NaCl pH7.4, autoclaved
TE (10X)0.1 M Tris-HCl; 0.01 M EDTA pH 7.5, autoclaved
MOPS and MES electrophoresis buffers1X solutions were prepared from commercial concentrates, 20X)

Software
SABiosciences Online/Web-Based Array Data Analysis Software
Used to analyze RT-qPCR gene expression array data, and calculate statistics.
BioRad iQData
Used to process raw data from RT-qPCR, to prepare for SABiosciences analysis.
PANDA Online/Web-Based Array Data Analysis Software
Used to analyze data from Full Moon Biosystems Antibody Array, and calculate
statistics.
ScreenHunter5.1 from Wisdom-Soft
Was used to capture images from computer desktop and save in convenient
digital photo formats.
Adobe photoshop
This image manipulation software was used to change the size and
improve the contrast of experimental images.
Primer3
This software was used analyze the secondary structure (hairpin etc.) and
annealing temperature of PCR primers.
GeneRunner
This software was used analyze the secondary structure (hairpin etc.) and
annealing temperature of PCR primers.
ClustalW Web Based NCBI
Used for comparing the homology between the target DNA and sequenced DNA.
Sequencher Sequence Analysis Software, Gene Codes Software Co.
ModFit LT 3.2 from Verity House Software and FCS Express V3 De Novo
Software

Methods I.: Molecular Biology Methods

Preparation and Purification of Plasmid DNA from Bacteria
Plasmid Midi and Mini preparations were carried out with QIAquick commercial
kits from Qiagen or the Zymo Plasmid Mini kit. The process followed the manuals
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provided with the kits. The Plasmid Midi Kit was used to purify up to 100 μg of plasmid
DNA. The Endo-free plasmid Max preparation Kit was used to obtain endotoxin-free
plasmid DNA for all transfections into mammalian cells.

Digestion of DNA with Restriction Endonucleases
The restriction digestions were performed by the protocol provided by the
supplier companies. For example, 1 μg plasmid DNA was digested with 5 units of a
given enzyme and 1x digestion buffer in 20 μl total volume for an incubation of 1 hour at
37°C.

Polymerase Chain Reaction (PCR)
Polymerase chain reaction was used to amplify DNA targets of interest, using
Applied Biosystems reagents, ABI thermocycler, and standard ABI protocol. Primers
noted in Oligonucleotides Section. PCR products were analyzed by agarose gel-sizing
and/or Sequencing.

Automated DNA Cycle Sequencing
Cycle sequencing was performed using the dye dideoxy chain termination
method based on the original dideoxy chain termination method developed by Sanger.
PCR products or plasmid vectors were sequenced in this work, using commercially preprepared solutions from Applied Biosciences: Big Dye Terminator Ready Reaction Mix
V1.3, and the manufacturer’s protocol. Unincorporated dye was removed from the
sequencing reaction using a resin-based clean-up column, the Qiagen Dye-Ex 2.0 spin
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prep system. Purified reactions were dried with heat in a Speed-Vac system and
resuspended in 15 μl Hi-Di Formamide. The suspension was denatured at 95°C for 5
min prior to loading onto an automated capillary sequencing analyzer, the ABI 3100 or
3130. Sequence results were analyzed using Sequencher Software or web-based tools
such as ClustalW.

Site-Directed Mutagenesis of DNA
Primer design for site directed mutagenesis, used the following guidelines:
The mutagenic oligonucleotide primers were designed to incorporate the desired point
mutations and bind to adjacent sequences of the template plasmids. The length of
primer should be between 25 and 45 bases with the melting temperature at least 75°C.
The GC percent of the whole primer should be more than 40% and at least 1 C or G at
3’ terminal. (Primer sequences are listed under Oligonucleotides Section) Primers
were designed using Primer3 web- program (http://frodo.wi.mit.edu/primer3/)105.
Mutagenesis Reactions used the Stratagene QuikChange® Lightning SiteDirected Mutagenesis Kit (Stratagene is now Agilent Technologies, USA) per
manufacturer’s protocol. Briefly, the following Mutagenesis PCR Reaction Mix was
prepared (per each reaction):
5 µl 10x rxn buffer
1.25 μl (125 ng) of primer L647R Fwd[100ng/µl]
1.25 μl (125 ng) of primer L647R Rev[100ng/µl]
1 μl of dNTP mix
8.5 uL mix each rxn, added to
3 μl (30 ng) of dsDNA template plasmid (pEGFP-C1-Myc-Lamin A)
dH20 to 50 μl TV=11.5 μl
1 μl PfuUltra HF DNA polymerase (2.5 U/μl)
And thermocycled with the following conditions:
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95° C 30 seconds
95°C 30 seconds
18 cycles
55°C 1 minute
68°C 5 minutes (1 minute/kb of plasmid length)
4°C Hold Infinity
After the PCR reaction had cooled to 37°C , 1µl Dpn I (10 units) was added to the
PCR reaction, followed by incubation at 37°C for 1 hour to digest the parental (i.e., the
nonmutated) supercoiled dsDNA.
Transformation of mutated plasmids into competent cells (Note: this protocol is
also used for transformation of other plasmids into bacteria, the specific feature related
to SDM, here, is the use of the Ultracompetent cells to enhance transformation,
otherwise, “traditional” competent cells are used in routine cloning exercises).
After Dpn I treatment, XL10-Gold® ultra competent E. coli cells were transformed
with the mutagenesis mixture. In this step, 1μl of the treated reaction mixture was
transformed into 50 μl of the ultra competent cells, which had been thawed on ice. After
gently swirling and incubating on ice 30 minutes, the tubes were heat pulsed at 42°C in
a waterbath for 45 seconds, then placed on ice for 2 minutes. Prewarmed (42°C) SOC
broth (0.5 ml aliquot) was added to the bacteria/mutagenesis mix in the Falcon tube,
and incubated, with 250 rpm shaking, for 1 hour at 37°C. Finally, 250 μl was plated on
each of 2 LB agar plates containing 25 μg/ml Kanamycin. The plates were incubated at
37°C overnight (>16 hours) and examined for colony formation.
Colony Selection: Isolated colonies were marked with a permanent marker on the
bottom of the agar plate and each (typically 5 colonies per transformation) was picked
up with a sterile 10 μl micropipette tip and transferred into prewarmed (37°C) LB broth
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medium containing 25 μg/ml Kanamycin. The cultures were incubated at 37°C, shaking
at 250 rpm, overnight (approximately 16-22 hours).

DNA Gel Electrophoresis
DNA gel electrophoresis was used to check the results of restriction enzyme
digestions, PCR reactions and DNA purification. Fragments of between 400 bp and 12
Kbp were separated by using 0.5% agarose gels. The gels were stained with ethidium
bromide (EtBr) at a concentration of 0.5 μg/ml and the DNA was visualized under UV
light (365 nm). DNA fragments less than 400 bp were separated on 1% or 1.5%
agarose gels.

Purification of DNA Fragments from Agarose
In order to obtain single DNA fragments from digested plasmids, gel
electrophoresis was performed, and the QIAquick Gel Extraction kit was used to extract
the DNA from the gel. The band of interest was excised from the gel and the weight of
the gel slice was determined. Three volumes solubilisation buffer (components
proprietary) from the kit were added into the sample tube. The tube was vortexed and
incubated at 50°C for 10 minutes or longer until the agarose was completely dissolved.
The solution was loaded onto the ion–exchange column by centrifugation at 12,000 x g
for 1 minute. 500 μl solubilisation buffer was added to wash the column followed by an
additional centrifugation at 12,000 x g for 1 minute. Three volumes high salt ethanol
wash buffer were used to wash the column. Elution of the DNA from the column was
carried out by adding 50μl of 10 mM Tris-HCl, pH8.5 to the column and centrifuging 1
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minute at 12,000 x g. In experiments where it was necessary to increase the DNA
concentration in the eluate, the eluate was centrifuged through the column an additional
time. This procedure was also used for the purification of PCR products.

Precipitation of DNA
When the DNA fragment was used for sequencing or some enzymatic reaction
that was sensitive to residual salt, it was necessary to precipitate the DNA. The
precipitation of DNA was achieved by adding 0.1 volume (of the starting DNA) of 3M
KAc and 2.5 volumes 100% ethanol, and incubating at –20°C for 10 minutes. After
removal of the supernatant the pellet was washed with 70% ethanol and air-dried.

Cloning and Sub-Cloning of DNA
Restriction Enzyme-Based Method. Cloning was performed by restriction
endonuclease digest to remove the Zmpste24 cDNA sequence from the pCMV6-XLZmpste24 construct (Entry Vector) and transfer to the pCMV6-AN-GFP destination
vector. Per manufacturer instruction, restriction enzymes MluI and AsisI were used.
Digests were performed according to manufacturer instructions. Following digests,
fragments were separated on an agarose gel and visualized with EtBr on an ultraviolet
lightbox. Size discrimination was used to discern insert fragment from vector. The
fragment was cut from the agarose and extracted/purified using the QIAquick Gel
Extraction protocol, as described.
PCR-Based Method. The EGFP and EGFP-Lamin A/ Lamin A-L647R/ Lamin Adel50 fragments were copied from the pEGFP-C1-Myc-Lamin A/ Lamin A-L647R/ Lamin
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A-del50 constructs by PCR amplification, using primers (described in Oligonucleotides
section), to copy the EGFP/EGFP-lamin fusion coding region and add on a restriction
enzyme cutting site. The Forward primer incorporated a NotI recognition site N-terminal
to the EGFP sequence, and the Reverse primer attached a SalI site to the C-terminus of
the coding section. PCR product was gel-purified and analyzed for appropriateness of
molecular weight of the amplified insert, with extraction by the QIAquick Gel Extraction
protocol, as described.
DNA Ligation. This procedure was performed to construct a new plasmid by
ligating the purified target fragment with vector plasmid. First, the target vector was
digested with the restriction enzymes compatible to the insert, and after heat
inactivation of that enzyme, the vector was then treated with shrimp alkaline
phosphatase (SAP) to prepare the ends for ligation. SAP catalyzes the removal of 5´
phosphate groups from DNA, thus preventing the recircularization and 49elegation of
linearized (empty) cloning vector DNA during ligation. The DNA ligation reaction was
performed following the protocol for Ligafast T4 DNA Ligase (Promega, USA). Briefly, 4
μl 5X Ligase Reaction Buffer (250 mM Tris-HCl (pH 7.6), 50 mM MgCl2, 5 mM ATP, 5
mM DTT, 25% PEG8000) from kit, 1 μl T4 DNA Ligase (1U/μl) and 3:1 (molar ratio)
insert DNA: vector DNA were mixed together in a microcentrifuge tube. The reaction
mix was incubated at room temperature for 2 to 4 hours or for 16 hours at 16°C.
Bacterial transformation was then carried out as in the Site Directed Mutagenesis
section, but Zymocompetent cells were used as the “ultracompetency” needed in
mutagenesis reactions is not required for this routine subcloning.
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Transfection of Mammalian Cells
Transient Transfections. Two different methods of introducing plasmid DNA into
mammalian cells (magnetic or cationic lipid polymer-mediated transfection) were used
in this work. The magnetic method was carried out as described by the manufacturer
(OzBiosciences, France) for the Polymag Magnetofection reagent, in which the DNA is
adhered to microscopic magnetic particles prior to bathing adhered cells with the
DNA/magnet particle suspension, then placing the dish on an ultrastrong magnet,
forcing the microscopic/DNA coated particles to pierce the membranes of the cells. The
Mirus Transit-3T3 or NEB TransPass D1 reagents are cationic lipid vesicle-based
reagents, that carry the complexed DNA through the membrane using those membranepermeation qualities. The tissue culture plates (0.5 x 106 cells per 100 mm plate) were
prepared 1 day before the transfection. The incubation time of plasmid DNA/liposome
mixture with the cells was about 24 hours at 37°C with 10% CO2, after which fresh
medium was added to the plates. Two days after transfection, the cells were harvested
or processed for selection, depending on the exact experiments. The transfection
efficiency was assessed by using fluorescence microscopy for the GFP-fused
constructs, or otherwise by indirect immunofluorescence. Transient transfections of WI38 and NIH 3T3-L1 cells with pCMV6-AN-GFP-ZMPSTE24 were performed using
Polymag Magnetofection Transfection Reagent, per manufacturer instructions.
Stable Transfections. To generate the RheoSwitch Inducible Gene Expression
Cell line system, RheoSwitch NIH3T3–47 cells (“Rheoswitch 3T3 cells”) were
purchased already harboring the optimally selected pNEBR-R1 regulator plasmid
encoding the RheoReceptor-1 and RheoActivator protein. The pNEBR-X1-Hygro EGFP
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and pNEBR-X1-Hygro EGFP-Myc-Lamin A/ Lamin A-L647R/ Lamin A del50 constructs,
as described under Plasmid Constructs section, were transfected with TransPass D1
according to the manufacturer’s instructions. The day before transfection, Rheoswitch
3T3 cells were seeded at 1.5 × 105 cells/cm2. The cells were then transfected with the
inducible pNEBR-X1-Hygro constructs. After 30 hours, 500 nM RSL1 or GenoStat
(“induction reagent”) was added to medium. The cells were incubated/induced 14 hours
and observed for GFP expression by fluorescence microscopy. Following visual
confirmation of transfection, medium containing induction reagent was removed, cells
were rinsed 2 times with 1X PBS, split, and plated out under sparse conditions in
medium containing both G418 and Hygromycin to establish stable cell lines. Single
colonies were picked, reseeded, and expanded. From expanded clonal populations,
cells were plated, induced 24 hours, then observed for GFP expression. Three clonal
lines with the strongest intensity of expression were selected for each construct and
further expanded, while other clones were discontinued. Finally, 1 clone was selected
as the best expresser and cultivated as the primary cell line for the stable expression of
each construct.
Cotransfection. This process involved transient transfection of GST-Pin1 as an
additional plasmid vector into the RheoSwitch Cell Lines (which already stably harbored
the pNEBR-X1-Hygro-EGFP-Lamin A-L647R construct). The cotransfection was
performed using Mirus TransIT-3T3, per manufacturer recommendations, and as noted
above. Cells were harvested after 48 hours.
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Methods II.: Protein Chemistry and Biochemistry Methods

Preparation of Mammalian Cell Lysates
In order to analyze target protein expression in mammalian cells, cells were
typically lysed in RIPA buffer. Transfected cells were washed with PBS 2 times at room
temperature, then 0.25% Trypsin/EDTA was added, followed by incubation at 37°C until
the adherent cells were detached. DMEM medium with fetal calf serum was added to
neutralize the activity of Trypsin. The cells were transferred to a fresh 15 ml tube and
centrifuged at 1500 rpm for 3 minutes. Ice-cold PBS was added to wash the cell pellet
2 times. The cell pellet was resuspended in 600 µl of RIPA buffer, containing Halt
Protease and Phosphatase Inhibitor Cocktail (1X). The resuspended cells were
transferred to a fresh microcentrifuge tube and incubated on ice for 30 minutes. The
sample was vortexed for 30 seconds every 10 minutes. Then the solution was
centrifuged at 10,000 x g for 10 minutes at 4°C. The supernatant was transferred to a
new microcentrifuge tube. The cell pellet was resuspended in an additional 300 µl Lysis
Buffer with inhibitors, sonicated on ice (on low setting), 5 times in 3 second pulses with
10 seconds between pulses. After an additional centrifugation at 10,000 x g for 10
minutes at 4°C, the supernatant was transferred to the microcentrifuge tube containing
the previous supernatant, and vortexed to mix well, forming the total cell lysate. Lysates
were stored briefly at -20°C, or at -80°C for longer term storage, thawed, and kept on
ice during experimental set-up. Protein concentration was assayed using Pierce BCA,
micro BCA, or detergent-compatible protein assay methods, per kit instructions, with
measurements taken spectrophotometrically, comparing to a standard curve generated
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by measurement of a dilution series, in the lysis buffer used for the cell lysates being
assayed, using BSA protein standard of known concentration.

Cellular Compartment Lysate Fraction Preparation
Cytoplasmic and Nuclear fractions were separated, per manufacturer
instructions, using the NE-PER nuclear protein extraction method. Stepwise lysis of
cells and centrifugal isolation of nuclear and cytoplasmic protein fractions, involving a
short series of progressively more harsh lysis buffers and faster speeds of
centrifugation, using a benchtop microcentrifuge. Whole cell fractions were maintained
for each lysate that underwent fractioning, as reference.

Electrophoretic Separation of Proteins
Protein samples were solubilized by boiling in the presence of 1X NuPAGE LDS
Buffer, with 10% reducing agent (Bond Breaker TCEP or DTT). An aliquot of the
sample was loaded onto a precast 1-dimensional denaturing NuPAGE Novex 4-12%
Bis-Tris SDS PAGE gel (typically 50 µg total protein for most applications, or other, as
noted for each experiment). Electrophoresis was performed at a constant 200 volts,
running time approximately 45 minutes to 1 hour, dependent upon the sizes of the
expected protein bands. Commercial protein standards enabled the estimation of
apparent molecular weights.

53

Protein Blotting
Protein transfer from gel to PVDF or nitrocellulose membrane was carried out by
electroblotting in a dry electroblotter, the iBlot, as described by the manufacturer
(Invitrogen/Life Technologies, USA). The protein transfer process lasted approximately
7 minutes. After transfer, gel and membranes were checked to verify the protein
standards were clearly visible on the membrane.

Immunodetection (Western Blotting)
The Western Blotting procedure was performed according to the protocols from
Santa Cruz Biotechnology, Cell Signaling Technology, and Abcam. Briefly, the
membrane was blocked against nonspecific binding by incubating the membrane in
freshly prepared 1X TBST/5% Nonfat Milk (or BSA, if instructed by antibody
manufacturer) for 1 hour at room temperature or overnight at 4°C. The membrane was
washed in 1X TBST 5 times (2 x 1 min, 3 x 5-10 min) and incubated with primary
antibody diluted at appropriate concentration for the antibody in 1X TBST/5% Nonfat
Milk (or BSA) for 1 hour at room temperature or overnight at 4°C. The membrane was
washed in 1X TBST 5 times (2x1 min, 3x 5-10 min), and incubated with the secondary
(2°) antibody-HRP (horseradish peroxidase) conjugate at room temperature for 1 hour.
After this, the membrane was washed in 1X TBST 5 times (2x1 min, 3x 5-10 min) at
room temperature to remove excess 2° antibody conjugate. The specific protein bands
were detected using ECL chemiluminescence reagent and developed for 5 minutes at
room temperature. Excess chemiluminescence reagent was drained, and membranes
with were wrapped in plastic film and imaged on a Fuji Chemiluminescence Imaging
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System, with digital photo-documentation using Multi Gauge Software that was also
used for digital semi-quantitative densitometry analysis for graphics production in some
experiments.

Zmpste 24 Protease Activity Assay
Zmpste24 was assayed in triplicate on crude human diploid fibroblast nuclei from
cells essentially as previously described26. A significant modification was that the
substrate used was the simple hexapepide: RSY*LLG, where Y* is a

14

C-labeled

tyrosine. The labeled peptide was prepared by conjugation with 14C-methylamineglutaraldehyde, also as previously described106. Briefly, nuclei were prepared from cell
pellets by resuspending the cells to a final density of 4 x 108 cells/ml in lysis buffer.
Nuclei were isolated after 2 more washes, in the same buffer, and pelleting by
centrifugation in a Beckman J-14 rotor for 10 minutes at 365 x g. For assay, the nuclei
were resuspended in the same buffer without NP-40. Protein concentration was
obtained by means of the Micro BCA Protein Assay Reagent Kit. The endoprotease
reaction is initiated by the addition of 14C-labeled peptide (RSY* LLG, final
concentration: 5 µM) to the nuclear preparation in a final volume of 200 µl in 10 mM
MES, pH: 6.0. The reaction stopped at the end of 20 min by the addition of 5 µl of
glacial acetic acid. The RSY* peptide reaction product was isolated by reverse phase
thin layer chromatography (Analtech, Inc. Newark, DE) and visualized by
autoradiography. A synthetic, 14C-RSY* peptide standard was run on each plate to aid
in the identification of this expected product. The amount of labeled RSY formed in the
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assay was determined by scraping the appropriate spots into tubes and quantitation of
radioactivity with a gamma counter.

Peptide Phosphorylation Residue Mapping by Edman Degradation
This assay detects phosphorylation of amino acid residues. HeLa cells
containing a Doxycline-Inducible GFP-LA or GFP-Progerin (A gift from Dr. R. Goldman,
Northwestern University) construct were induced for expression for 24 hours prior to
labeling, as described in “Cell Culture” section. Labeling of phosphopeptides was
achieved by removing growth medium from adhered, induced cells, rinsing with
phosphate-free medium containing 10% phosphate-reduced fetal-bovine serum,
doxycyclin, and [32P]-orthophosphate (1mCi/ml). Cells were incubated overnight at
37°C in 5% CO2107,108. Lysates were prepared in immunoprecipitation buffer from
expression induced, phospho-labeled cells expressing GFP-fused wild type LA or GFPProgerin that had been incubated overnight with 32P to label phospho-proteins.
Immunoprecipitation was performed with anti-GFP antibody bound to Protein Aconjugated sepharose beads overnight at 4°C. Immunoprecipitated protein was
digested with 3-bromo-3-methyl-2-l(2-nitrophenyl)thiol-3H indole (BNPS-skatole), as
previously described109. Briefly, cleavages were performed in 70% distilled acetic acid
0.1%/phenol for 48 hours at room temperature by using a 10-fold excess of the reagent.
After the addition of β-mercaptoethanol (10-fold excess) and a further incubation for 5
hours at 37°C, the excess BNPS-skatole was extracted with ethyl acetate and the
resulting aqueous phase dried by evaporation. The protein was precipitated 1 hour in
the presence of BSA and 15-20% ice cold trichloroacetic acid (TCA) then centrifuged at
3000 rpm for 5 minutes at 4°C. Supernatant was removed and pellet was centrifuged
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again to remove additional supernatant before washing with ice cold absolute ethanol.
Ethanol supernatant was removed in 2 additional centrifugation-supernatant removal
steps, and the pellet was air dried then resuspended in 250 µl 1X LDS Sample Buffer.
25 µl aliquots of the suspensions were loaded onto SDS gels alongside protein ladders,
electrophoresed, and transferred to PVDF by electroblotting. Coomasie staining
revealed 5 peptide fragments generated by the BNPS-skatole, and the C-terminal band
was identified by Western blot with an antibody directed to C-terminal Lamin A. Using
the staining gels as a guide, the portions of the PVDF membranes containing the
Western Blot-identified C-termini were excised and incubated with trypsin110,111. To
avoid the formation of oxidation-state isomers, the protein was oxidized to completion
by resuspension of the TCA pellet in 50 μl cold performic acid and incubating for 1 hour
on ice, before adding 400 μl deionized water, freezing, and lyophilizing. Manual Edman
degradation was initiated by resuspending the lyophilized pellet in 50 μl 6 M HCl and
incubating for 1 hour at 110°C to hydrolyze the protein to liberate the individual
phosphoamino acids. After additional lyophilization to remove HCl, Hunter Thin Layer
Electrophoresis (HTLE) was performed as directed for phosphoamino acid analysis by
the manufacturer (CBS Scientific, USA), and as previously described 112.

Preparation of Cell Extracts for Mass Spectrophotometry
Proteins were separated and purified by SDS-PAGE, visualized by Coomassie
staining and the appropriate bands excised. The isolated proteins were treated with
iodoacetamide and digested with trypsin. MALDI-TOF was performed with a PerSeptive
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Voyager DE-RP mass spectrometer in the linear or reflector mode by staff at the Protein
Chemistry Core Facility at Columbia University.

Methods III.: Cell Biology Methods

Cell Culture-General Cell Culture Techniques
All mammalian cell lines were cultured in a humidified incubator at 37°C with 5%
or 10% CO2, per cell requirements. Cell culture work was done in a laminar-flow hood
for which sterility was promoted by UV light treatment at all times when not in use. All
work surfaces within, and materials used inside the hood were surface-cleaned with
70% ethanol before and after work in the hood.
HeLa cells, BJ human diploid fibroblasts, and WI-38 human diploid fibroblasts
were plated in standard DMEM growth supplemented with 10% fetal bovine serum
(FBS) in 5% CO2, at 37°C. Tet-On HeLa cells containing pEGFP-C1-Myc-LA/LA-del50
had 2 μg/ml doxycyclin added to the growth medium for 24–50 h when induction of
expression was desired only. All 3T3 cells were cultivated in DMEM supplemented with
10% calf serum (CS) and incubated at 37°C with 5% or 10% CO2. As the DMEM
formulation contains 3.7% NHCO3, 10% CO2 was used to prevent ammonia buildup in
the medium, when required to optimize growth pH for the transfected cell cultures, as
recommended by NEB and Invitrogen. DMEM from ATCC was also used, and as it
contains 1.5% NHCO3, 5% CO2 was used. The fibroblast RheoSwitch Cell Line
NIH3T3–47 (“Rheoswitch Cells,” New England Biolabs, Frankfurt, Germany) were
derived from mouse NIH 3T3 cells, stably transfected with pNEBR-R1 Vector
(“Regulator Plasmid,” see details below describing plasmid constructs), and selected for
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optimal RSL1 inducible expression properties. These cells were additionally
supplemented with 800 µg/mL G418 antibiotic as selection reagent to maintain the
stable transfection with the Regulator Plasmid, as well as 200 µg/ml Hygromycin B to
maintain the Expression Plasmid.

Induction of Rheoswitch Expression System
RSL1 ligand (New England Biolabs, Frankfurt, Germany) or GenoStat (Millipore,
Billerica, MA, USA) are both synthetic diacylhydrazine [(N-(2-ethyl-3-methoxybenzoyl)N´-(3,5-dimethylbenzoyl)-N´-tert-butylhydrazine]. Diacylhydrazine is one member of a
family of compounds that have been found to act as nonsteroidal ecdysone agonists
and can function as gene inducers113,114.

Indirect Immunofluorescence and Protein-Protein Co-Localization in Mammalian Cells
To examine intracellular protein localization, fluorescent microscopic analysis of
the green fluorescent protein-fused proteins was used. Growth medium was removed
prior to visualization, cells were rinsed with 1X PBS, and medium was replaced using
DMEM without additives (including no Phenol Red) for visualization under fluorescence
microscopy. The cells were cultured in coverslip chamber cell culture dishes or plated
as usual in culture dishes and harvested by trypsinization prior to transferring to
coverslip chamber dishes. For microscopic visualization using indirect
immunofluorescence, cells were plated on glass coverslips in culture dishes, treated,
and incubated as per the requirements of the specific experiment, then rinsed with 1X
PBS prior to fixing by incubation in 4% formaldehyde PBS (pH 7.4) for 15 minutes at
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room temperature, or 100% methanol for 5 minutes at -20oC. Following 3 washes in
PBS, the cells were permeabilized with 0.2% Triton X-100 in PBS for 5 minutes on ice,
quickly washed, and blocked with 10% BSA in PBS for 5 minutes on ice. The coverslips
were incubated for 1 hour at room temperature with primary antibody at concentrations
noted per experiment. Cells were then washed and incubated at room temperature for 1
hour with fluorophore-conjugated 2o antibody. After 3 final PBS washes, DAPIperfused antifade mounting edium was used to seal the stained cells between the
coverslip and a microscope slide. Images were obtained by on a Nikon Diaphot 200
microscope equipped with a Photometrics Sensys cooled CCD digital camera.

Cell Cycle Manipulation
For serum starvation experiments, medium was removed from actively growing
cells, cells were rinsed with PBS, and medium was added containing the minimum
amount of serum required for survival (0.5% serum for HeLa, WI-38, or BJ cells; 0.3%
serum for the 3T3 cells). The minimal serum is insufficient to supply mitogens for cell
proliferation. Cells were collected at stated time points after serum removal. For
contact inhibition experiments, the cells were seeded sparsely (2.5 × 103 cells/cm2) or
densely (1 × 105 cells/cm2) and cultivated for indicated times.

Cell Cycle Analysis Methods:
Cell Cycle Analysis by Flow Cytometry. Cells were plated at the same density
and control and experimental cells treated the same way except that no DMSO was
added instead of induction reagent, in a volume to duplicate the DMSO vehicle of the

60

induction reagent used for the experimental cells. Cells were harvested by trypsinization
using 0.25% Trypsin-EDTA, washed 3 times with 5-10 ml 1X PBS, and fixed in ice cold
70% ethanol, added dropwise with gentle trituration, with tubes in ice, to a volume of 3-5
ml ethanol. Tubes were then transferred to –20oC for a minimum of 2 hours, or
overnight to allow for complete fixation. To stain DNA for flow cytometric DNA
content/cell cycle analysis, cells were centrifuged to form a loose pellet, washed 3 times
with 10 ml PBS, then after removal of supernatant PBS, cells were spun again to
remove residual PBS. After removal of ethanol, cells were stained with 50 μg/ml
Propidium Iodide/RNase in the dark for 30 minutes at room temperature and analyzed
on an Accuri C6 flow cytometer. Collected data were further analyzed by using FCS
Express V3 or ModFit LT 3.2 cell cycle analysis software programs. Gates were set
over each of the sub-G1, G0/G1, S, and G2/M peaks, and then the percentages of cells
in different cell cycle phases were calculated to determine percentages of cells in
different cell cycle phases.
Assay of Cellular Proliferation by BrdU Incorporation. 3T3 cells or L647R
RheoSwitch cells were seeded in triplicate at 4 x 103 cells/well in a 96-well plate and
incubated overnight. Cells were then treated with various concentrations of GenoStat
inducer, or DMSO as vehicle control, for 48 hours. Finally, 10 μM BrdU was added to
the plate and cells were incubated for 4 hours. BrdU incorporated into DNA was
detected by incubation with monoclonal anti-BrdU antibody linked to horseradish
peroxidase (HRP). The HRP substrate 3,3’, 5,5”-tetramethyl-benzidine (TMB) was used
to develop the color. Stop solution was added after 30 minutes of development, and
absorbance at 450 nm was measured using a platereader, with quantification of
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absorbance representing amount of BrdU incorporated into cells to indicate level of
proliferation occurring in the corresponding cells.
Assay of Cellular Proliferation by Incorporation of [3H]-Thymidine. This
proliferation assay was performed in conjunction with the Zmpste24 activity assay.
DNA synthesis was monitored by pulse labeling for 30 mm with (1 uCi/ml) [3H]thymidine at various times. The plates (1 x l06/100mm plate) were washed 2 times with
cold PBS (1X), and the cells harvested by scraping with a rubber policeman into 1 ml of
PBS. The suspension was homogenized by sonication, and a 0.2-ml aliquot was mixed
with 1 ml of 10% cold trichloroacetic acid (TCA). The insoluble material was collected on
a Millipore filter and washed with cold TCA. The filter was dried and the radioactivity
incorporated was determined by liquid scintillation counting.
Assay of Cellular Proliferation by Detection of Ki-67. Ki-67 is a nuclear protein
commonly used as a negative marker for quiescence, as G0 is the only cell cycle phase
in which it is not found. Detection was carried out by immunostaining with an anti-Ki67
primary antibody and a fluorescence-conjugated secondary antibody, as described in
“Indirect Immunofluorescence” on L647R PreA construct Rheoswitch cells that were
plated on coverslips and treated with induction reagent or DMSO, as indicated.
Presence of Ki-67 indicates active cell cycling.

Methods IV.: Gene Expression Analysis Methods

Whole Genome Exon Transcript Microarray
Total RNA was isolated and pooled from 3 culture dishes 48-hours
posttransfection, for whole genome microarray gene expression profiling, using an

62

Affymetrix Mouse Exon 1.0ST GeneArray, as directed by the Affymetrix GeneChip
Whole Transcript (WT) Assay for Exon Chips Labeling Manual Ver 4 (Affymetrix, Santa
Clara, CA). Processing of the GeneChip and initial extraction of raw data was
performed at the University of Tennessee-Knoxville, Microarray Corelab Facility. In
brief, RNA reduction was performed using a RiboMinus kit from Invitrogen using 1 µg
total RNA starting material, which was subjected to first and second strand cDNA
synthesis with the GeneChip Sample Cleanup Module for cRNA. The resultant cRNA
product was quantified with the Nanodrop ND-1000. A second round of cDNA synthesis
was performed with the GeneChip WT cDNA synthesis kit with 10 µg of cRNA. The
remaining cRNA strand was hydrolyzed with RNase H and the single-stranded cDNA
was isolated with the GeneChip Sample Cleanup Module for cDNA. The single
stranded cDNA was quantified by Nanodrop and 5.5 µg of ssDNA was fragmented to
50-200 bp with WT Terminal Labeling kit UDG and APE1 enzymes. The fragmented
ssDNA was terminally labeled with the DNA labeling reagent and TdT enzyme from the
kit. A hybridization cocktail was prepared with the resultant cDNA and recommended
controls then injected into the Mouse Exon 1.0ST arrays prior to hybridization for 16
hours at 45oC in Affymetrix’s 640 Hybridization Oven. Hybridized arrays were washed
and stained using the Affymetrix 450 Fluidics Station and the GeneChip Hybridization
Wash and Stain kit. Arrays were held in the dark at room temperature and immediately
scanned with the Affymetrix 7G GeneChip Scanner. Resultant raw signal files were
imported into Partek Genomics Suite 6.4 (St. Louis, MO) using the RMA (robust
multichip algorithm) for normalization. All data were log2 transformed during the
importation process, and a PCA (Principle Components Analysis) plot was generated
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with all probe sets to determine that samples grouped according to treatment. Initial
results indicated the chips grouped according to treatment as expected (quality
evaluation plots not shown). A gene level summary was created as recommended by
the EXON flow path in Partek using the following parameters: Mean, Exclude outliers
above and below 3 standard deviations from the mean. Detection of differentially
expressed genes was performed by ANOVA with exclusion criteria of p-value</=0.05.
After receiving the raw data, these were uploaded to Ingenuity Pathways Analysis™
Software (Ingenuity® Systems, www.ingenuity.com) for further evaluation. This software
was use to formulate a “Functional Analysis,” a “Canonical Pathways Analysis,” and to
generate “Networks” and “Pathways” of the implicated molecules. Molecules from the
dataset that met the differential gene expression value cutoff of p-value</=0.05, as
determined by the ANOVA analysis from the Partek software, were considered for the
Ingenuity analyses. The Functional Analysis identified the biological functions and/or
diseases that were most significant to the dataset, while the Canonical pathways
analysis identified the pathways from the IPA library of canonical pathways that were
most significant to the data set. For the Functional Analysis, molecules from the dataset
were associated with biological functions and/or diseases in the Ingenuity Knowledge
Base, and a Right-tailed Fisher’s exact test was used to calculate a p-value determining
the probability that each biological function and/or disease assigned to that data set is
due to chance alone. The Canonical Pathway Analysis associated the molecules with a
canonical pathway in the Ingenuity Knowledge Base. The significance of the
association between the data set and the canonical pathway was measured in 2 ways:
1) a ratio of the number of molecules from the data set that map to the pathway divided
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by the total number of molecules that map to the canonical pathway is displayed. 2)
Fisher’s exact test was used to calculate a p-value determining the probability that the
association between the genes in the dataset and the canonical pathway is explained
by chance alone. For the “Network Generation,” the molecules, were overlaid onto a
global molecular network developed from information contained in the Ingenuity
Knowledge Base. Networks were then algorithmically generated based on their
connectivity. The “My Pathways” Path Designer produces graphical representations of
the molecular relationships between molecules. Molecules are represented as nodes,
and the biological relationship between 2 nodes is represented as an edge (line). All
edges are supported by at least one reference from the literature, from a textbook, or
from canonical information stored in the Ingenuity Knowledge Base. Human, mouse,
and rat orthologs of a gene are stored as separate objects in the Ingenuity Knowledge
Base but are represented as a single node in the network. The intensity of the node
color indicates the degree of up- (red) or down-(green) regulation. Nodes assayed in the
dataset but not revealing a statistically significant change in regulation are in gray, while
genes not assayed but contained in the IPA knowledge base as related to the assayed
genes are represented as white nodes. Nodes are displayed using various shapes that
represent the functional class of the gene product. Edges are displayed with various
labels that describe the nature of the relationship between the nodes (e.g., P for
phosphorylation, T for transcription).

Cell Cycle Pathway-Focused RT-qPCR Array
Cell cycle gene expression was determined using SABiosciences RT-qPCR Cell
Cycle Gene Expression Analysis Assay (RT2 Profiler PCR Array Cell Cycle Pathway
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Focused Assay), and the My iQ5 system (Bio-Rad) according to the manufacturer's
protocol. In preparation for the cells from the Rheoswitch 3T3 inducible construct
expression cell lines (as described in “Development of a Model System of Inducible
Stable Lamin Isoform Expression Cell Lines” section), cells were plated in standard
growth medium for the Rheoswitch Inducible cell lines (as described in Cell Culture
section) at 3 x 106 cells/50 cm2 tissue culture dish and allowed to adhere in the
incubator for at least 4 hours prior to adding induction reagent (Genostat) or DMSO.
500nM Genostat was used for induction, with a corresponding volume of DMSO added
to the media of control (uninduced/NI “Not-Induced”) plates. The cells were incubated
for an additional 24 hours, at which time they were collected by brief trypsinization,
which was neutralized by addition of serum-containing medium, prior to gentle (1,300 x
g) centrifugation in a 50 ml conical tube for 5 minutes, followed by rinsing 2x in cold 1X
PBS. Cells were then flash frozen in liquid nitrogen and stored at -80oC until RNA
isolation was performed. For the RNA isolation, the cells were thawed briefly on ice, 3
samples were pooled for each genotype and purified using the Qiagen™ RNeasy Mini
kit protocol. RNA quantity and purity were determined using a NanoDrop ND-1000, and
aliquots were submitted to the ETSU Molecular Biology Core Facility for assessment of
RNA integrity by determining the 28S/18S ratio and RNA integrity number using the
Expert Eukaryote Total RNA Nano assay on the Bioanalyzer 2100 (Agilent
Technologies, USA). Results indicated excellent RNA quality (RNA Integrity Scores
ranged from 9.7/10-10/10), and concentrations varied from 59 ng/µl to 768 ng/µl. A
quantity of 2µg of high-quality RNA (260/280 ratios slightly higher than 2.0 and 260/230
ratios higher than 1.7, RIN>8.0) for each pooled sample was used to perform each cell
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cycle gene pathway-focused quantitative RT-PCR (RT-qPCR) array plate assay. The
assays were performed as directed by the manufacturer, beginning with Genomic DNA
Elimination, followed by first strand cDNA synthesis using the RT2 First Strand cDNA
Kit. All RT-qPCR reactions use the RT2 SYBR Green qPCR Master Mix. Each cDNA
sample is used to prepare a single reaction mix aliquoted equally into all wells of a
single 96-well reaction plate. This plate contains a primer set for 84 separate cell cycle
pathway-focused genes, along with a standard set of 5 routinely used “housekeeping
genes” for normalization of experimental runs. In addition, each plate has 3 control
wells for demonstration of genomic DNA contamination, reverse transcription efficiency,
and PCR efficiency. All significant changes in gene expression levels are reported in
the article; the complete list of genes assayed on the array are presented in the full
assay results in Appendix A. Further information can be found at the manufacturer's
website (http://www.sabioscience.com/rt_pcr_product/HTML/PAMM-020A.html).
The BioRad iQcycler Raw data were analyzed on BioRad iQ5 software, with
parameters set uniformly for all plates as follows: Data Analysis Window was set at Full
cycle scan, Rolling Boxcar Intracycle Digital Filter, PCR Baseline Subtracted Curve Fit
Analysis Method, with Base Line Cycles set automatically by the software using the
built-in optimization algorithm, and a baseline threshold set at 61 (above background
and within lower ¾ of logarithmic amplification phase for all samples assayed). For
each gene included on the array, the threshold cycle (Ct) data, representing the cycle
number at which amplification for a given analyte surpassed the baseline threshold,
indicating amplification above background, and, once normalized, represents the
amount of a given transcript that is present within the assayed sample. The Ct data
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were assembled into an Excel upload file per SABiosciences Data Analysis Instructions
and uploaded to the SABiosciences web-based data analysis module. In determining
which genes available on the array to use as our reference (“housekeeping”) gene,
Heat-Shock Protein 90 (Hsp90) was selected because no significant effect on its
expression level had been detected in any of our gene expression analyses involving
these lamin constructs or the EGFP-only construct, compared to uninduced cells.
Hsp90, along with data for the Reverse Transcription Control and Positive PCR Control,
were used to normalize the data for comparison. Initial data from 2 array plate assays
of uninduced cells (DMSO-treated/NI, “Not Induced”), per cell line (wtLA, L647R PreA,
and del50 cells), were compared to each other to establish consistency of “baseline
gene expression” among uninduced cells. The establishment of a consistent baseline
of gene expression between uninduced cells is critical for comparative evaluation of
gene expression changes, between each cell line, that are due to induction of
expression of the lamin constructs. As the cells used in development of the cell lines
were each originally taken from the same parent culture, transfected with the different
constructs and then clonally selected, we expected to see only the most subtle
differences in gene expression between the 3 uninduced cell lines. Upon comparison to
each other, we found more gene expression variation among the uninduced cell lines
than we had expected. Therefore, subsequent experiments were postponed for wtLA
and del50, and a triplicate assay for statistical relevance focused only upon comparing
L647R PreA induced cells and the uninduced cells of the same line. After determining
cell line-cell line variation of gene expression was exhibited among uninduced cells of
each cell line, a third assay of uninduced cells was performed only for the L647R PreA
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cell line, followed by a triplicate set of array plates for the induced L647R PreA cell line.
The gene expression profile of the induced L647R PreA-expressing cells was compared
to the uninduced cells of the same line. Using the SABiosciences data analysis
software, Volcano Plot analyses were prepared, representing the statistical significance
of gene expression changes. In those graphic analyses, the X-axis plots the log2 of the
fold-differences, while the y-axis plots their p-values based on the student’s t-test of the
uploaded replicate raw Ct data. Symbols outside the gray area indicate fold-differences
larger than the user defined threshold, which was set to 2-fold-expression for these
analyses. The red symbols identify up-regulated genes, and the green symbols identify
down-regulated genes. Symbols in the Volcano Plots above the blue line identify folddifferences at least as statistically significant as the defined threshold, which was set to
p</=0.05. The Volcano Plot can be found as Appendix B. Using the Volcano Plot data,
Excel graphics were prepared for further visual comparison of the data, and are
included within Chapter 3 Results Section text.
RT qPCR Cycling Conditions: Cycles—Duration--Temperature
1 cycle--10 minutes--95°C
40 cycles--

15 seconds 95°C
1 minute2 60°C

Followed by 2-Step Amp+Melt.tmo Dissociation (Melting) Curve, as
recommended by SABiosciences for BioRad: iCycler®, MyiQ cycler, iQ5.

Cell Cycle Control Pathway-Specific Antibody Array (Protein Array)
The Full Moon Biosystems Cell Cycle Control Phospho Antibody Array
(PCC238) Assay was performed as per manufacturer instructions. Briefly: L647R PreA
cells that had been plated in 2 50 cm2 cell culture dishes and induced 72 hours using
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500 nM GenoStat, or, for control, treated with DMSO for 72 hours, were rinsed twice in
1X PBS, before adding 500 µl of ice cold 1X PBS containing 1X Halt Protease and
Phosphatase Inhibitors, and using a cell scraper to scrape the cells from the dish culture
surface and transfer to a microcentrifuge tube on ice. Culture density at harvest was
approximately 60-70%. Cell lysates were prepared as previously described, except
using the Protein Extraction Buffer provided in the Full Moon Biosystems Antibody Array
Kit, to which Halt Protease and Phosphatase Inhibitors had been added (1X final
concentration). The protein concentration was measured by performing a micro BCA
assay per manufacturer protocol (Pierce/Thermofisher), and concentration was adjusted
to10 µg/µl using additional Lysis Buffer with inhibitors. Lysates were packaged in
parafilm-secured microcentrifuge tubes and shipped on dry ice overnight to the Full
Moon Biosytems Facility in California, USA, to the attention of Dr. Yaping Zong, who
graciously performed the next steps of the assay in his laboratory, where conditions and
equipment are optimized for the processing.
Proteins were labeled in Labeling Buffer, using the Biotin/Dimethylformamide,
both reagents from the Antibody Array kit, with a 2-hour incubation at room temperature.
Stop Reagent (from the kit) was added and the mix was incubated an additional 30
minutes at room temperature, with mixing. Full Moon Biosystems Cell Cycle Control
Phospho Antibody Array (PCC238) Slides were submerged in Blocking Buffer (from the
kit) and shaken 40 minutes at room temperature. After rinsing the slides with Milli-Q
grade water, they were incubated in the Coupling Chamber (from the kit) with 85 µg of
labeled protein sample in 6 ml Coupling Solution (from the kit) on an orbital shaker for 2
hours at room temperature. Slides were removed from the coupling chamber and
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washed 3 times with fresh Wash Buffer then rinsed extensively with deionized (DI)
water. For detection, each slide was submerged in 30 ml of Cy3-Streptavidin solution (5
µg/ml), and incubated on an orbital shaker for 45 minutes at room temperature in the
dark. Slides were then washed 3 times with fresh Wash Buffer and rinsed extensively
with DI water, then dried with compressed nitrogen before scanning on the Axon
GenePix Array Scanner. PANDA software was used for analysis.

Peptidyl Prolyl Isomerase (Pin1) Inhibition with Juglone
Juglone, a chemical derived from the Black Walnut, has been shown to
specifically and irreversibly inhibit the prolyl isomerization/rotamase activity of
mammalian/human Pin1, Ess1 in yeast, or parvulin in E. coli. Cells were treated with 515 µM Juglone for 72 hours, as previously described115.

Lamin A Multi-Isoform Motif Analysis
The publicly available online databases Human Protein Reference Database
(HPRD, www.HPRD.org), Phospho.ELM Database (http://elm.eu.org/)116 and
PhosphoSite (www.Phosphosite.org)117-119 were used to survey the LA protein
sequence (with a focus on the PreA C-Terminal 66-Amino Acid Residue Fragment), for
sites known to be substrates of indicated kinases or binding sites of indicated proteins,
or sites known to, in similar context, act as substrates or bind the proteins. The sites
were queried, cross-referenced among each other and among published scientific
literature. HPRD is a compendium of annotated motifs for which curated literature is
cross-referenced to support the indicated interactions with the recognized motifs 120.
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The Phosphosite website is also a curated database of protein phosphorylation
information that was valuable. While curated data are maintained in the Phospho.ELM
Database, this database also generates predictive interaction information 116.
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CHAPTER 3
RESULTS
PreA Expression is Detected in Cell Cycle Arrest
PreA expression is not readily detected in proliferating cells but can be induced
by conditions that stimulate cell cycle exit, as in quiescence induced by serum
starvation, contact inhibition, or as in senescence by passaging cultured cells to high
population doublings. Ukekawa and associates described a dramatic increase in PreA
expression in cells induced to enter senescence and postulated PreA might cause cells
to become senescent in response to a disruption of interaction of chromatin, pRb, or
other molecules with mature LA121. The Kennedy group found short-term
overexpression of PreA to reduce cellular proliferation, while they associated long-term
overexpression with delayed entry to senescence103. Additionally, Ragnauth et al.
recently suggested PreA expression occurred prior to vascular smooth muscle cells’
arrival at senescence, under inducing conditions, and furthermore, this expression
accelerated entry to senescence122. To investigate whether PreA expression is directly
related to quiescence, as well, we first address the question of whether PreA expression
appears to be a side effect or cause of quiescence. Initially, we demonstrated PreA
expression when cells are induced to enter quiescence by serum starvation. In Figure
4, immunoblotting of lysates collected from HeLa cells at 24 and 48 hours after removal
of serum from the culture reveal increasing accumulation of PreA. Detection of this
expression in serum starved cells is in contrast to the absence of detectable PreA in
lysates from proliferating cells maintained in full serum. The levels of mLA are
consistent, with a minimal degree of decreasing expression as the precursor
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accumulates rather than contributing to the continuing supply of processed lamin.
Panel A: Western Blot

-Prelamin A
-Lamin A
-Lamin C

Panel B: Serum Starved Cells

Panel C: Proliferating Cells

Figure 4. Accumulation of Prelamin A as Cells Enter Quiescence. Panel A: Western
Blot of lysates from proliferating HeLa cells in full serum (+FBS), 24 hours and 48 hours
after removal of serum (-FBS), using a PreA C-terminus specific antibody (Top blot
panel), and an antibody that detects multiple LA isoforms (Lower blot panel). Immunofluorescence using the PreA C-terminus antibody in 48-hour serum starved BJ (human
foreskin) fibroblasts (Panel B), and full serum (Panel C).

In Figure 4, the smaller A-type lamin isoform, Lamin C, is demonstrated as a
band below the mature LA (mLA) band. PreA presents as an additional band situated
above the mLA band, present in the –FBS lanes only, with increased accumulation
evident at 48 hours compared to 24 hours of serum starvation. Immunofluorescence
using the PreA c-terminus antibody demonstrates PreA accumulation in the nuclei of
serum-starved BJ fibroblasts that is completely absent from the proliferating cells in full
serum.
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Accumulated PreA is Farnesylated and Carboxymethylated
As mitogen deprivation and contact inhibition are able induce quiescence and
PreA accumulation, and FTI-treATMent of cells also causes quiescence and
accumulation of PreA, we asked the question if mitogen deprivation or contact inhibition,
then, might interfere with the enzyme-mediated modifications that trigger proteolytic
cleavage of PreA? We subjected lysates isolated from serum-starved or contactinhibited, quiescent cells to analysis by mass spectrometry (Figure 5).

Figure 5. Mass Spectrometry Analysis Reveals Accumulated Prelamin A is FarnesylCarboxymethylated (FC’d). A Mass Spectrometry Trace of Serum-starved BJ
demonstrates the presence of FC-PreA (arrow), Left Panel. The graphic in the right
panel compares the ratio of FC-PreA in proliferating BJ Fibroblasts, to that in RD
Fibroblasts (Zmpste24-null or -deficient) which accumulate PreA. Lamin B is
permanently FC’d.

As shown in Figure 5, Mass Spectrometry demonstrates accumulated PreA in
serum starved or Zmpste24-deficient cells is farnesylated and carboxy-methylated. The
farnesylated-carboxymethylated status of PreA in these cells indicates that
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accumulating PreA has undergone FC-processing. This means the posttranslational
enzymatic processing system that prepares PreA for the Zmpste24-specific cleavage is
intact in these cells. Therefore, the accumulation of PreA seen in serum-deprived,
quiescent cells is not due to lack of FT or ICMT activity.

Zmpste24 Expression Level Does Not Parallel Activity Level in Quiescent Cells
As we demonstrated, the enzymatic modification pathway that prepares the PreA
substrate for proteolytic processing remains intact in quiescent cells, yet Zmpste24
proteolysis fails to occur. We reasoned, therefore, some direct inhibition of the
Zmpste24 protease must occur. To investigate if Zmpste24 activity is hindered in
conditions that induce quiescence, such as serum starvation, we assayed Zmpste24
activity in proliferating cells and serum starved cells, as they progress toward
quiescence. We used a fluorescently-tagged synthetic substrate to measure Zmpste24
activity, and radioactively labeled thymidine to simultaneously measure cell proliferation
(Figure 6). Measurement of the fluorescence level produced by cleavage-fluorophore
activation serves to indicate the level of Zmpste24 activity in the lysates, while the level
of retained radioactivity indicates rate of proliferation of the cells.
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Zmpste24 Activity (pmol/mg protein)

Thymidine Incorporation (dpm/mg protein)

B.
Zmpste24 Activity (pmol/mg protein)

Thymidine Incorporation (dpm/mg protein)

A.

Figure 6. Zmpste24 Activity Decreases Parallel to the Rate of Cellular Proliferation as
Serum Starvation Induces Quiescence. Cells were incubated with 3H-Thymidine for 30
minutes prior to collection of lysates. In Panel A, lysates were collected at the time of
serum removal (0 h), and at 4-hour increments over a 32-hour serum deprivation time
course. Scintillation counting measured the radioactive nucleotide in the lysate, which
indicates the rate of DNA synthesis in the cells assayed, and thus the rate of cellular
proliferation (dpm/mg protein,Y1-axis, left). Lysates from the same timepoints were
incubated with a fluorophore-conjugated synthetic peptide substrate, homologous to the
PreA cleavage site. Zmpste24 cleavage exposes the fluorophore, allowing measurable
fluorescence emission. Cleaved substrate was measured in proportion to the input
substrate to indicate the level of Zmpste24 activity in the lysates (pmol/mg protein, Y2axis, right). In Panel B, following quiescence, cellular proliferation and Zmpste24
activity are measured upon return of serum to the cultures. Timepoints are shown on
the X-axis.
Clearly, the rate of substrate cleavage declines in parallel to the rate of DNA
synthesis, indicating Zmpste24 activity is decreased in quiescent cells and correlates
with the accumulating levels of PreA we previously demonstrated. When serum was
returned to these cells, proliferation was stimulated, and a concurrent spike in Zmpste24
activity is observed. Proliferation and Zmpste24 activity then gradually decrease as the
dividing cells progress toward contact-inhibition-induced quiescence.
Next, we asked whether the mitigation of Zmpste24 activity in quiescence is
related to a decreased level of expression of the endoprotease. While it was previously
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noted that PreA expression in senescence was accompanied by a decreased
expression level of Zmpste24 mRNA121, it is important to note the transcript was
measured after 3 days of senescence induction, and that senescence and quiescence
might not, necessarily, follow the same paths. Also, as we found the enzymatic activity
level was significantly abolished in less than 10 hours following removal of serum and
had reached a state of virtual inactivity within approximately 30 hours, we were
interested to measure the expression level of Zmpste24 during the first 2 days after
serum removal, as well.
As shown in Figure 7, we measured expression levels of Zmpste24 protein and
mRNA transcripts in proliferating cells in full serum culture conditions (10% FBS), and
daily during a quiescence-inducing 5-day course of serum starvation (0.5% FBS).
Figure 7. Zmpste24
Expression and Proteolytic
Activity Do Not Decrease
at the Same Rate with
Induction of Quiescence.
Western blot (Panel A)
using anti-Zmpste24
antibody on lysates
collected from proliferating
cells in full serum, and at
24-hour timepoints for 5
days after removal of
serum from cultures (AntiHsp90 loading control).
Northern blotting of RNA
collected at the same
timepoints, was performed
with a Zmpste24-directed
oligonucleotide probe
(Panel B, anti-Actin-probe
loading control).
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The Western blotting with a Zmpste24 antibody revealed a decrease in the
expression of Zmpste24 protein after approximately 3 days of serum starvation (Panel
A), while Northern blotting demonstrates the level of Zmpste24 mRNA is diminished
after 2 days (Panel B). Both findings are consistent with the previous study121.
Importantly, however, neither the Zmpste24protein nor transcript levels decrease during
the initial 24 hours of serum starvation, in contrast to enzymatic activity that dropped
sharply (by at least 60%) within 10 hours. After 48-hours of serum deprivation, the
Zmpste24 protein level is unchanged, and although the level of transcript is decreased
compared to the full serum- or 24-hour timepoints, a significant quantity of RNA
remains, findings that are incongruous with the lack of activity of the enzyme observed
within approximately 30 hours of serum removal. In fact, both transcript and protein
levels persist at significant, though progressively decreasing, levels for the entire 5 days
of serum starvation. Taken together these results demonstrate the expression of
Zmpste24 is not significantly decreased in a mode parallel to quiescence-associated
accumulation of PreA, suggesting a posttranslational mode of Zmpste24 regulation is
likely. Given the tendency of cell cycle regulated proteins to be controlled by
phosphorylation, and the presence of several kinase substrate motifs within the amino
acid sequence of Zmpste24, indicated by Phosphosite117-119, Phospho.ELM116, and
HPRD120,123-125 databases, phosphorylation seems an obvious likelihood for this
regulatory mechanism. This prediction is supported by evidence that at least one
residue, Ser-310, undergoes cell-cycle-related phosphorylation, specifically in
mitosis126. Further studies will reveal if phosphorylation is, indeed, the mechanism
controlling Zmpste24 activity, and if so, which residues and kinases are involved.
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Overexpression of Zmpste24 Leads to Bypass of Quiescence
Our results indicate PreA accumulation upon stimulation of quiescence
corresponds to a decrease in Zmpste24 activity and not directly to a decreased
Zmpste24 expression level. However, in diseases in which Zmpste 24 expression is
deficient or otherwise inhibited, cells also chronically accumulate PreA. We asked
whether, as the reverse, overexpression of Zmpste24 protein may serve to provide
sufficient excess of Zmpste24 to overwhelm the activity-limiting mechanism(s) that
appear to be initiated upon quiescence-inducing stimuli. If so, we could test whether
prevention of PreA accumulation has an effect on cell cycle progression. We used
transient transfection of WI-38 human diploid fibroblast cells with a vector expressing
the Zmpste24 endoprotease (pCMV6-XL-Zmpste24) to demonstrate effects of
Zmpste24 overexpression. Zmpste24 expression was verified by Western Blot (data
not shown). Transfected cells and mock-transfected control cells (empty vector) plated
at high- or low-density were treated with BrdU to measure cell proliferation. Detection of
BrdU foci in treated cells by fluorescence microscopy indicates active proliferation. High
density plating normally induces quiescence. Figure 8 reveals WI-38 cells expressing
exogenous Zmpste24 continue to proliferate despite high density plating conditions,
apparently bypassing cell cycle arrest. These results suggest the cells may be unable
to arrest in the absence of accumulated PreA.
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Panel A (DAPI)

Panel B (Anti-BrdU/FITC)

Figure 8. Zmpste24-Overexpressing Cells Bypass Cell Cycle Exit Under QuiescenceInducing Conditions. WI-38 human diploid fibroblasts were plated on glass coverslips at
low density (upper panels), or high density (lower panels), transiently transfected with
Zmpste24 expression vector (right panels), or left untransfected (left panels), incubated
for different timepoints, BrdU pulse labeled (30 min). Anti-BrdU-FITC left panels),
incubated for different timepoints, BrdU pulse labeled (30 min). Anti-BrdU-FITC foci
highlight replicating cells, nuclei are DAPI stained. Panels A (DAPI) and B (anti-BrdUFITC) are from the timepoint at 48-hours posttransfection.

Figure 9 plots time after Zmpste24 transient transfection against the percentage
of cells containing BrdU foci. These experiments suggest quiescence-inducing
treatments lead to accumulation of PreA protein that is dependent on Zmpste24 activity
level, but not on normally-limited Zmpste24 expression levels. Additionally, when
Zmpste24 is exogenously overexpressed, we observe cells’ failure to arrest as usual,
also suggesting that preventing PreA accumulation prevents cell cycle arrest. Taken
together, these findings support the suggestion that PreA accumulation is necessary for
cell cycle exit, indicating it to be a cause of cell cycle exit rather than a byproduct.
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Figure 9. Cells Overexpressing Zmpste24 Bypass Quiescence. Graphic demonstrates
failure of Zmpste24-overexpressing cells to properly quiesce when exposed to high
density cell plating conditions that otherwise cause a drastic contact-inhibition-mediated
decrease in proliferation. Proportions of BrdU-foci-containing cells in untransfected cells
at low density (red circles) and high density (red triangles), to Zmpste24-transfected
cells at low density (blue circles) and high density (blue triangles).

Development of an Uncleavable PreA Expression Construct
We reasoned if preventing accumulation of endogenous PreA prevents cell cycle
exit, then overexpression of PreA might induce cell cycle exit and would offer further
evidence that PreA accumulation induces cell cycle exit. Progression through the
mitotic cell cycle is governed by a complex program regulating gene expression 127-129
and by many posttranslational modifications126,130,131. Therefore, a PreA-mediated role
controlling cell cycle arrest would require PreA protein expression to alter the
expression pattern of genes involved in cell cycle control. To investigate, we used sitedirected mutagenesis to mutate the Zmpste24 cleavage site in the LMNA cDNA
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sequence in a green fluorescent protein-tagged recombinant vector-based expression
system, thus generating a full-length PreA protein that is unable to undergo the final
maturation cleavage to form mature Lamin A. The construct, pEGFP-C3-EGFP-LMNAL647R, produces an EGFP-tagged protein termed “L647R PreA,” in which the CaaXbox is intact, so the farnesyl modification, -aaX cleavage and carboxyl methylation can
occur as for Wild-Type PreA.

Effects of Accumulated PreA on Global Gene Expression by Microarray Analysis
To examine effects of PreA expression on functional gene pathways, we first
assayed for effects on global gene expression. We transiently transfected mouse 3T3
cells with either the EGFP-L647R PreA- expressing construct or the pEGFP-C3 empty
vector, which expresses EGFP alone, and isolated total RNA from these cells 48 hours
after transfection. We elected to use the EGFP-expressing vector as a control for
comparison because a model over-expressing “wild-type” (unmutated) LA can quickly
become an expression system for PreA, instead, once available Zmpste24 in the cells is
exhausted from processing the exogenous protein. From the total RNA, cDNA was
prepared and used to interrogate mouse whole genome-scale transcript microarrays
(Affymetrix). We note results indicating altered expression levels on the microarray for
the cyclin dependent kinase inhibitors (CKIs) p16INK4A, p19ARF, p21Waf1, and
p27Kip1, all of which demonstrate upregulated transcript expression levels in L647R
PreA-expressing cells (each upregulated approximately 1.5- to 2-fold). Also, Cdc25A,
CDK2, and c-Myc, genes associated with promotion of proliferation, each demonstrate
decreased transcript expression levels (approximately -2-fold). Rather than making an
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attempt to study individual genes that demonstrate altered regulation with L647R PreA
expression in the cells, we chose to first evaluate the microarray data in terms of likely
functional roles and affected pathways for gene expression changes, then narrow the
scope in subsequent investigations.

Ingenuity Pathways™ Analysis: Physiological Function Analysis
Ingenuity Pathways Analysis™,132 software was used to interpret the impact on
gene expression in the context of cellular functions in “Functional Analysis” (Figure 10).
In this analysis, changes in gene expression related to particular cellular functions or
disease conditions indicate which of these cellular functions experience the most
statistically significant impact from L647R PreA expression, compared to EGFP
expression.
The functional analysis indicates expression of L647R PreA affects cell cycle, cell
growth and differentiation, cell death, and numerous metabolic processes and disease
states that would be largely impacted by altered cell cycle regulation. Aside from the
distinct cell-cycle regulation pathways, an impact on cell cycle regulation could indirectly
impact several of the other functional processes found to be affected by expression of
L647R PreA, but the implications may be less obvious. For instance, genes involved in
“Organismal Injury” or “Cellular and Tissue Development” would certainly be affected by
altered control of the cell cycle, as these are pathways involving cell proliferation, cell
death and turnover, and tissue repair or regeneration. Loss of LA has been previously
shown to be associated with disease recurrence in colon cancer133, and it is not unlikely
that potential roles in apoptosis, cellular proliferation, and growth would implicate PreA
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expression in other Gastrointestinal Diseases, Reproductive System Diseases, or
Responses to Infection or Inflammation. Modes of Cellular Signaling could affect, and
be affected by, any factor that would affect cell cycle regulation, as well as the obvious
role the nuclear lamina would play in maintaining nuclear pore complexes and overall
nuclear structure and integrity.
Biological Function

p-value

-Log (p-value)

Biological Function

p-Value

-Log (p-Value)

Cancer

3.24E-16

15.49

Gastrointestinal Disease

8.94E-12

11.05

Genetic Disorder

3.63E-11

10.44

Cellular Growth and Proliferation

2.72E-09

8.57

Cell Cycle

1.09E-08

7.96

DNA Replication and Repair

6.69E-08

7.17

Cell Death

4.81E-07

6.32

Reproductive System Disease

2.21E-06

5.66

Cellular Movement

3.53E-06

5.45

Immune Cell Trafficking

2.18E-05

4.66

Cell-To-Cell Signaling and Interaction

2.33E-05

4.63

Tissue Development

2.33E-05

4.63

Cellular Development

2.61E-05

4.58

Skeletal and Muscular System Development and Function

3.92E-05

4.41

Nervous System Development and Function

4.12E-05

4.39

Organismal Injury and Abnormalities

4.35E-05

4.36

Infectious Disease

7.12E-05

4.15
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7.67E-05
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7.67E-05
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Figure 10. Ingenuity Pathways Analysis™ “Functional Analysis.” Shows the 22 most
statistically significant gene expression changes induced by transient L647R PreA
expression in 3T3 cells, in the context of cellular functions and diseases, as compared
to levels in EGFP-expressing cells. Analysis used data from a mouse whole genomescale transcript assay (Affymetrix). Genes with altered expression levels were
compared and grouped by function according to the Ingenuity Knowledge Base. A
Right-tailed Fisher’s exact test was used to calculate a p-value (converted to –Log of
the p-value).
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Ingenuity Pathways™ Analysis: Canonical Pathways Analysis
Pathways of gene expression influenced by expression of L647R PreA were
evaluated for pathway-relevance by the “Canonical Pathways Analysis.” (Table 1,
Figures 11-12). This analysis associated the genes in the dataset having altered
expression with known canonical pathways in the IngenuityTM Knowledge Base. The
significance of the association between the data set and the canonical pathway was
measured in 2 ways: 1) a ratio of the number of genes from the data set that map to the
pathway divided by the total number of genes that map to the canonical pathway, and 2)
Fisher’s exact test was used to calculate a p-value determining the probability that the
association between the genes in the dataset and the canonical pathway is explained
by chance alone. Table 1 lists the 21 canonical pathways that demonstrate statistically
significant changes in gene expression in L647R PreA-expressing cells, versus those
expressing EGFP alone.
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Table 1. The Canonical Pathway AnalysisTM
Ingenuity™ Canonical
Gene Pathway

-Log (pValue)

Overall
FoldChange
Pathway
Gene
Expression

CCNE1, CCNE2, CCNA2, CDKN1A, CHEK1, NR2F1,
GSTT1, FOS, RARA, TGFB2, DHFR, GSTO2, ALDH3A1,
ALDH6A1, MGST1, MCM7, P300, RB, SUMO, AHR,
ARNT, AIP, MYC, SP1, ESR, NFKB
GSTT1, MGST1, TRHDE, IDH3A, GSTO2, GSS, ANPEP,
GSTT3, IDH1
PTX3, TLR2, IFIH1, TLR1, IRF7, C3, DDX58, TLR6,
CCL5, TLR3
NNMT, DAPK1, ENPP1, NEK2, SGK1, ENPP5, AOX1,
TTK, CDC2, AOX3
SMARCA2, CDKN1A, SLC19A1, RFC5, STAT1, CHEK1,
RFC3
STAT2, IRF9, IFNAR2, STAT1, TAP1
LIPA, ADH7, ALDH1A7, ADH1C, ALDH3A1, ACAA2
TYMS, PRIM1, NME1, POLR2D, APOBEC1, DCK,
DPYSL3, RFC5, UMPS, RRM1, NME3, TK1, RFC3
CCNE2, CCNE1, PA2G4, SUV39H1, CDKN1A, CDKN1B,
CDKN2A,TGFB2, HDAC9, MYC, CDK2, CDC25A
RRAS, CISH, CDKN1A, SOCS2, SOCS6, STAT2, STAT1
IL18, TIFA, DDIT3, DUSP1, TGFB2, MEF2C, STAT1,
FAS, PLA2G4C
ALDH1A7, MCEE, AOX1, ALDH3A1, ACAA2,
ALDH6A1, AOX3
GSTT1, ADH7, MGST1, AKR1C3, ADH1C, CYP2J2,
CYP2J9, GSTO2, ALDH3A1, GSTT3, EPHX1

Aryl Hydrocarbon Receptor
Signaling
3.72E00

-3.28

3.01E00

-3.46

2.82E00

-3.13

2.39E00

-3.69

2.36E00
2.27E00
2.19E00

-2.89
-2.54
-4.01

2.11E00

-4.13

2.09E00
1.89E00

-3.07
-3.20

1.83E00

-3.40

1.82E00

-3.93

1.78E00

-4.25

1.75E00

-3.38

1.72E00
1.67E00

-3.46
-2.91

1.56E00

-3.48

1.56E00
1.39E00
1.37E00

-4.18
-3.51
-3.81

DHX58, IFIH1, IRF7, DDX58, STAT2, IRF9, STAT1
CCNE2, CCNE1, FZD4, CDC6, FZD3, TGFB2, MEF2C,
FZD7
FUCA2, MAN2B2, GM2A, HEXB
PRKDC, TP53INP1, SNAI2, CDKN1A, HDAC9, BIRC5,
CHEK1, SERPINE2
NAGA, LIPA, ADH7, ALDH1A7, LPL, ADH1C, LIPG,
ALDH3A1
SPP1, IL1RL1, CDKN1A, TGFB2, HES1, VDR, CCL5
PTGIR, AKR1C3, PLA2R1, PTGS2, WISP2, PTGER4

1.32E00

-3.43

TLR2, TLR1, FOS, TLR6, TLR3

Glutathione Metabolism
Bacteria/Virus Pattern
Recognition Receptors
Nicotinate and
Nicotinamide Metabolism
BRCA1DNA Damage
Response
Interferon Signaling
Bile Acid Biosynthesis
Pyrimidine Metabolism
Cell Cycle: G1/S
Checkpoint Regulation
JAK/Stat Signaling
p38 MAPK Signaling
Valine, Leucine and
Isoleucine Degradation
Metabolism of Xenobiotics
by Cytochrome P450
IRF Activation by
Cytosolic Pattern
Recognition Receptors
Factors Promoting
Cardiogenesis in Vertebrates
N-Glycan Degradation
p53 Signaling
Glycerolipid Metabolism
VDR/RXR Activation
Eicosanoid Signaling
Toll-like Receptor
Signaling

Genes in Pathway

Similar to the Functional Analysis, results of analyzing the canonical pathways
affected by expression of L647R PreA indicate an effect on cell cycle regulation. While
other pathways not clearly related to cell cycle regulation are indicated, we have
concentrated further analysis of results on those functional pathways with a clear
relationship to cell cycle control, as investigation of the cell cycle regulatory role of PreA
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is the focus of this study. Some genes show overlap among pathways, such as the cell
cycle inhibitory kinase, Chk1, and the cyclin dependent kinase inhibitor CDKN1A (also
known as p21WAF1). Figure 11 shows the statistical significance of L647R PreA
expression effects on gene expression within cell cycle-related pathways, versus EGFP
expression. Those pathways containing the highest proportion of genes demonstrating
effects on expression are considered to be the most significant pathways for this
analysis. Level of expression changes of the implicated genes is not factored into this
part of the analysis.

Aryl Hydrocarbon Receptor Signaling
3.72

Role of BRCA1 in DNA Damage
Response

2.36

Cell Cycle: G1/S Checkpoint Regulation

2.09

JAK/Stat Signaling

1.89
1.83

p38 MAPK Signaling

1.56

p53 Signaling

1.32

Toll-like Receptor Signaling

0

1

2

3

4

-Log (P-value)

Figure 11. Ingenuity Pathways AnalysisTM Pathways Demonstrating Statistically
Significant Gene Expression Regulation. Analysis of expression data from Affymetrix
microarray indicates Cell Cycle-Related Pathways of Gene Expression that are affected
by L647R PreA expression with statistical significance. Significance is determined by
dividing the total number of genes in the pathway by the number of genes in the
pathway with changed expression in cells expressing L647R PreA versus EGFP,
Fisher’s exact test was used to calculate p-value (converted to –Log of the p-value).
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Surprisingly, the AHR Pathway was determined to be the most statistically
significantly regulated gene expression pathway in L647R PreA-expressing cells
compared to cells expressing EGFP only. Not a well known factor in cell cycle
regulation, the AHR is a transcriptional regulator implicated in development and a
variety of physiological processes such as response to hypoxia, hormone receptor
function, and toxin metabolism134. As a number of compounds, including several toxic
chemicals, act as AHR ligands135, most literature involving this pathway is focused on
studies of toxin metabolism. Other studies, however, have also recently found AHR
contributes to the inhibition of cell cycle progression by directly interacting with the
RB/E2F complex to block its phosphorylation in G1136,137. This interaction constitutes a
major G1 checkpoint in cells exposed to AHR ligands138, and according to some
researchers, in the absence of ligand, as an elemental, though relatively little known,
mechanism of cell cycle control137. As for the BRCA1 Role in DNA Damage Response
pathway, the statistically significant indication of a role for L647R PreA expression is
consistent with previous studies indicating LA roles in DNA damage repair and
perturbation of the assembly of DNA damage repair response proteins in cells
expressing PreA69,139 [reviewed in 101]. Also, BRCA1 overexpression has been shown to
have an inhibitory effect on cell cycle progression and affect the expression of various
other cell cycle regulatory genes140. Thus, perhaps PreA-induced effects on gene
expression within this pathway may indicate it is a mechanism of PreA-related cell cycle
control, or that PreA expression is used as a mechanism to affect expression of other
cell cycle genes by the BRCA1-mediated DNA damage repair and cell cycle control
pathway.
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Significant regulation of the G1/S checkpoint and p53 signaling is an important,
and expected, indication from this data, and these pathways comprise an integral part of
our further investigation of the cell cycle regulatory roles of PreA. In fact, in another
type of evaluation of the L647R PreA effects on cell cycle-related gene pathways in the
Ingenuity Pathway AnalysisTM, we consider the magnitude of impact from L647R PreA
expression, compared to EGFP expression, on the expression levels of genes within the
indicated pathways, and we find p53 signaling to be most affected (Figure 12).
Whereas the previous measure counted statistical significance as the proportion of
genes within the pathways demonstrating any level of changed expression, this analysis
looks at the actual level of gene expression changes within the pathways, regardless of
the affected number of genes within that pathway.

Cell Cycle: G1/S
Checkpoint Regulation,
-3.07
Role of BRCA1 in DNA
Damage Response,
-2.89

-2.50

JAK/Stat Signaling,
- 3.20

-2.00

Aryl Hydrocarbon
Receptor Signaling,
-3.28

-1.50

Toll-like Receptor
Signaling,
- 3.43

-1.00

p38 MAPK Signaling,
-3.40

-0.50

p53 Signaling,
- 3.48

Expression Fold-Change vs. EGFP Control

0.00

-3.00

-3.50

Figure 12. Ingenuity Pathways AnalysisTM Pathways Demonstrating the Highest Level
of Impact from L647R PreA Expression. These pathways experienced the most altered
levels of gene expression when L647R PreA was expressed, compared to EGFP.
demonstrating statistical significance of effects from expression of L647R PreA.
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As shown in Figure 12, the genes involved with or affected by p53 signaling
experience the most change in expression levels when L647R PreA is expressed
compared to levels in the EGFP-expressing cells. A similar level of gene expression
downregulation is indicated for genes related to Toll-Like Receptor Signaling, p38MAPK
signaling, the Aryl Hydrocarbon Receptor Pathway, JAK/Stat signaling, G1/S checkpoint
regulation, and the BRCA1-DNA damage response.

Ingenuity Pathways™ Analysis: Integrated Pathway Network Analysis
As a form of integrated analysis of overlapping gene expression pathways, the
patterns of regulated gene expression specifically indicated in our test system were
considered by Ingenuity Pathways Analysis™ to generate the “Networks and Pathways”
analyses (Figures 13-16). These analyses generated a series of “GeneNetworks” by
comparing gene expression in cells expressing L647R PreA compared to cells
expressing EGFP (48 hours posttransfection), and overlaying the altered genes onto a
global molecular network developed from information contained in the Ingenuity
Knowledge Base. Networks were then algorithmically generated based on their
connectivity. Graphical representations of relationships between molecules were
produced, each relationship indicated is supported by at least one reference from the
literature or from canonical information stored in the Ingenuity Knowledge Base. Each
gene occupying a position within a Network is called a “node.” The intensity of the node
color in the figures indicates the degree of regulation. Also, included in the graphics are
assayed gene products not demonstrating a statistically significant expression change,
and genes not assayed but related to the assayed genes according to the IPA
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Knowledge Base. Nodes are displayed using various shapes that represent the
functional class of the gene product. Edges (connecting lines) are displayed with
various labels describing the nature of the node relationships (e.g., P for
phosphorylation, T for transcription).

Figure 13. Ingenuity Pathways Analysis™ GeneNetwork1(with L647R PreA
Expression): G1/S Checkpoint Regulation Part 1. Generated from gene expression
change data in L647R PreA expressing cells vs. EGFP-expressing cells.
Green=downregulated/ Red=upregulated/ Gray=not regulated/ No color=not assayed,
but related to assayed genes.
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Figure 14. Ingenuity Pathways Analysis™ GeneNetwork 2(with L647R PreA
Expression): G1/S Checkpoint Regulation Part 2. Network generated from gene
expression change data in L647R PreA expressing cells vs. EGFP-expressing cells.
Green=downregulated gene expression/ Red=upregulated gene expression/ Gray=no
change/ No color=not assayed, but related to assayed genes.
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Extracellular Environment

Cytoplasm

Nucleus

Figure 15. Ingenuity Pathways Analysis™ GeneNetwork 3 (with L647R PreA
Expression): p53 Signaling Regulation. Generated from gene expression change data in
L647R PreA expressing cells vs. EGFP-expressing cells. Green=downregulated gene
expression/ Red=upregulated gene expression/ Gray=no change/ No color=not
assayed, but related to assayed genes.
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Figure 16. Ingenuity Pathways
Analysis™ GeneNetwork 4 (with L647R
PreAExpression): AHR-RB-p300
Control of E2F Transcription. Adapted
from Gene Network generated by IPA
analysis of gene expression changes in
L647R PreA expressing 3T3 cells (48
hours post-transfection), compared to
those expressing EGFP. Figure
enhanced to reflect AHR ability to
displace p300 from E2F promoters, thus
inhibiting E2F-regulated gene
transcription, and AHR role enhancing
RB inhibitory effects.
Green=downregulated gene
expression/Red=upregulated gene
expression. No color=not assayed, but
related to assayed genes. Red dashed
line=enhances activity.
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Development of a Model System of Inducible, Stable
Lamin Isoform Expression Cell Lines

While the pathway-focused gene expression analysis of cells transiently
transfected to express L647R PreA demonstrated a significant level of impact on gene
expression in several cell cycle-related gene expression pathways, including the p53
signaling pathway, the AHR pathway, the G1/S cell cycle checkpoint, BRCA1-mediated
DNA damage repair pathway, and signaling within Jak/Stat, p38 MAPK, and Toll-Like
Receptor Pathways, an acknowledged limitation of the transient transfection is the likely
dilution of effects of subtle changes in gene expression, as transfection efficiency does
not approach 100%. To further distill the cell cycle-specific gene expression effects of
L647R PreA, generated a stable system of inducible expression cell lines. To do this,
we transferred the N-terminally EGFP-fused LMNA-L647R cDNA cassette to the
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RheoSwitch Mammalian Inducible Expression System (New England Biolabs, MA), for
construction of a stable cell line. This is a dual vector switch system in which the target
cells are cotransfected with 2 plasmids, one that requires an induction reagent to
express a ligand, this ligand is required to activate target gene expression from the
second plasmid141-144.

ON

OFF
RheoReceptor (RR)

RheoReceptor (RR)

RheoActivator (RA)

pNEBR-R1 plasmid

RheoActivator (RA)

pNEBR-R1 plasmid
RSL1/GenoStat

Basal Transcription
Complex
Basal Transcription
Complex

5X RE

RR
pNEBR-X1-Hygro plasmid

5X RE
RA
RR
pNEBR-X1-Hygro plasmid

Gene of Interest

Gene of Interest

Figure 17. The RheoSwitch® Mammalian Dual Vector Inducible Expression System.
Dual vectors are transfected into the target cell, where the ligand is expressed by the
pNEBR-R1 plasmid when induction reagent (RSL1 or GenoStat brands of synthetic
diacylhydrazine, in these experiments) is added to the culture medium. The expressed
ligand is necessary for target gene expression to occur from the pNEBR-X1Hygro
plasmid. (Adapted From New England Biolabs, Inc.)

The induction reagent, [N-(2-ethyl-3-methoxybenzoyl)-N´-(3,5-dimethylbenzoyl)N´-tert-butylhydrazine], is a synthetic diacylhydrazine. Diacylhydrazine is a nonsteroidal
analogue of the insect molting hormone, ecdysone114,145. The synthetic reagent (RSL1
from New England Biolabs, Inc., MA; or GenoStat from Millipore Corp., MA) has been
shown to be invisible to mammalian nuclear receptors and inert within all cell lines
tested141. The result is an expression system not affected by the sometimes “leaky”
expression of the target DNA seen in many inducible systems, as well as quick
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response of activating or deactivating expression by addition or removal, respectively, of
the induction reagent. After using restriction enzyme digestion to remove the EGFPLMNA-L647R cDNA sequence from the pEGFP-C3 plasmid, it was ligated into the
second plasmid in the RheoSwitch® pNEBR-X1Hygro vector, and the resulting
expression construct, pNEBR-X1Hygro-EGFP-LMNA-L647R was transfected into the
target cells. The cells used were mouse NIH3T3 fibroblast cells already containing the
ligand-expressing plasmid vector (pNEBR-R1). Retention of pNEBR-R1, which
contains a Neomycin resistance cassette, was maintained by supplementing the culture
medium with G418 antibiotic. Following transfection with the pNEBR-X1Hygro-EGFPLMNA-L647R plasmid vector, which contains a Hygromycin resistance cassette, cells
containing the second plasmid in addition to the first were selected by additionally
supplementing the G418-containing culture medium with Hygromycin. Twelve separate
cell colonies were selected and transferred to new culture vessels for propagation, and
after a sufficient number of cells were present, a sampling of these were transferred to
coverslip culture chambers in medium containing 500 nM GenoStat induction reagent.
After 24 hours of induction, cells were observed under fluorescence microscopy for
evaluation of EGFP-fused L647R PreA expression. The 3 colonies with cells
expressing the most EGFP-tagged protein were identified, and cultures of the other 9
cell colonies were discarded. The 3 colonies selected for further propagation were
evaluated for morphology, growth patterns, in addition to induction of EGFP-L647R
PreA. In the absence of induction reagent, the cell lines demonstrated normal
morphology resembling that of the cells prior to transfection, all 3 appeared to proliferate
at a rate within a range similar to the proliferation rate of the untransfected cells
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(empirical observations, not quantitatively measured), and upon induction all 3
expressed EGFP-tagged protein in a pattern consistent with documented PreA
expression62,146. Expression of some genes can be detected within 1 hour of induction
in the RheoSwitch® system, with maximal levels of expression at 48-72 hours, and
some dosage-effect can be obtained with different dose amounts of the induction
reagent. We were able to detect faint expression of some GFP-tagged protein after
approximately 4-hours, with maximal levels reached around 72 hours. The cell line that
consistently expressed a slightly more intense fluorescence of its EGFP-tagged protein
was selected for future experiments, and cells from the other 2 cultures were frozen and
maintained as back-up cell lines. We also used this system, and the same procedures,
to construct stable inducible cell lines expressing the wild type Lamin A sequence
(wtLA), a mutant Lamin A sequence (del50), and the EGFP protein alone. The wtLA
construct expresses the full length immature PreA protein, modified only by the Nterminal EGFP fusion, and undergoes the full maturation processing to yield LA, and
likely, though unconfirmed, alternative splicing to produce Lamin C. The del50 mutant
construct, with a deletion of 150 nucleotides near the C-terminus of the Lamin A coding
sequence, expresses a 50-amino acid-truncated protein that mimics the HGPS mutant
protein progerin. While expression of progerin in HGPS patients typically results from a
point mutation introducing a cryptic alternative splice site that leads to deletion of the
corresponding nucleotides from the processed RNA transcript, this methodology of
engineering the truncated protein by deleting nucleotides from the cDNA sequence is
commonly used by researchers and regarded to yield a mutant protein equivalent to
progerin60,147,148.
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To characterize the expression of the constructs from these cell lines, DNA was
extracted from the cells and sequenced with an EGFP primer and LA C-terminal primer
to confirm expression of the EGFP/lamin fusion-constructs. Also, the protein expression
patterns were evaluated by fluorescence microscopy detection of the GFP fused to the
lamins. In Figure 18, fluorescence microscopy images reveal the expected expression
pattern of the EGFP-fused L647R PreA protein, demonstrating GFP concentration at
the nuclear rim with amorphous-shaped aggregates in the nucleoplasm with an uneven
nuclear topography demonstrating ridges, invaginations, and some blebbing. Likewise,
expression patterns of GFP-fused LA and del50 were examined and found to match
expected patterns: LA presents as a smooth veil over and throughout rounded, oval, or
slightly bean shaped nuclei with smooth-appearing surface texture with a subtle
concentration of GFP at the nuclear rim. The del50 expression manifests as dramatic
intranuclear aggregate clumps and highly irregular nuclear membranes. These nuclei
present the same type of blebbing, ridges, and invaginations as the L647R PreAexpressing cells but on a more extreme scale. These patterns are consistent with all
known descriptions of these isoforms. Finally, EGFP-only expressing cells, the control
line, presents light green fluorescence throughout the cell that is not localized in the
nucleus.
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Figure 18. Evaluation of Induced Recombinant Protein Expression in the RheoSwitch®
Lamin Isoform-Construct Expression Model System (GFP). Fluorescence microscopy
(Top, L-R) demonstrates expression from the GFP-fused L647R-Lamin A (PreA) cell
line and GFP-Lamin A (LA), and (Bottom, L-R) demonstrates expression from the GFP
control cell line and the GFP-Lamin A-del50 cell line. Expression represented is after
48 hours induction with 500 nM Genostat.

In addition to the direct fluorescence detection of expression of the GFP- lamins,
we also further examined the induced expression in the L647R PreA cell line by indirect
immunofluorescence with an antibody to GFP, after imaging the direct GFP expression
(Figure 19).
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(Anti-GFP)

(GFP)

Figure 19. Immunostaining of
EGFP-L647R Lamin A (PreA),
with Antibody to GFP. This
imaging demonstrates indirect
immunofluorescence, and
enhanced microfluoroscopic
visualization of lamin
distribution after induction
(500 nM Genostat, 48 hours),
compared to detection of the
direct fluorescence emission
from the protein (inset). Cells
were plated on coverslips and
induced 48 hours to express
the protein (500 nM
Genostat). After imaging the
direct fluorescence of GFPconstruct expression, cells
were immunostained as
described for indirect
immunofluorescence
detection.

While the recombinant GFP-lamin expressed in the engineered cell lines
demonstrates the appropriate subcellular localization, to further evaluate the integrity of
the expressed proteins, we performed immunoblotting of lysates prepared from each
cell line to confirm the protein is reactive with an antibody specific for Lamin A/C as well
as anti-GFP. Reactivity of the same bands with both anti-Lamin A/C and anti-GFP, is
indicative of an expressed fusion protein (Figure 20).
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Figure 20. Immunoblotting of Expressed Lamin Isoforms Using the Rheoswitch
Inducible Expression System. Rheoswitch cells (Del50, L647R PreA, or wtLA) were
induced with 500 nM Genostat for 48 hours. L647R cells treated with equal volume of
DMSO were used for the uninduced control. A volume of each cell lysate to equal 50
µg total protein per lane was separated by SDS PAGE on two 4-12% gradient Bis Tris
Gels, in duplicate, and transferred to nitrocellulose membranes. One membrane was
immunoblotted with a Lamin A/C antibody (Panel A) and β-actin antibody, and the
second membrane was probed with anti-GFP antibody (Panel B), and Lamin B
antibody, as a loading control.

As it was critical that the isoform expressed by the L647R PreA cell line was the
uncleaved isoform, and that we were certain it is posttranslationally modified in the
same manner as endogenous protein (specifically, farnesylation and carboxymethylation), we also prepared lysates from the L647R PreA cells, induced for 48 hours
with 500 nM Genostat, for mass spectrometry analysis (Figure 21). The trace patterns
in the analysis indicate that the FC-PreA isoform is abundant in the L647R PreAexpressing cells (barely detectable in cycling cells not exogenously expressing it), while,
as we would expect, endogenous mLA is present in the cells, as well.
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Figure 21. Mass Spectrometry Demonstrates RheoSwitch® Model L647R PreA Recombinant Protein Expressed is FCPreA. Peak A represents a peptide fragment representative of unprocessed PreA, while Peak B specifically represents
Farnesylated, Carboxymethylated (FC) PreA. Peak C represents cleaved, mature LA.
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Effects of Uncleavable PreA (L647R PreA) Expression on Cell Cycle Progression
Using these stable cell lines, we further investigated the effects of PreA protein
accumulation on cell cycle progression. In support of our earlier suggestion that PreA
accumulation is a cause, rather than a byproduct, of cell cycle exit, we show cells
induced to express L647R PreA exhibit decreased proliferation. First, a -bromo-2’deoxyuridine (BrdU, a pyrimidine analogue)-uptake assay demonstrates cellular
proliferation by labeling newly synthesized DNA (Figure 22). Using 3T3 cells that do not
contain a lamin expression vector as controls, they, as well as cells from the
RheoSwitch L647R PreA cell line, were treated with various concentrations of the
induction reagent, GenoStat, or DMSO, for 48 hours before addition BrdU to the
medium to label cells undergoing active proliferation.
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Figure 22. Decreased Rate
of Cellular Prolifer-ation in
L647R PreA-Expressing
Cells (BrdU Incorporation
Assay). This assay
demonstrates L647R PreA
Expression inhibits cell
proliferation. 3T3 cells
(Squares) or L647R PreA
Rheoswitch cells (Triangles)
were treated with various
concentrations of GenoStat
inducer (filled symbols) or
DMSO (empty symbols) for
48 hours. BrdU (10 μM) was
added to the plate and cells
were incubated for 4 hours.
Incorporated BrdU was
detected by monoclonal antiBrdU antibody linked to
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HRP. HRP substrate TMB
was used to develop the
color (Absorbance: 450 nm).

Figure 22 also demonstrates repressed proliferation in L647R PreA-expressing
cells does not result simply due to toxicity of increasing GenoStat inducer dosage, per
the lack of effects on proliferation in the unmodified 3T3 cells (ie, 3T3 cells not
adulterated with recombinant DNA construct) treated with the same doses of GenoStat.
The lack of effects on proliferation in DMSO-treated cells ensures the effects on
GenoStat-treated RheoSwitch cells are due to induction of the expression system.
To further explore the effects of L647R PreA expression on cell cycle
progression, we used flow cytometry to assay DNA content as an indicator of cell cycle
phase. Cell cycle phase distribution analyses of asynchronously growing cells induced
to express L647R PreA were compared to uninduced (passage-matched, L647R PreA
construct-containing, DMSO-treated) cells under the same conditions. We also used Ki67 protein-staining as a final measure of cell proliferation in these cells. Ki-67 is a
nuclear protein associated with DNA replication and proliferation, though its exact role is
not well understood. Ki-67 protein expression is absent only in the G0 stage of the cell
cycle, and it is a commonly-used and widely available indicator of cellular proliferation.
We assayed for presence of the Ki-67 protein using immunofluorescence microscopy
and an antibody directed to the Ki-67 protein (Figure 23).
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Figure 23. Decreased Rate of Cellular Proliferation in L647R PreA-Expressing Cells
(Flow Cytometry and Ki67 Immunofluorescent Stain Assay). Flow cytometry analysis
reveals L647R PreA affects cell cycle progress. In Panel A, Flow cytometry was used
to measure propidium iodide (PI)-stained cellular DNA content to demonstrate cell cycle
phase, where 2N DNA content represents G0/G1 phase cells, 4N represents G2/M
phase cells, and S-phase cells are located between the 2N-G0/G1 and 4N-G2/M peaks.
Uninduced Cells (DMSO-treated) are shown in Left Panel, Induced L647R PreA Cells in
Center Panel, with a bar graph quantitative comparison in Panel A, far right. Panel B
shows Ki67 immunostaining of Uninduced Cells (Left), and Induced L647R Cells
(Right). Induction method: 500 nM GenoStat, 48 hours.

As expected, flow cytometry analysis reveals uninduced cells cultured in full
serum demonstrate normal proliferation, while, in comparison, a G0/G1 peak-shift
(representative of progression toward cell cycle arrest, and consistent with a developing
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quiescent phenotype) is seen in cells induced to express L647R PreA for 48 hours.
Ki67 protein is readily detected in uninduced cells but almost absent in the induced
cells, further indicating exit from the cell cycle. Taken together, results of the
proliferation assays by measurement of BrdU uptake, flow cytometry approximations of
cell cycle progress, and nuclear immunostaining for Ki67, suggest expression of L647R
PreA has an inhibitory effect on cell cycle progression.

Effects of Accumulated PreA on Cell Cycle
Pathway-Specific Gene Expression (by RT-qPCR Array)

To more specifically evaluate the effects of PreA expression on cell cycle specific
genes, we used cDNA derived by reverse transcription of total RNA extracted from cells
induced 72 hours to express L647R PreA in a quantitative real-time polymerase chain
reaction (RT-qPCR) assay of cell cycle related genes. For comparison, RheoSwitch
cells induced to express wtLA and del50 were also assayed. Uninduced cells
(passage-matched to their induced counterparts) from each cell line were used to
determine baseline expression of the assayed genes for each cell line. When results of
the gene expression assays on uninduced cells of each cell line were compared, there
were some modest differences in the expression profiles (data not shown). We attribute
these “baseline” expression differences in uninduced cells to clonal variation. The cell
lines were all created by transfection into cells from the same original host cell line, from
the same culture, and from within a few passages of the same culture. However, it is
common for subtle differences to arise in cells derived after the repeated passages
involved in clonal expansion of populations from single cell isolates of a common

107

culture. In addition to clonal variation, another possibility we considered to explain the
different baselines of gene expression among the uninduced L647R PreA cells and
wtLA cells is the difference in passage number, as the passage numbers were not
matched between cell lines (after the clonal expansion process and maintenance
passaging of working cultures). In future studies, matching of passages of compared
cells could provide more uniformity of cell line-to-cell line expression baselines, allowing
a more reliable comparison of the L647R PreA and wtLA cell lines. However, we do
acknowledge accumulation of endogenous LA occurs as PreA and note the likelihood
that the endoproteolytic processing capability of endogenous Zmpste24 could be quickly
overwhelmed by increasing accumulation of EGFP-wtLA protein. This would result in
the presence of some processed EGFP-wtLA, and some unprocessed EGFP-wtPreA.
Therefore, this model would become another model for overexpressing the PreA
isoform and would not suffice as a control for comparison to the L647R PreA-expressing
model. Future experiments might include a cell line containing a LA construct in which
the cDNA is modified to directly encode a truncated protein equivalent to a
posttranslationally modified mature LA protein. This model could allow a more accurate
comparison of effects of overexpressing a PreA isoform, represented by the L647R
PreA construct, to effects of overexpressing mLA isoform. Additionally, with replicates
in future experiments, it could be possible to determine if a ratio can be deconvolved for
“housekeeping” reference genes to allow meaningful comparison among all of the cell
lines. Regardless, for the purposes of the current study, we have chosen not to
compare the gene expression data from the induced cells to each other, as such
comparison could yield false exaggeration of differences in gene expression, or fail to
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detect subtle, but true, changes in expression of some genes. Rather, we simply
compare the expression profile of cell cycle-related genes in the cells induced to
express L647R PreA versus the uninduced (treated with DMSO vehicle only), passagematched cells split from the same culture, to determine expression level changes
related to the expression of the uncleavable lamin mutant.
Table 2 lists all genes demonstrating a fold-change in expression with statistical
significance, which we define here as having at least a 2-fold change in expression level
with a p-value </= 0.05 (-log p-value of >/= 1.3). A complete listing of all assayed genes
is presented as Appendix A, with a corollary Volcano Plot as Appendix B. For ease of
reference, this assay is referred to herein simply as “the RT-qPCR assay.” Also, for
simplification purposes, all gene references using the short-hand notations of
“upregulated,” or “downregulated,” mean the gene expression levels have the indicated
regulation as indicated by RT-qPCR assay of transcript levels for the gene in induced
L647R PreA-expressing cells (24-hours/500nM GenoStat) compared to the expression
levels in the passage-matched, DMSO-treated, uninduced control cells.
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Table 2. Cell Cycle-Related Genes Demonstrating Statistically Significant Altered
Expression in Response to L647R PreA Induction†
Gene
Fold
Symbol Regulation
Actb
14.8
Ak1
7.9
Apbb1
40.9
Atm
4.0
Brca1
19.4
Brca2
14.1
Camk2a
13.8
Camk2b
15.2
Casp3
4.5
Ccna1
6.2
Ccna2
4.5
Ccnb2
-2.1
Ccnc
10.0
Ccnd1
5.8
Ccne1
18.4
Cdk2
2.1
Cdk4
37.3
Cdk5rap1
9.0
Cdkn1a
6.3
Cdkn1b
23.2
Chek1
22.1
Ddit3
4.6
Dst
25.4
E2f1
6.4
E2f3
2.8
E2f4
9.6
Gapdh
3.8
Hus1
17.6
Inha
7.0
Itgb1
9.6

p-value
0.001826
0.007293
0.024349
0.000362
0.001086
0.000323
0.00348
0.000098
0.007064
0.043674
0.000071
0.035362
0.002486
0.003651
0.002771
0.000622
0.001031
0.000637
0.001935
0.000095
0.000703
0.000761
0.000002
0.00158
0.000833
0.00157
0.003657
0.000044
0.001369
0.000031

-Log
(pvalue)
2.74
2.14
1.61
3.44
2.96
3.49
2.46
4.01
2.15
1.36
4.15
1.45
2.60
2.44
2.56
3.21
2.99
3.20
2.71
4.02
3.15
3.12
5.70
2.80
3.08
2.80
2.44
4.36
2.86
4.51

Gene
Fold
-Log
Symbol Regulation p-value (pvalue)
Macf1
9.8
0.001208 2.92
Mad2l1
2.7
0.002314 2.64
Mcm2
17.7
0.003508 2.45
Mdm2
2.1
0.004183 2.38
Mre11a
6.3
0.000679 3.17
Mtbp
17.5
0.001469 2.83
Nek2
15.6
0.000507 3.29
Nfatc1
5.5
0.000785 3.11
Notch2
10.7
0.000094 4.03
Npm2
16.5
0.000513 3.29
Pkd1
4.6
0.000072 4.14
Ppm1d
4.3
0.003941 2.40
Ppp2r3a
20.5
0.001368 2.86
Ppp3ca
2.8
0.020588 1.69
Psmg2
3.0
0.00115
2.94
Rad9
5.4
0.002484 2.60
Rad21
2.4
0.000601 3.22
Rbl1 p107
11.5
0.000749 3.13
Rbl2 p130
2.5
0.011955 1.92
Sesn2
5.5
0.000701 3.15
Sfn
25.3
0.000532 3.27
Shc1
6.0
0.00036
3.44
Skp2
4.0
0.00511
2.29
Smc1a
19.5
0.000743 3.13
Stag1
2.4
0.001397 2.85
Taf10
2.5
0.004552 2.34
Terf1
3.4
0.000185 3.73
Tfdp1
2.8
0.001374 2.86
Trp53
2.8
0.000597 3.22
Wee1
24.9
0.000156 3.81

†

SABiosciences Cell Cycle Pathway specific RT-qPCR analysis results demonstrating expression
fold-change in total RNA isolated from RheoSwitch 3T3 cells induced 24 hours with 500 nM GenoStat
to express L647R PreA versus from uninduced control cells (DMSO-treated)
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The variety among genes demonstrating altered levels of transcript expression in
the L647R PreA expressing cells compared to the uninduced cells complicates
interpretation of the specific and direct PreA-interactions that lead to the overall effect of
PreA on cell cycle gene expression. Is it possible all of these gene products directly
bind or associate with PreA? While possible, the more likely explanation of the variety
is related to the very nature of cell cycle regulatory signaling, which occurs with
cascades of gene activation or repression among individual pathways, as well as
crosstalk with other pathways. In an effort to focus on particular gene-types in
evaluating the expression data from the qPCR assay, we used literature sources and
databases (GeneCards149 and Entrez Gene150) to categorize the data as follows: 1Cyclins, Cyclin Dependent Kinases, Cyclin Dependent Kinase Inhibitors; 2-Kinases and
Phosphatases; 3-Transcription Factor-Related Genes; 4-DNA Damage-Related Genes;
and 5-Genes Associated with Chromosomal/ Nuclear/Cellular Integrity or Microtubule/
Mitotic Assembly. To begin to unravel the direct effects of PreA expression on cellcycle related gene expression, we examined the expression profile in the context of the
known functions of affected genes.

Cyclins, Cyclin Dependent Kinases (CDKs), Cyclin Dependent Kinase Inhibitors (CKIs)
Cyclins are eukaryotic proteins that play an active role in controlling nuclear cell
division cycles151. In brief review: in vertebrates, there are 2 G2-phase cyclins, A and
B, and at least 3 G1 cyclins, C, D, and E152. It has been shown recently that, upon
mitogenic signaling, Cyclin C, in complex with CDK3, helps cells to exit the G0 state and
enter the G1 phase by stimulation of retinoblastoma protein (pRb) phosphorylation at
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S807/811153. From the G1 phase, Cyclin D complexes with CDK4/6 to begin the
phosphorylation of pRb that is complexed with the transcription factors E2F/DP.
Following pRb phosphorylation, cyclin E activates CDK2 to effect further
phosphorylation of pRb, thereby enabling the cells to cross the G1-restriction point. The
pRb-E2F/DP complex disassociates, providing a positive signal for DNA synthesis in the
S phase. Cyclin E is replaced by cyclin A, which binds to CDK2 and leads to
phosphorylation of DP-1 subunits (inhibitor of DNA binding), and CDC6 (initiator of DNA
replication) to complete DNA replication. On completion of the S phase, Cyclin B-CDK1
complex (mitosis-promoting factor) is activated. Progression from G2 to M phase
requires sustained activity of CDK1-Cyclin B complex within the nucleus. Subsequent
entry into anaphase relies critically on the sudden destruction of the CDK1-Cyclin B
activity that guarantees the global inhibition of protein biosynthesis, DNA replication,
and DNA transcription154,155.
It was surprising to find an overall increase in cyclin gene expression in L647RPreA expressing cells compared to uninduced cells, as this seems contrary to our
observations of PreA expression leading to decreased cell proliferation and potential
cell cycle exit. In the cyclin gene expression profile (Figure 24), upregulation was
demonstrated for Cyclin A1/2, C, D, and E. The key regulator of G2–M transition of the
cell cycle is M-phase promoting factor (MPF), a complex composed of CDK1/CDC2 and
a B-type cyclin. Cyclin B was the only gene we observed to be significantly
downregulated, possibly indicating a modest inhibition of entry to mitosis in these cells.
Cyclin F interacts with Cyclin B to control Cyclin B nuclear localization, thus controlling
activation of MPF through regulation of the amount of Cyclin B available in the nucleus
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to form the MPF complex150,156. Notably, there was no change in Cyclin F expression in
L647R PreA-expressing cells compared to uninduced cells, thus no increased level of
nuclear localization of Cyclin B should be expected, perhaps correlating to an overall
downregulation of Cyclin B activity.

Cyclins, CDKs, CKIs
Expression Fold-Change upon
L647R PreA Expression
37.3
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Figure 24. L647R Effects on Gene Expression (RT-qPCR Assay of Transcript
Expression): Cyclins, CDKs, CKIs. Results compare cells induced 24 hours (500 nM
GenoStat), versus uninduced cells treated with DMSO only. P-values </=0.05 for each
fold-change value, see Table 2.

Although cyclin levels vary with cell cycle stage, the kinases regulated by them
are described to be constitutively expressed, dependent on the varying cyclin levels to
direct control of the complexes in cell cycle regulation. Considering this, altered
expression levels of the CDKs between different cells may or may not be of
consequence, but we observed a slight expression upregulation of CDK2 (2.1-fold) and
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a strong upregulation of CDK4 (37.3-fold) in L647R PreA expressing cells compared to
uninduced cells (Figure 24). As described, Cyclin E-CDK2 complexes initiate the G1/S
transition of the cell cycle, and Cyclin D-CDK4 complexes phosphorylate Rb protein,
leading to liberation of E2F. E2F transcription factors, several of which (E2F1, 3, and 4)
were observed to be upregulated by L647R PreA, control expression of key genes in
controlling the transition from G1 to S phase. Increases in CDK2 and CDK4 expression,
as well as in their respective cyclin counterparts, Cyclin E and Cyclin D, within the same
cells, accompanied by E2F-upregulation, surely indicates pressure to progress forward
in the cell cycle.
An important consideration, however, in cyclin-CDK control of cell cycle
progression, is the fact CKIs bind these complexes and potently inhibit their activity. We
observed the CKI Cdkn1a/p21Cip1/Waf (herein p21Waf1) demonstrates a 6.3-fold
upregulation of expression, while Cdkn1b/p27/Kip1 (herein p27 Kip1) is upregulated 23.2fold (Figure 22). These inhibitors, along with p19Arf (for which no statistically significant
change in expression was observed between cells expressing L647R PreA and
uninduced cells), are known to be the primary mediators of cell cycle arrest and are
associated with quiescence, senescence, and/or apoptosis[as reviewed in 157]. The transcript
upregulation of these inhibitors could imply early stage initiation of cell cycle arrest
despite the increased expression levels of the cyclins and CDKs. Several researchers
have demonstrated p21Waf1 has a “threshold level” of activation, whereby modest
induction stimulates proliferation, which is quickly staunched upon reaching the p21Waf1
expression level threshold[as reviewed in 158]. Additionally, Cdk5rap1 (expression
upregulated 9-fold, Figure 24) is a specific inhibitor of CDK5, a CDK shown to
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phosphorylate and activate the p53 transcription factor, promoting apoptosis150,159, so
upregulation of Cdk5rap1 would favor cell survival over apoptosis. Overall, the Cyclin,
CDK, CKI profile in 24-hours-induced L647R PreA-expressing cells suggests a forward
pressure to cycle and avoid apoptosis with strong indications of early-stage cell cycle
arrest initiation in progress.

Kinases (Non-Cyclin-Dependent) and Phosphatases
Other kinases, besides those dependent on cyclins, are active in regulation of the
cell cycle, as well. Whereas phosphorylation activates the functions of some proteins,
others are deactivated or tagged for degradation by the modification, thus phosphatases
are also important in regulation of expression and activity of kinase substrate proteins.
Several kinases and phosphatases demonstrate altered expression levels in response
to induction of L647R PreA expression (Figure 25). Among these, Adenylate kinase 1
(AK1) is associated with metabolic sensing of body energy and facilitating
phosphotransfer in the adenosine triphosphate (ATP) synthesizing pathway in which a
phosphate is transferred from one adenosine diphosphate to another, leaving an
adenosine monophosphate (AMP) as an ATP is formed (ADP+ADPAMP+ATP energy
producing exchange)160. In addition, an AK1 isoform that is associated with the nuclear
membrane and is a transcriptional target of the transcription factor p53 (p53 transcript
expression is elevated 2.8-fold in cells induced to express L647R PreA versus control,
Figure 26-Transcription Factors and Related Genes).
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Kinases & Phosphatases
Expression Fold-Change with L647R PreA Expression
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Figure 25. L647R Effects on Gene Expression (RT-qPCR Assay of Transcript
Expression): Kinases & Phosphatases. Expression of Kinase and Phosphatase Genes
in L647R PreA-expressing cells was altered. Changes shown are between cells
induced (24 hours, 500 nM GenoStat) to express L647R PreA, compared to uninduced
cells (DMSO-treated control), as assayed by RT-qPCR. P-values </=0.05 for each foldchange value, see Table 2.

The p53-activated AK1 was shown to be a critical part of p53-mediated cell cycle
arrest in response to cellular stresses such as hypoxia or DNA damage from irradiation.
AK1 overexpression is sufficient to induce a reversible p53-mediated cell cycle arrest
without apoptosis induction for extended periods of time161. Also, in this metabolic
stress pathway, the Ca+/Calmodulin dependent kinase II isoforms (Camk2a/b) were
upregulated. Camk2a/b inhibit activity of the cAMP response element binding protein
(CREB) transcription factor, which lists c-Fos, Cyclin A1, and Cyclin D2 among its
nearly 5000 transcriptional targets162. Camk2b also activates AMP-activated protein
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kinase (AMPK), a critical regulator of cellular energy homeostasis. AMPK is activated
following periods of cellular stress during which the ATP to AMP ratio decreases (such
as during mitogen deprivation/starvation), which correlates to an increase in intracellular
calcium, thus activating the Ca+/calmodulin dependent kinases163. The activation of
AMPK serves to stimulate several metabolic processes to conserve energy or use
energy stores, activate cell cycle checkpoints, and halt cell cycle progression. AMPK
inhibits protein synthesis by downregulating growth factor and nutrient sensing mTORmediated S6 ribosomal translation. AMPK partners with p53 in these processes, as its
expression and activity are shown to be upregulated by p53, and p53 transcriptional
targets Sestrin1 (Sesn1, expression level not measured in RT-qPCR assay) and Sestrin
2 (Sesn 2, transcript expression upregulated 5.5-fold in L647R PreA-expressing cells,
Figure 26-Transcription Factors and Related Genes) have also been shown to activate
AMPK. The Ataxia telangiectasia-mutated (ATM) kinase also phosphorylates AMPK in
response to depleted cellular energy and metabolic stress164. Transcript expression,
according to the RT-qPCR assay, of the ATM serine/threonine kinase, a phosphatidylinositol-3 kinase-like kinase (PIKK) family member, is upregulated 4-fold in L647R PreAinduced cells compared to control. Though the AMPK transcript expression level is not
directly measured in the RT-qPCR assay, increased expression of ATM and Camk2b,
as well as p53 and Sesn2, creates a favorable set of conditions for activation of AMPK.
Control of cell cycling, cellular homeostasis and aging, cell fate decisions between
apoptosis, quiescence, and senescence by p53 and mTOR is significant, and we
discuss this in more detail in other sections of this work.
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ATM and Checkpoint kinase 1 (Chek1/Chk1) are most commonly associated with
response to DNA damage but also have important functions in mediating cell cycle
progression and control of traversing cell cycle checkpoints. ATM is activated by autophosphorylation or trans-phosphorylation in response to double strand DNA breaks
(DSBs), whether these are caused by a genotoxic insult or as a normal phenomenon in
the course of DNA replication, transcription, or V(D)J and class-switch recombination.
ATM phosphorylates a number of effector proteins, primarily Chk2 (expression not
assayed in the qPCR) but also Chk1. Chk1 (expression upregulated 22.1-fold) is most
often part of the single strand DNA break (SSB) response and is thus typically activated
by the Ataxia telangiectasia-related kinase (ATR, not included in the qPCR assay), the
close PIKK relative of ATM that is most frequently associated with response to
SSBs165,166. As both DSBs and SSBs can occur during DNA replication, ATM and ATR
are both often recruited to the DNA breaks that occur in DNA replication167. In fact, ATR
activity is activated by ATM, and possibly vice-versa168.
Increased expression and activation of Chk1 can negatively regulate cell cycle
progression even when checkpoints are unperturbed. This occurs in part by inhibitory
phosphorylation of CDKs and by phosphorylation of Cdc25 proteins, which leads to their
degradation thus, decreases the rate of dephosphorylation of CDK. Chk1 has been
shown to repress gene transcription (of, for example, cyclin genes) through participating
in histone modifications. In addition to being required for the intra-S-phase checkpoint
response to stalled replication forks, Chk1 plays a role in proper formation of the mitotic
spindle and in activation of the spindle checkpoint to prevent entry to mitosis with
spindle aberrances. Chk1 phosphorylates Rb to enhance its binding to E2F, thus
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antagonizing E2F-related transcription169, although, as an apparent negative-feedback
loop, Chk1 is an apparent E2F transcriptional target153. To further introduce fine-tuned
control to this regulatory loop, E2F1 is one of the transcription factors phosphorylated by
ATM (E2F1 demonstrates a 6.4-fold expression upregulation with L647R PreA
expression, in the qPCR assay, Figure 26).
Another transcription factor substrate for ATM phosphorylation is p53 (slightly
upregulated, Figure 26), which is also phosphorylated by Chk1 and Chk2. Chk1/2dependent phosphorylation of the tumor suppressor protein p53 leads to its stabilization
and activation of both the G1 and G2 checkpoint pathways166,170-173. Chk1 also interacts
with, and recruits the activity of, the nucleolar protein nucleophosmin, which stabilizes
p53 and p21 by preventing their degradation174,175. Nucleophosmin (Npm2), which
demonstrates a 16.5-fold upregulation in L647R-expressing cells (Figure 23Transcription Factors and Related Genes), functions as a threshold modulator for p53,
acting to repress its tumor suppressive and apoptosis-induction activities when p53
expression is below a threshold level. Once p53 expression level reaches a high level,
Npm2 switches to its strong role as a p53- and p21-stabilization factor176.
Ppp2r3a (upregulated 20.5-fold) is a subunit of a protein phosphatase
holoenzyme (formerly known as “Pp2A”) that is 1 of 4 major serine/threonine kinases
implicated in negative regulation of cell growth and division, as it actively reverses the
phosphorylations carried out by kinases, especially the cyclin dependent kinases 150,177.
For example, the cell division control protein 6 (Cdc6) is required for DNA replication by
its action in forming the pre-replication complexes necessary for “licensing” of
replication origins to control the timing of replication. Cyclin dependent kinases
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phosphorylate Cdc6 to protect it from ubiquitination and degradation, thus promoting Sand M-phase entry, replication of genetic material and cell division. Protein
phosphatase 2 reverses Cdc6 phosphorylation, leading to its degradation and
consequently prevents DNA replication and arrests the cell cycle178. Additionally, this
phosphatase is reported to dephosphorylate pRb to mediate the hypophosphorylated
status required for pRb to remain in its inhibitory complex with the E2F transcription
factor.
Wee1 is tyrosine kinase responsible for inhibitory phosphorylation of Cdc2/Cdk1
in complex with CyclinB. This modification disables the Cyclin B/Cdk1-mediated entry
of cells to mitosis, and thus results in cell cycle arrest at the G2/M transition 179. In the
RT-qPCR assay, we find a 24.9-fold upregulation of Wee1, implying the possibility of its
actions in negative regulation of cell proliferation and division.
The phosphatases Ppmd1/Wip1 and Ppp3a were upregulated in L647R PreAexpressing cells. Ppmd1/Wip1 (herein Wip1) dephosphorylates and thus inhibits p53
(Ser 15) and Chk1 (Ser 345), thereby abrogating cell cycle checkpoints. While this is an
antiapoptotic action, and necessary for cells to re-enter the cell cycle following a
completed checkpoint, it can also serve to promote potential tumorigenesis and Wip1 is
often deregulated in cancers180. Ppp3a is a subunit of another protein phosphatase
holoenzyme, protein phosphatase 3 (formerly called 2B), and functions in calciumdependent dephosphorylation of proteins149. Taken together, the kinase/phosphatase
profile of L647R PreA-expressing cells is difficult to interpret in terms of elucidating
specific mechanisms of direct PreA effects on cell cycle gene-regulation; however, it
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does strongly suggest activation of several moieties that participate in cell cycle arrest
processes.

Transcription Factors and Associated Genes
In addition to the transcription factors and related genes already mentioned (p53,
E2Fs, Npm2, Sesn2) several others demonstrate expression level effects from L647R
PreA expression (Figure 26). As the 2 primary systems of cell cycle-related
transcriptional control, expression of genes related to Rb-E2F association or p53
function are critical in evaluating regulation of the cycle. These pathways are controlled
by a multitude of posttranscriptional and posttranslational mechanisms. Therefore,
measurement of transcript expression levels, alone, for Rb-family suppressors, and
E2F-family transcription factors, might not ultimately be informative regarding actual
function.
While pRb expression was not directly measured in the qPCR assay, the other
pocket proteins, Rbl1 (p107) and Rbl2 (p130), were assayed and shown to have
transcript expression upregulation, while E2Fs 1, 3, and 4 also demonstrate
upregulation. Also slightly upregulated in this gene category is Tfdp1 (DP-1), a
transcription cofactor protein that complexes with E2F transcription factors to enhance
inhibitory binding of hypophosphorylated pRB to the E2F/DP complex, or, when pRB
becomes phosphorylated and dissociates from the complex, DP-1 actually stimulates
E2F-mediated transcription of its target genes.
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Figure 26. L647R Effects on Gene Expression (RT-qPCR Assay of Transcript
Expression): Transcription Factors & Related Genes. Changes were found in
expression of transcription factors and related genes in L647R PreA-expressing cells.
Transcript levels in cells induced (24 hours, 500 nM GenoStat) to express L647R PreA
were compared to uninduced cells (DMSO-treated control) by RT-qPCR assay. Pvalues </=0.05 for each fold-change value, see Table 2.

In terms of regulating the actual expression level of p53, few other genes are
more important than “mouse double minute 2” (Mdm2). Mdm2 (upregulated 2.1-fold
with L647R PreA expression) is an E3 ubiquitin ligase that negatively regulates p53
function by promoting its proteasomal degradation181 [and reviewed in 182 ]. Interestingly,
Mdm2 is a p53 transcriptional target apparently expressed as part of a negative
feedback regulator of p53 expression183. In another layer of control, Mdm2 can also
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undergo autoubiquitination in which it directs its own targeting for proteasomal
degradation. As a result, Mdm2 inhibitory effects on p53 are relieved, resulting in
stabilization and increased activity of p53 in its cell cycle arrest and apoptotic functions.
In addition to a role in negative regulation of the expression level of p53, Mdm2 also
negatively regulates the expression levels of p21Waf1 184 and pRb185, as well as the
Mdm2-binding protein (Mtbp). Mtbp, which is upregulated with L647R PreA expression,
has an apparent “switch” mechanism in which it can either function to stabilize or
destabilize Mdm2 expression and function, depending on the ratio of expression
between the 2 proteins. When Mdm2 expression levels are higher, Mtbp levels are
lower, and Mdm2-autoubiquitination is blocked, thus directing Mdm2 ubiquitin ligase
activity toward p53. Mtbp also enhances Mdm2 binding to p53, facilitating p53
degradation and promoting cell survival. Conversely, when expressed at higher levels,
Mtbp can effectively reverse its stabilizing effects on Mdm2, facilitating Mdm2
autoubiquitination and degradation, thereby promoting p53 stabilization and increased
p53 activity186. Rb can be ubiquitinated and downregulated by Mdm2. In another
negative regulatory role toward Mdm2, Mtbp interacts with pRb to elicit a p53independent cell cycle arrest187. Possibly, this set of opposing activities exists as a
means to arrest the cell cycle when necessary without activating apoptosis.
The stratifin gene (Sfn), more commonly known as 14-3-3σ, is significantly
upregulated (25.3-fold), at the transcript level in cells expressing L647R PreA versus
control. Members of the 14-3-3 family of proteins are directly involved in many of the
cellular processes crucial for normal growth and development, including cytokinesis,
cell-contact inhibition, anchorage-independent growth, and cell adhesion--the same
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pathways often dysregulated in disease states such as cancer. Most 14-3-3 family
members enhance the activity of survival and/or proliferation-associated proteins (such
as the Raf kinase), or they antagonize the activity of proteins that promote cell death
and senescence (such as Bad, Bim, and Bax). In contrast, however, 14-3-3σ acts as a
tumor suppressor and its expression is typically upregulated coordinately with p53 and
BRCA1. This isoform serves to sequester Cdk1-Cyclin B complexes in the cytoplasm,
thus delaying cell cycle progression, and is also a crucial regulator of translation during
mitosis. Additional 14-3-3σ tumor suppressor activity comes from its dual roles in
stabilization of p53. First, it binds and negatively regulates Mdm2 by promoting its
ubiquitination and degradation, thus stabilizing p53 by protecting it from Mdm2mediated ubiquitination. Second, 14-3-3σ enhances p53 stability and activity by
scaffolding it to assist formation of p53 tetramer structures188.
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is an essential glycolytic
enzyme that is expressed in all prokaryotic and eukaryotic organisms and found to be
upregulated 17.6-fold in cells expressing L647R PreA in our RT-qPCR assay. Studies
suggest that GAPDH is a multifunctional protein with a number of functions independent
of its role in glycolysis. These activities include phosphorylating transverse-tubule
proteins189, stimulating RNA transcription190, interacting with microtubules191, influencing
RNA catalysis192, and acting as a diadenosine tetraphosphate binding protein to
influence DNA replication and DNA repair193. GAPDH is also upregulated by p53 after
exposure to apoptotic insult194.
The transcription factors BRCA1 and BRCA2 (upregulated 19.4-fold and 14.1fold, respectively) are activated by ATM, ATR, and Chk1 in response to DNA damage

124

upon genotoxic exposure, as well as in the DNA breakage that occurs in DNA
replication. They mediate intra-S phase and cell cycle checkpoints and function to
ensure error-proof DNA repair. It has previously been demonstrated that BRCA1 can
transcriptionally activate expression of p27Kip1 [195] , upregulate p21Waf1 and
GADD45196,197, as well as coactivate the transcription of other p53-regulated genes196.
BRCA2 has also been shown to be phosphorylated in a cell cycle dependent manner by
cyclin dependent kinases, to potentially mediate cytokinesis, and functions
nonredundantly with BRCA1, especially in the G2/M cell cycle checkpoint198.
Expression of the gene mutated in Polycystic Kidney Disease, Pkd1, is
upregulated 4.6-fold in the L647R PreA-induced cells compared to the uninduced cells.
The gene product of Pkd1, the Polycystin protein, inhibits mTOR by complexing with
Tuberous Sclerosis 1 and 2 (TSC1/2) to stabilize the complex by inibiting ERK-mediated
phosphorylation of TSC1/2. The Polycystin-stabilized TSC1/2 complex inhibits the
mTORC1 activating GTPase activity of Rheb, thereby inactivating the mTOR promotion
of S6 ribosomal translation of a multitude of proteins199. Polycystin-1 also activates the
JAK/STAT pathway, thereby upregulating p21Waf1, and inducing cell cycle arrest in
G0/G1200. Suppressing DNA synthesis as well as protein synthesis, and also serving to
upregulate p21Waf1 expression, is the Notch signaling pathway receptor protein Notch2.
Notch2 demonstrates a 10.7-fold transcript upregulation with L647R PreA expression
over uninduced cells. In contrast to the Notch1-mediated inhibition of transcription of
the phosphatase and tensin homologue (PTEN) protein, Notch2 has been shown
upregulate PTEN expression and lead to Akt dephosphorylation, thus inhibiting the Aktmediated mTOR pathway of protein synthesis201.
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Amyloid β–precursor binding protein B (Apbb1/Fe65), herein Fe65, is an adapter
protein that binds the β-amyloid precursor protein, which has a central role in the
pathology of Alzheimers Disease. Recent studies have also shown overexpression of
Fe65 is sufficient to effectively block cell cycle progression in G1 phase by completely
abolishing the activation of a key S phase gene, the thymidylate synthase (TS) gene,
which is driven by the transcription factor LSF/CP2/LBP1 (LSF)202. Additionally, Fe65
has been shown to stabilize p53203. The significant upregulation of expression of Fe65
(40.9-fold) in cells induced to express L647R PreA, compared to uninduced cells,
certainly warrants further investigation as a potential PreA mechanism of inducing cell
cycle arrest. A PreA-mediated increase in Fe65 at such a dramatic level could lead to
cell cycle arrest202,203, although posttranslational factors would likely play a critical role in
determining if that phenomenon occurs.
The DNA damage inducible transcript 3(Ddit3) transcription factor, also known
as Chop10/Gadd153 (herein Chop10), is modestly upregulated in L647R PreA
expressing cells. Chop10 is a Forkhead box O1 (FoxO1) transcriptional target
expressed in response to cell stresses, especially those directly affecting the
endoplasmic reticulum, such as increased reactive oxygen species and presence of
unfolded proteins204. Chop10 dimerizes with the C/EBP transcription factor to inhibit
transcription and induces growth arrest or apoptosis205. Interestingly, the amyloid β–
precursor protein (APP, which regulates and is regulated by Fe65206) potentiates
Chop10 induction and cell death in response to ER Ca2+ depletion207. The RT-qPCR
assay revealed that the spectrum of transcription factors and transcription factor-related
genes demonstrating altered transcript levels is quite broad upon L647R PreA
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expression. Therefore, the data offer little clarification of specific mechanisms of PreA
in regulating the cell cycle. However, the response to L647R PreA-expression by such
a multitude of these factors strongly suggests the activation and involvement of multiple
pathways in arrest of the cell cycle.
DNA Damage-Related Genes
As mentioned, although ATM phosphorylation has roles in unperturbed cell cycle
progression, its primary functions are in relation to DNA damage response. In addition
to the previously noted substrates involved in unperturbed cell cycling in addition to the
response to DNA damage (BRCA1/2, p21/p27, Chk1, Ddit3, p53), ATM also
phosphorylates the mediator and adaptor proteins MDC1, 53BP1, H2AX, and Mre11, all
which assist in the assembly of multiprotein complexes at the sites of DSBs and in the
subsequent DNA repair activities149,150,167,168. Of those 4 target proteins, only the Mre11
(meiotic recombination 11) transcript level is assayed in our RT-qPCR panel and is
upregulated 6.3-fold (Figure 27). The nuclease activity of ATM-activated Mre11 is
required for the processing of DNA double-strand breaks (DSBs) to generate the
replication protein A (RPA)-coated ssDNA needed for ATR recruitment and the
subsequent phosphorylation and activation of Chk1 167.
Structural maintenance of chromosomes 1a (Smc1a), as the central component
of the Cohesin complex required for proper cohesion of sister chromatids after DNA
replication, is most aptly fit into the category for mitotic structure proteins; however, it is
activated by ATM and does participate with ATM- or ATR-activated BRCA1 in mediating
S-phase checkpoint control and DNA repair and thus bears mention in this category.
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Figure 27. L647R Effects on Gene Expression (RT-qPCR Assay of Transcript
Expression): DNA Damage-Related Genes. Expression changes were seen in several
DNA damage-related genes in L647R PreA-expressing cells. Cells induced (24 hours,
500 nM GenoStat) to express L647R PreA were compared to uninduced cells (DMSOtreated control), using the RT-qPCR assay. P-values </=0.05 for each fold-change
value, see Table 2.

As seen in Figure 27, the Smc1a transcript expression level in L647R PreAinduced cells is upregulated a substantial 19.5-fold over the level found in uninduced
cells. As demonstrated by altered expression of several kinases, transcription factors
and transcription factor-associated genes, and DNA damage response and repair
effectors, some role for PreA accumulation in affecting the gene expression program in
DNA damage response appears evident. Although previous studies have suggested a
potential inhibitory role for PreA in modulating DNA repair208, considering the complexity
of the response and the potentially PreA-regulated participants, future studies should
consider PreA-mediated roles of these genes.
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Genes Associated with Cell Structure and Integrity/Chromatin/Chromosome
Organization and Maintenance/Mitotic Assembly
Actin is one of the most highly-conserved proteins known and is ubiquitously
expressed in all eukaryotic cells. Actin polymers form polar intracellular 'tracks' for
kinesin motor proteins, allowing the transport of vesicles, organelles, and other cargo.
These polymers also give mechanical support to cells and attach them to each other
and the extracellular matrix at adherens junctions. In combination with myosin, actin
forms the myofibrils that polymerize and depolymerize to function in cell motility. As
manipulation of the cell cycle involves rearrangement and trafficking of many cellular
components, as well as morphological changes to the cell (and even cytokinesis), it
comes as no surprise to find β-Actin upregulated (14.8-fold) in cells overexpressing a
protein (the L647R PreA) that has apparent functions in alteration of the progress of the
cell cycle.
Expression of other filamentous cytoskeletal components are upregulated in the
L647R PreA-expressing cells, as well, such as the Microtubule-actin crosslinking factors
1 and 2 (Macf1/2). These proteins link intermediate filaments, actin, and microtubules
to play a role in organizing the cytoskeletal and nuclear envelope structure of the cell.
Macf1 is upregulated 9.8-fold, while Macf2, also known as Dystonin (Dst), and noted as
important in adhesion junctions as well as anchoring keratin-containing intermediate
filaments to hemidesmosomes209, is upregulated 25.4-fold. Integrin β1(Itgb1), for which
cells expressing L647R PreA demonstrate a 9.6-fold upregulation, also functions in cell
adhesion and cell signaling.
Several genes with products responsible for regulating formation of the mitotic
spindle demonstrate an increased expression in cells induced to express L647R PreA,
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such as the NIMA (never in mitosis gene A)-related expressed kinase 2 (Nek2). The
Nek2 protein kinase (upregulated 15.6-fold) is involved in regulating the G2/M transition
by controlling the mitotic spindle-assembly checkpoint that is necessary for proper
chromosome segregation during metaphase-anaphase transition. Nek2 activity is
required for association of another protein, mitotic arrest deficient 2-like 1 (Mad2l1), to
the kinetochore. Mad2l1 (upregulated 2.7-fold) is also required for the execution of the
mitotic checkpoint and monitors the process of kinetochore-spindle attachment,
functioning to inhibit the activity of the anaphase promoting complex (APC), thus
preventing onset of anaphase, by sequestering Cdc20 until all chromosomes are
properly aligned at the metaphase plate.

Genes Involved in Chromosomal/Nuclear/Cellular Integrity or
Microtubule/Mitotic Assembly
Expression Fold-Changes when L647R PreA is Expressed
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Figure 28. L647R Effects on Gene Expression (RT-qPCR Assay of
TranscriptExpression): Genes Involved in Chromosomal/Nuclear/Cellular Integrity or
Microtubule/Mitotic Assembly. L647R PreA-expressing cells had altered expression of
genes involved with chromosomal organization, structural integrity, assembly of
microtubules, and the mitotic spindle. Expression levels in cells induced (24 hours, 500
nM GenoStat) to express L647R PreA were compared to levels in uninduced cells
(DMSO-treated control), by the RT-qPCR assay. P-values </=0.05 for each fold-change
value, see Table 2.
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Mcm2, a phosphorylation substrate of Cdc2/Cdk1 and Cdc7, is one of the highly
conserved mini-chromosome maintenance proteins (MCM) that are involved in the
initiation of eukaryotic genome replication and is upregulated 17.7-fold in the L647R
PreA-induced cells. The hexameric protein complex formed by MCM proteins (Mcm2,
along with Mcm4, 6, and 7) is the putative replicative helicase essential for 'once per cell
cycle' DNA replication initiation and elongation in eukaryotic cells. Mcm2 is reported to
be the regulator of the helicase activity of the Mcm-complex, and as such, it is a key
component of the prereplication complex (pre-RC) and may be involved in the formation
of replication forks and in the recruitment of other DNA replication related proteins 149,150.
Finally, the expression level of the TRF1/Terf1 gene, the transcript of which is
translated to yield a component of the Shelterin telomere-capping protein complex, is
upregulated 3.4-fold upon expression of L647R PreA. While this is not a spectacular
increase, it is potentially significant given the critical nature of maintenance of telomeric
structure in the preservation of genomic integrity, activation of senescence, apoptosis,
and cellular aging210-213.
Effects of Accumulated PreA on Cell Cycle Control-Specific Protein
Expression and Phosphorylation Assay by Antibody Array

While the data from the RT-qPCR assay of transcript levels of cell cycle related
genes present compelling evidence of some role for the PreA isoform of LA in the
regulation of the genes that control the cell cycle, we acknowledge significant regulation
of many of these factors occurs primarily at the level of the protein and through
posttranslational modifications. To expand the profiling of PreA-mediated effects on cell
cycle, we assayed the expression level of a number of proteins involved in cell cycle
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control. We used a commercially available protein/antibody microarray comprising
biotinylated antibodies specific to proteins that control the cell cycle (Fullmoon
Biosystems). Additionally, as the bulk of cell cycle-related posttranslational modification
occurs in the form of protein phosphorylation, this array system also features phosphospecific antibodies to measure the comparative levels of phosphorylation of many cell
cycle control proteins. Analysis of the array results revealed changes in expression
levels and phosphorylation status of several key cell cycle proteins when we induced
expression of L647R PreA.
From cells of the Rheoswitch 3T3 L647R PreA cell line, whole cell lysates were
prepared as per the antibody array manufacturer instructions in a lysis buffer containing
both protease and phosphatase inhibitors. Two lysate samples were prepared from
replicate cultures, one from cells induced with 500 nM GenoStat for 72 hours to express
the L647R PreA mutant protein and the other, an uninduced control sample (treated
only with DMSO for the 72-hour period). A 72-hour timepoint was selected to
encourage an optimal level of L647R PreA expression induction in asynchronously
growing cells (as we have tried to avoid “artificial interruption” of the cell cycle by
commonly used synchronization methods). The antibody array slides were hybridized
and scanned at the Fullmoon Biosystems facility to ensure correctness of the
processing steps without the expense of conducting trials necessary to optimize the
processing in house. Each antibody was spotted in replicates of 6 on each slide,
statistical evaluation of the 6 antibody fields per protein and hybridization and
fluorescence controls were conducted on an “interslide basis,” in comparison between
the L647R PreA-induced cell lysate slide and the noninduced slide, as well as on an
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“intraslide” basis to determine outliers resulting from any inefficient or uneven labeling or
hybridization within the replicates on the same slide. After subtracting fluorescence
background of negative controls, outliers were excluded and relative expression levels
of proteins compared. In addition, we analyzed the levels of phosphorylation of the
proteins using PANDA, (Phosphor Antibody Array Data Analysis), which is a webbased software program developed at Emory University for analyzing phosphorylation
antibody arrays214. It identifies phosphorylated antibodies in the microarray and
statistically quantifies the extent of phosphorylation for targets of these antibodies,
enabling the quantitative evaluation of the phosphorylation changes, at each
phosphorylation site, with a 95% confidence interval. Results of the antibody array
assay are shown in Table 3. In the text, references to a particular protein’s
“upregulation” or “downregulation” are intended, for simplicity to refer to the expression
level or the phosphorylation level of the protein, in L647R PreA-expressing cells (after
72 hours of expression, induced by 500 nM GenoStat), compared to uninduced control
cells.
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Table 3. Results of Antibody Array: Changes in Protein Expression Levels and Phosphorylation
Total Protein
Expression
Ratio

Total Protein

L647R/NI

log2 of
Ratio
CV of 6
(Fold
Replicates on a
Change)
Slide

Protein List
14-3-3 theta/tau (Ab-232)

14-3-3 zeta (Ab-58)
14-3-3 zeta/delta (Ab-232)
ABL1 (Ab-204)
ABL1 (Ab-754/735)
c-Abl (Ab-412)
Average for ABL1/c-Abl

AKT(Ab-473)
AKT1 (Ab-246)

AKT (Ab-308)
AKT (Ab-326)
AKT1 (Ab-124)

AKT1 (Ab-450)
AKT1 (Ab-72)
AKT1 (Ab-474)

Average for AKT1
AKT2 (Ab-474)
ATM (Ab-1981)
ATRIP (Ab-68/72)

Beta actin
BRCA1 (Ab-1423)

BRCA1 (Ab-1457)
BRCA1 (Ab-1524)
Average for BRCA1

CDC25A (Ab-124)
CDC25A (Ab-75)
Average for CDC25A

CDC25B (Ab-323)
CDC25B (Ab-353)
Average for CDC25B
CDC25C (Ab-216)
CDC2 (Ab-15)

CDK1/CDC2 (Ab-14)
Average for CDK1/CDC2
CDK2 (Ab-160)

CDK7 (Ab-170)
Chk1 (Ab-280)
Chk1 (Ab-286)
Chk1 (Ab-317)
Chk1 (Ab-345)
Average for Chk1

Phospho
Protein Ratio†

Phospho-Residue-Specific
Protein

NI

L647R

Phospho protein

0.84
1.38
0.76
0.98
0.88
0.88
0.88

-0.26
0.47
-0.40
-0.03
-0.19
-0.18
-0.19

0.03
0.03
0.17
0.33
0.03
0.13

0.02
0.02
0.19
0.38**
0.02
0.07

14-3-3 theta/tau (Phospho-Ser232)
14-3-3 zeta (Phospho-Ser58)
14-3-3 zeta/delta (Phospho-Thr232)
Abl1 (Phospho-Tyr204)
ABL1 (Phospho-Thr754/735)

0.61
0.86
0.72
0.82
0.90
0.66
0.77
1.01
0.79
0.72
0.98
1.02
1.91
1.04
0.66
0.85
0.82
0.63
0.85
0.75
0.79
0.50
0.65
1.44

-0.70
-0.21
-0.46
-0.29
-0.15
-0.61
-0.38
0.14
-0.35
-0.48
-0.03
0.03
0.93
0.06
-0.60
-0.23
-0.29
-0.66
-0.24
-0.42
-0.34
-0.99
-0.62
0.53

0.14
0.03
0.07
0.02
0.10
0.07
0.06
0.03

0.16
0.03
0.06
0.03
0.14
0.09
0.09
0.03

0.05
0.03
0.07
0.02
0.09
0.16
0.03

0.84
0.80
0.82
0.82
0.67
0.75
0.70
0.79
0.80
0.76
0.78
0.82
0.57
0.94
0.78
0.63
0.66
0.65

Chk2 (Ab-387)

Chk2 (Ab-516)
Chk2 (Ab-68)

Average for Chk2
Cyclin A(A1/A2) (inter)
Cyclin A1 (C-term)
Average for CyclinA1/2

NI

L647R

0.08
0.13
0.18
0.09
0.12
0.05
0.24
0.18
0.05
0.33**
0.09
0.20
0.04
0.14
0.03
0.05

0.06
0.20
0.05
0.07
0.06
0.06
0.13
0.10
0.02
0.05
0.19
0.01
0.02
0.09
0.03
0.03

AKT1 (Phospho-Tyr474)

0.69
0.27
0.63
2.00
0.59
0.88
0.87
0.41
0.78
0.65
0.80
0.27
0.15
0.95
0.98
0.59

-0.53
-1.90
-0.66
1.00
-0.75
-0.18
-0.21
-1.27
-0.36
-0.62
-0.31
-1.90
-2.70
-0.07
-0.03
-0.76

0.02
0.09
0.09
0.06
0.09
0.05
0.05

AKT2 (Phospho-Ser474)

0.82

-0.29 0.16

0.05

ATRIP (Phospho-Ser68/72)

0.54

-0.89 0.10

0.09

BRCA1 (Phospho-Ser1423)

0.88
1.02
1.64

-0.19 0.10
0.03 0.11
0.72 0.11

0.06
0.06
0.02

0.02
0.05

0.02
0.05

CDC25A (Phospho-Ser124)

0.04
0.04

0.03
0.01

CDC25B (Phospho-Ser323)

0.16

0.13

CDC25C (Phospho-Ser216)
CDC25C (Phospho-Thr48)

-0.25
-0.32
-0.29
-0.28
-0.57
-0.42
-0.51
-0.34
-0.31
-0.39

0.07
0.08

0.06
0.06

CDC2 (Phospho-Tyr15)

0.06
0.02
0.10
0.05
0.07
0.02

0.14
0.08
0.04
0.01
0.02
0.04

CDK2 (Phospho-Thr160)

-0.37
-0.29
-0.81
-0.09
-0.36
-0.68
-0.59
-0.62

0.09
0.11
0.09
0.08

0.05
0.12
0.06
0.08

0.05
0.11

0.05
0.10

Abl1 (Phospho-Tyr412)
c-Abl (Phospho-Tyr412)

c-Abl (Phospho-Tyr245)
AKT (Phospho-Ser473)
AKT1 (Phospho-Ser246)

AKT (Phospho-Thr308)
AKT (Phospho-Tyr326)
AKT1 (Phospho-Ser124)
AKT1 (Phospho-Thr450)
AKT1 (Phospho-Thr72)

BRCA1 (Phospho-Ser1457)

BRCA1 (Phospho-Ser1524)

CDC25A (Phospho-Ser75)

1.04
1.16

0.06 0.16
0.21 0.35**

0.85
1.10

-0.24 0.03
0.14 0.07

0.57
0.47
0.44
0.60

-0.82
-1.09
-1.17
-0.73

Chk2 (Phospho-Thr383)

0.81
0.97
1.06
1.26
1.14
0.75
0.00
1.02
0.91

-0.30
-0.04
0.08
0.33
0.19
-0.42
0.00
0.03
-0.13

Chk2 (Phospho-Thr387)
Chk2 (Phospho-Ser516)
Chk2 (Phospho-Thr68)

1.49
0.57

CDC25B (Phospho-Ser353)

CDK1/CDC2 (Phospho-Thr14)

CDK7 (Phospho-Thr170)
Chk1 (Phospho-Ser280)

Chk1 (Phospho-Ser286)
Chk1 (Phospho-Ser317)

Chk1 (Phospho-Ser345)
Chk1 (Phospho-Ser296)
Chk1 (Phospho-Ser301)

Chk2 (Ab-383)

P/NP-L647R /
P/NP-NI

log2 of
Ratio
CV of 6
(Fold
Replicates on a
Change)
Slide

0.55

0.08
0.14
0.14
0.16

0.07
0.05
0.10
0.20
0.15
0.17
0.11
0.10
0.08
-0.87 0.14
0.58 0.04
-0.80 0.15

0.17
0.11
0.09
0.04
0.09
0.01
0.28**
0.02
0.11
0.06
0.06
0.02
0.08
0.09
0.07
0.12
0.09
0.05
0.09
0.07

****Table continues, next page****
Green Text=Expression Significantly Downregulated (>/= 0.31-fold down = a ratio of 0.80 or less); Red Text=Expression Significantly Upregulated (>/=
0.26-fold up= a ratio of 1.20 or more)
*L647R="L647R PreA": Lysates extracted from 3T3 RheoSwitch cells induced 72 hours (500nM GenoStat) to express L647R PreA; NI="Not Induced":
Lysates extracted from cells treated with DMSO only (no induction reagent)
**Not Statistically Significant: A data-point contained within the set demonstrated a high CV (>0.20)
Text Highlighted in Blue=An Average of the Expression Data Values from Multiple Antibodies to the Same Protein, or for Phospho-protein, the Total
Protein Expression Average was used in calculating the Phosphorylation Ratio for some phospho-sites in proteins for which a matched "non-phospho
specific" antibody was unavailable or had a high CV
†P/NP-L647R/P/NP-NI= Phosphorylation Ratio (Phosphospecific protein detected in assay/Total protein detected in assay) of L647R PreA Expressing
"L647R" (Test) Cell Lysate/Phosphorylation Ratio of "NI" (Not Induced) Control Cell Lysate

134
Table X Page 2 of 3

Table 3 (continued)

Total Protein

Total Protein log2 of
Expression
Ratio
CV of 6
Ratio
(Fold
Replicates on a
L647R/NI Change)
Slide

Protein List
Cyclin B1 (Ab-126)
Cyclin B1 (Ab-147)
Average for CyclinB1
Cyclin D1 (ab-286)
Cyclin D2 (Ab-280)
Cyclin D3 (Ab-283)
Cyclin E1 (Ab-395)
Cyclin E1 (Ab-77)
Average for CyclinE1
Cyclin E2 (Ab-392)
DNA-PK (Ab-2638)

DNA-PK (Ab-2647)
Average for DNAPK
E2F1 (Ab-433)

E2F2 (inter)
E2F4 (N-term)
E2F6 (inter)
FKHR (Ab-256)
FKHR (Ab-319)
FKHRL1/FOXO3 (Ab-253)
FOXO1/3/4-PAN (Ab-24/32)
FOXO1A (Ab-329)
Average for FoxO1/3/4
Average for FoxO1/FKHR

GAPDH
GSK3 beta (Ab-9)
GSK3a-b (Ab-216/279)
HDAC1 (Ab-421)
HDAC2 (Ab-394)

HDAC3 (Ab-424)
HDAC4 (Ab-632)

HDAC5 (Ab-259)
HDAC5 (Ab-498)
Average for HDAC5
HDAC6 (Ab-22)
HDAC7 (C-term)
HDAC8 (Ab-39)

HDAC9 (C-term)
HDAC10 (inter)
Histone H2A.X (Ab-139)
MDM2 (Ab-166)

MDM4 (Phospho-Ser367)*
Myc (Ab-358)
Myc (Ab-373)
Myc (Ab-58)

Myc (Ab-62)
Average for Myc
MYT1 (Ab-83)
P15INK (C-term)
p18INK (inter)

p21Cip1 (Ab-145)
p27Kip1 (Ab-10)
p27Kip1 (Ab-187)
Average for p27Kip1

0.76
0.74
0.75
0.75
0.74
0.67
0.77
0.62
0.71
0.94
0.81
1.80
1.31
0.84
0.76
0.56
0.31
1.79
0.79
0.88
0.73
0.59
0.99
1.06
1.39
0.20
0.68
0.90
0.91
0.73
0.82
0.74
0.79
0.76
0.69
0.60
0.81
0.57
0.55
1.12
0.97
0.75
0.72
0.83
0.82
0.68
0.75
0.68
0.75
0
0.75
0.79
0.65
0.67

-0.40
-0.42
-0.41
-0.41
-0.43
-0.58
-0.37
-0.68
-0.49
-0.09
-0.30
0.84
0.39
-0.26
-0.39
-0.84
-1.69
0.84
-0.33
-0.18
-0.46
-0.77
-0.02
0.08
0.48
-2.36
-0.55
-0.16
-0.13
-0.46
-0.28
-0.43
-0.33
-0.39
-0.54
-0.73
-0.30
-0.81
-0.85
0.16
-0.04
-0.42
-0.48
-0.27
-0.29
-0.56
-0.42
-0.55
-0.41
0
-0.42
-0.33
-0.62
-0.57

Phospho
Protein Ratio†

Phospho-Residue-Specific
Protein

NI

L647R

0.03
0.07

0.03
0.04

Cyclin B1 (phospho-Ser126)

0.13
0.09
0.07
0.02
0.17

0.12
0.05
0.05
0.03
0.11

0.02
0.05
0.06

0.04
0.02
0.08

0.13
0.09
0.05
0.10
0.06
0.07
0.06
0.07
0.05

0.09
0.06
0.04
0.06
0.05
0.09
0.04
0.07
0.04

Phospho protein
Cyclin B1 (phospho-Ser147))

NI
-0.17 0.01
-0.16 0.10

L647R

0.89
0.89

Cyclin D1 (Phospho-Thr286)

0.83

-0.27 0.20

0.07

Cyclin D3 (Phospho-Thr283)
Cyclin E1 (Phospho-Thr77)

0.82
0.79
1.26

-0.29 0.09
-0.34 0.07
0.33 0.13

0.02
0.08
0.04

DNA-PK (Phospho-Thr2638)
DNA-PK (Phospho-Thr2647)

0.76
0.35

-0.40 0.11
-1.52 0.13

0.03
0.16

E2F1 (Phospho-Thr433)

0.73

-0.45 0.12

0.04

FKHR (Phospho-Ser256)
FKHR (Phospho-Ser319)

0.41
0.61
0.97
0.19
1.06
0.68

-1.28
-0.71
-0.05
-2.42
0.08
-0.56

0.18
0.08
0.11
0.03
0.05
0.04

0.19
0.06
0.11
0.03
0.05
0.04

HDAC5 (Phospho-Ser498)

2.79
0.62
0.73
0.96
0.93
0.98
0.94
0.94

1.48
-0.68
-0.45
-0.05
-0.11
-0.03
-0.08
-0.09

0.06
0.07
0.17
0.09
0.09
0.08
0.04
0.10

0.02
0.38**
0.06
0.08
0.03
0.04
0.06
0.08

HDAC6 (Phospho-Ser22)

0.40

-1.33 0.30

0.04

HDAC8 (Phospho-Ser39)

0.85

-0.23 0.09

0.05

Histone H2A.X (Phospho-Ser139)
MDM2 (Phospho-Ser166)

0.67
0.66

-0.58 0.11
-0.59 0.08

0.13
0.09

Myc (Phospho-Thr358)

0.42
0.84
0.64
1.39

-1.25
-0.25
-0.64
0.48

0.10
0.03
0.10
0.08

0.05
0.04
0.06
0.12

0.82
1.57
1.29

-0.28 0.07
0.65 0.09
0.37 0.11

0.03
0.08
0.04

Cyclin E1 (Phospho-Thr395)

FKHRL1 (Phospho-Ser253)
FOXO1/3/4-PAN (Phospho-Thr24/32)
FOXO1A (Phospho-Ser329)

FOXO1A/3A (Phospho-Ser322/325)
0.05
0.02
0.02
0.12
0.02
0.10
0.09
0.04
0.10

0.07
0.03
0.02
0.26**
0.19
0.04
0.08
0.08
0.05

0.02
0.05
0.05
0.07
0.04
0.07
0.12
0.10
0.21
0.16
0.13
0.03

0.06
0.03
0.02
0.07
0.03
0.07
0.06
0.08
0.08
0.05
0.04
0.08

0.09
0.07
0.08
0.03
0.03
0.04

0.06
0.06
0.08
0.04
0.02
0.04

P/NP-L647R /
P/NP-NI

log2 of
Ratio
CV of 6
(Fold
Replicates on a
Change)
Slide

GSK3 beta (Phospho-Ser9)
GSK3a-b (Phospho-Tyr216/279)

HDAC1 (Phospho-Ser421)
HDAC2 (Phospho-Ser394)
HDAC3 (Phospho-Ser424)
HDAC4 (Phospho-Ser632)
HDAC5 (Phospho-Ser259)

Myc (Phospho-Ser373)

Myc (Phospho-Thr58)
Myc (Phospho-Ser62)

p21Cip1 (Phospho-Thr145)
p27Kip1 (Phospho-Ser10)
p27Kip1 (Phospho-Thr187)

0.09
0.11

****Table continues, next page****
Green Text=Expression Significantly Downregulated (>/= 0.31-fold down = a ratio of 0.80 or less); Red Text=Expression Significantly Upregulated
*L647R="L647R PreA": Lysates extracted from 3T3 RheoSwitch cells induced 72 hours (500nM GenoStat) to express L647R PreA; NI="Not Induced":
Lysates extracted from cells treated with DMSO only (no induction reagent)
**Not Statistically Significant: A data-point contained within the set demonstrated a high CV (>0.20)
***Total Protein Not Measured, Expression is in terms of Phospho-specific Protein only; Ratio of phos/total protein not available
Text Highlighted in Blue=An Average of the Expression Data Values from Multiple Antibodies toward the Same Protein, or for Phospho-protein, the
†P/NP-L647R/P/NP-NI= Phosphorylation Ratio (Phosphospecific protein detected in assay/Total protein detected in assay) of L647R PreA Expressing
"L647R" (Test) Cell Lysate/Phosphorylation Ratio of "NI" (Not Induced) Control Cell Lysate
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Table 3 (continued)

Total Protein

Total Protein log2 of
Expression
Ratio
CV of 6
Ratio
(Fold
Replicates on a
L647R/NI Change)
Slide

Protein List
p300 (N-term)
p300/CBP (C-term)
Average for p300
p53 (Ab-15)
p53 (Ab-18)
p53 (Ab-20)

p53 (Ab-315)
p53 (Ab-33)

p53 (Ab-37)
p53 (Ab-376)
p53 (Ab-378)
p53 (Ab-387)
p53 (Ab-392)
p53 (Ab-46)

p53 (Ab-6)
p53 (Ab-9)

Average for p53

Phospho
Protein Ratio†

Phospho-Residue-Specific
Protein

NI

L647R

0.22
0.38
0.30
0.63
0.76
0.93
0.55
0.94
0.74
0.61
1.63
0.59
0.85
0.93
0.59
0.83
0.80

-2.20
-1.39
-1.74
-0.67
-0.39
-0.10
-0.86
-0.08
-0.43
-0.70
0.70
-0.77
-0.24
-0.10
-0.77
-0.28
-0.30

0.05
0.01

0.06
0.03

0.06
0.01
0.10
0.15
0.17
0.22
0.05
0.04
0.04
0.09
0.08
0.04
0.11

0.05
0.03
0.07
0.04
0.06
0.15
0.03
0.13
0.13
0.09
0.06
0.04
0.02

Phospho protein

1.11
0.78
0.77
0.89
0.80
0.79
0.93
0.64
0.82
0.78
0.98
1.01
0.94
0.79
0.90
0.75
0.70
0.44

0.15
-0.36
-0.38
-0.17
-0.32
-0.35
-0.11
-0.64
-0.28
-0.35
-0.02
0.02
-0.09
-0.34
-0.10
-0.42
-0.51
-1.20

0.08
0.05
0.06

0.09
0.08
0.09

P90RSK (AB-380)
P90RSK (Ab-573)

P90RSK (Phospho-Thr359/Ser363)

Average for p90RSK

p95/NBS1 (Ab-343)
PLK1 (Ab-210)

0.16
0.20
0.17
0.05
0.13
0.07
0.08
0.11
0.11
0.06

0.05
0.20
0.27
0.05
0.08
0.15
0.09
0.11
0.07
0.03

PP2A-a (Ab-307)
RAD51 (Ab-309)
RAD52 (Ab-104)
Rb (Ab-608)
Rb (Ab-780)
Rb (Ab-795)
Rb (Ab-807)
Rb (Ab-811)
Average for pRb

Smad2/3 (Ab-8)
Smad3 (Ab-179)
Smad3 (Ab-204)

0.03
0.02
0.06

0.01
0.05
0.14

0.88
0.63
0.66
0.77
1.09
0.17
0.64
0.52
0.57
0.74
0.81
0.78

-0.18
-0.67
-0.60
-0.37
0.13
-2.54
-0.65
-0.93
-0.82
-0.43
-0.30
-0.36

0.03
0.06

0.06
0.07

Smad3 (Ab-425)
Average for Smad3
Smad4 (inter)
SMC1 (Ab-957)

0.03
0.20
0.04
0.15
0.05

0.03
0.04
0.14
0.06
0.15

TGFBR1 (Ab-165)
TGF beta receptor II (inter)
TGFBR2 (Ab-250)
Average for TGFBR2
TGF beta1 (inter)
TGF beta2 (inter)

0.06
0.06
0.06

0.03
0.03
0.03

TGF beta3 (inter)
TOP2A/DNA topoisomerase
II (Ab-1106)
Topoisomerase II beta (inter)

0.57
0.65
0.61
0.65

-0.81 0.06
-0.63 0.04
-0.71
-0.61 0.07

0.08
0.04

L647R

p53 (Phospho-Ser20)
p53 (Phospho-Ser315)
p53 (Phospho-Ser33)
p53 (Phospho-Ser37)

-0.22
-0.11
-0.52
0.51
-0.94
-0.31

0.14
0.06
0.04
0.05
0.17
0.09

0.08
0.04
0.03
0.04
0.05
0.02

p53 (Phospho-Ser378)

0.49

-1.03 0.04

0.04

p53 (Phospho-Ser392)

P90RSK (Phospho-Thr573)

0.70
0.82
0.94
0.25
0.93
0.89
0.67
0.97
0.91

-0.52
-0.29
-0.08
-2.00
-0.11
-0.18
-0.59
-0.05
-0.14

0.04
0.04
0.04
0.03
0.07
0.15
0.08
0.13
0.03

p95/NBS1 (Phospho-Ser343)

0.78

-0.35 0.12

0.16

PP2A-a (Phospho-Tyr307)

Smad3 (Phospho-Ser425)

0.80
1.15
0.99
1.00
0.78
0.61
0.63
1.05
0.56
0.89
0.73
0.79
0.89
0.68
1.12

-0.31
0.20
-0.02
0.00
-0.36
-0.70
-0.67
0.07
-0.84
-0.16
-0.46
-0.35
-0.17
-0.55
0.17

0.12
0.05
0.09
0.11
0.03
0.10
0.04
0.04
0.08
0.20
0.01
0.09
0.02
0.09
0.14

0.09
0.03
0.05
0.06
0.08
0.08
0.04
0.10
0.04
0.09
0.06
0.02
0.03
0.07
0.04

SMC1 (Phospho-Ser957)

0.69

-0.54 0.04

0.03

TOP2A/DNA topoisomerase II (PhosphoSer1106)

1.16

0.22 0.02

0.03

p53 (Phospho-Thr18)

p53 (Phospho-Ser46)
p53 (Phospho-Ser6)
p53 (Phospho-Ser9)
p53 (Phospho-Ser366)

P90RSK (Phospho-Ser380)

RAD51 (Phospho-Tyr315)
RAD52 (Phospho-Tyr104)
Rb (Phospho-Ser608)

Rb (Phospho-Ser780)
Rb (Phospho-Ser795)
Rb (Phospho-Ser807)
Rb (Phospho-Ser811)

Rb (Phospho-Thr821)
Smad2/3 (Phospho-Thr8)

Smad3 (Phospho-Thr179)
Smad3 (Phospho-Ser204)
Smad3 (Phospho-Ser208)

Smad3 (Ab-213)

NI

0.86
0.92
0.70
1.42
0.52
0.80

p53 (Phospho-Ser15)

p53 (Phospho-Thr81)
P90RSK (Ab-359/363)

P/NP-L647R /
P/NP-NI

log2 of
Ratio
CV of 6
(Fold
Replicates on a
Change)
Slide

Smad3 (Phospho-Ser213)

0.11
0.08
0.07
0.30**
0.12
0.15
0.08
0.10
0.05

Average for TOPO2
WEE1 (Ab-53)
0.04 WEE1 (Phospho-Ser642)
1.01
0.01 0.09 0.03
Green Text=Expression Significantly Downregulated (>/= 0.31-fold down = a ratio of 0.80 or less); Red Text=Expression Significantly Upregulated
(>/= 0.26-fold up= a ratio of 1.20 or more)
*L647R="L647R PreA": Lysates extracted from 3T3 RheoSwitch cells induced 72 hours (500nM GenoStat) to express L647R PreA; NI="Not Induced":
Lysates extracted from cells treated with DMSO only (no induction reagent)
**Not Statistically Significant: A data-point contained within the set demonstrated a high CV (>0.20)
Text Highlighted in Blue=An Average of the Expression Data Values from Multiple Antibodies toward the Same Protein, or for Phospho-protein, the
†P/NP-L647R/P/NP-NI= Phosphorylation Ratio (Phosphospecific protein detected in assay/Total protein detected in assay) of L647R PreA Expressing
"L647R" (Test) Cell Lysate/Phosphorylation Ratio of "NI" (Not Induced) Control Cell Lysate
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Cross-Referencing Transcript Expression and Protein Expression
In terms of proteins included in the antibody array for which the qPCR array had
indicated transcription was upregulated at 24 hours after L647R PreA expression
induction, several indicate a decreased protein level at 72 hours after induction. Among
these are Cyclins A, D, and E, cyclin dependent kinase inhibitors p21 and p27, Chk1,
E2F4, p53, and Wee1. Cyclin B, for which downregulation of the mRNA transcript was
indicated at 24 hours of L647R PreA expression induction, maintained downregulation
at the protein level. Differential phosphorylation analysis reveals some additional
information about the protein products of those transcripts. The remaining Cyclin E
present in the L647R PreA expressing cells has downregulated phosphorylation at one
site (Ser 395) on which phosphorylation blocks ubiquitination. At the same time, it has
upregulated phosphorylation on a different site (Thr77) where phosphorylation is
associated with targeting the protein for ubiquitin-mediated degradation. With the
downregulation and upregulation of phosphorylation occurring at -0.34-fold, and +33fold, respectively. It would seem further Cyclin E degradation is likely to occur in these
cells.
Despite an overall downregulation of protein expression, the remaining p27
exhibits a pattern consistent with stabilization of the protein, as phosphorylation of
Ser10 phosphorylation is associated with stabilization and upregulated 0.65-fold in
L647R PreA- expressing cells. Notably, however, Ser 187 is thought to be a site on
which phosphorylation signals ubiquitination, and it demonstrates 0.37-fold upregulation
of phosphorylation with L647R expression. However, the stabilizing Ser10
phosphorylation is reported to be more potent215. Similarly, though p53 total protein is
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downregulated, the remaining p53 should be protected from the degradation-promoting
ubiquitin ligase effects of Mdm2, as the demonstrated dephosphorylation of Mdm2
(Ser166) indicates inactivation216. The p53 phosphorylation profile (with upregulated
phosphorylation of Ser315 along with downregulated phosphorylation of Ser20, 33, and
37, and no change in phosphorylation of Ser 6, 15, 46 or Thr 18 or 81) is most
consistent with replicative senescence217.
The tumor suppressor gene BRCA1 indicated upregulation of transcript
production at 24 hours on the RT-qPCR array, but at 72 hours, the protein level of
BRCA1 is either at normal levels or is slightly downregulated with a modest -0.29-fold
change from the protein level detected in uninduced cells. The phosphorylation level,
however, of Ser1524 is upregulated 0.72-fold. Phosphorylation of this site aids BRCA1
facilitation of ATM-mediated phosphorylation of p53 in response to DNA damage (ATMmediated but not ATR-mediated response), as part of induction of the G1/S cell cycle
arrest program of DNA damage response218.
Other DNA damage related proteins downregulated at 72 hours after induction of
L647R PreA expression, for which transcript levels had been upregulated at 24 hours,
include the DNA DSB-induced S-phase checkpoint-activating protein Smc1a and the
phosphatase PP2A/Pppr2r3a. These demonstrate a decreased level of phosphorylation
on sites that are known to functionally activate these proteins, thus indicating
downregulation of activity of these proteins in L647R PreA-expressing cells219,220.
Significantly Altered Expression of Key Cell Cycle Proteins
The antibody array assayed a number of proteins whose transcripts were not
included in the RT-qPCR assay, several of which were significantly affected, either at
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the level of expression or phosphorylation, in L647R PreA-expressing cells. Among
these, the Rb protein did not demonstrate any significant changes in the expression
level but was found to be significantly hypophosphorylated and was thus indicated to be
actively repressing E2F-related transcription. Coordinately, in addition to the previously
mentioned E2F4, the E2F2 and E2F6 transcriptional regulator proteins are
downregulated with 72 hours of L647R PreA expression. Whereas the RT-qPCR
measured the transcript levels of the genes encoding p107 and p130, but not pRb, the
antibody array measures pRb expression/ phosphorylation, but not that of p107 or p130.
Among other proteins included on the antibody array that were not measured at
the transcript level by the RT-qPCR array is the Cdc25 phosphatase family, members A,
B, and C. Cdc25A acts during the G1/S phase of the cell cycle in concert with the
CDK2/cyclin E complex, which it dephosphorylates to enhance cell cycle progression,
and this activity is specifically required for the progression from G1 to S phase. Cdc25A
expression is appreciably downregulated (by as much as -0.66-fold) by L647R PreA on
the antibody array. CDK2 is not significantly hypophosphorylated, which supports the
indication of the relative lack of Cdc25A activity in L647R cells. Also downregulated, by
as much as half the normal expression level is Cdc25B, which is required for the G2/M
phase transition. Cdc25B is phosphorylated and activated by aurora kinase A at the
start of mitosis, and as mitosis progresses is then further phosphorylated in an autoamplification loop, along with Cdc25C, by the CDK1/Cyclin B complex. Both Cdc25A
and Cdc25B can be inactivated by the DNA damage checkpoint kinase, Chk1, thereby
inhibiting progression to mitosis.149 In contrast to members A and B of the Cdc25
phosphatase family, Cdc25C is significantly upregulated with L647R PreA expression,
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at 0.53-fold over normal. Cdc25C phosphorylation, whether mediated by the
CDK1/Cyclin B complex-autophosphorylating feedback route or by polo-like kinase
1(Plk1, which also phosphorylates Cdc25C during mitosis), leads to greater activity of
the CDK1/Cyclin B complex. CDK1, the M-Phase Promoting Factor serine/threonine
kinase required for both G1/S and G2/M phase transitions is tightly controlled in
regulation of the cell cycle, and inhibition of its activity is maintained by constitutive
phosphorylation of Thr14 and Tyr15. These 2 sites are the targets of dephosphorylating
activity of Cdc25C, resulting in activation of CDK1, cell cycle progression at G1/S or
G2/M phase transition, and the ability to block p53-induced growth arrest149. Notably, in
addition to an M-phase promoting upregulation of Cdc25C protein level, the Cdc25C
hypophosphorylation at Ser216 is also indicative of activated Cdc25C. The inhibitory
phosphorylation of Cdc25C at Ser216 facilitates its complexing with 14-3-3, which
occurs throughout interphase but not in mitosis, and results in Cdc25C localization and
sequestration in the cytoplasm221. On the contrary, the hypophosphorylation of Cdc25C
Thr48 indicates inactivation, though it is noted that transitional variants exist between
full inactivation and full activation of the phosphatase, featuring combinations of hyperand hypophosphorylated inhibitory and/or activating regulatory phosphor-sites222.
Meanwhile, although its total protein level is downregulated, CDK1 is
hypophosphorylated at Thr14 (Tyr15 demonstrates hypophosphorylation as well, but the
CV is too high for this data point to be reliably informative). This implies an activated
status for CDK1 (which, in order to be functional, would have to be in complex with
either Cyclin A or B, a variable not measured in this study). As previously mentioned,
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the expression levels of both Cyclin A and Cyclin B are decreased in this expression
profile.
Glycogen synthase kinase 3 (Gsk3) is a kinase involved in glycogen processing
and energy metabolism, Wnt signaling, and cellular proliferation via modulation of Cyclin
D levels. Gsk3β is constitutively active, promoting nuclear export and degradation of
Cyclin D, but is inactivated by mitogenic stimuli and growth factors that induce
phosphorylation on Gsk3β Ser9 (mediated by Akt, p90Rsk/MAPKAPK1, others)223,224.
While we note inactivating Ser9 hyperphosphorylation of the detected Gsk3β in the
antibody array, it is concurrent with a total protein expression level downregulation of
almost 2.4-fold compared to cells not induced for L647R expression, indicating a
substantial overall downregulation of Gsk3β. However, as the Cyclin D levels are also
significantly downregulated in the L647R PreA expressing cells, the decrease in Gsk3β
likely has more implication for energy metabolism than for proliferation.
The cytokine known as transforming growth factor β (TGFβ) has effects on cell
proliferation that are context-dependent. In some situations, it can cause “transforming”
cellular proliferation, as in the experiments involving its overexpression in normal rat
kidney in which it was first described, and from which it derives its name 225.
Alternatively it can, apparently more commonly, act as an instigator of cell cycle arrest
and apoptosis226. In the L647R PreA expressing cells, TGFβ, its signal transducing
proteins, the Smads, and its receptors, TGFβR1 and TGFβR2, each demonstrate
downregulated expression on the antibody array. This multi-component downregulation
within the pathway seems to clearly demonstrate that, at least by 72 hours of L647R
PreA expression, the TGFβ pathway is thoroughly inactivated in these cells.
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The global transcriptional coactivator p300 demonstrates a significantly
decreased expression level in cells induced 72 hours to express L647R PreA. p300
demonstrates 2 modes of activity in transcriptional regulation: as a histone acetyl
transferase (HAT)227 or as a critical bridging coactivator linking the activation domains of
numerous transcription factors to the DNA transcriptional machinery, and the RNA pol
II, in particular228. p300 shares a very high level of homology with another such
transcriptional coactivator, Creb Binding Protein (CBP), and the 2 are frequently
referred to as a single entity, p300/CBP149. (Herein, I will simply refer to p300, with the
implication CBP could serve many of the same functions.) p300 acetylates
nucleosomal histones to activate transcription [reviewed in 229]230,231 , while deacetylation of
histone tails by histone deacetylases (HDACs) generally results in transcriptional
repression232. It is required for cell and tissue function during embryonic development,
cell differentiation in vitro233,234,235, indicating a lack of redundant functions from other
coactivators. According to the protein expression levels detected by two different
antibodies on the antibody array, one directed toward the N-terminus and the other to
the C-terminus of the protein, the L647R PreA-expressing cells demonstrated between 1.39-fold and -2.20-fold change in p300 expression, respectively. Considering p300 cell
cycle functions, which include direct regulation of CyclinE expression levels and activity
and, consequently, activity of the Cyclin E-Cdk1 complex and E2F transcription factors
in promoting cell cycle progression, a decreased p300 protein level could mediate PreArelated cell cycle arrest.
The kinase Akt (also known as protein kinase B, PKB), is a downstream target of
the phosphatidylinositol 3-kinase, is stimulated by growth factors and has many
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functions in metabolism, differentiation, proliferation, and apoptosis149,236. One
important Akt function is to positively regulate the mTOR pathway, controlling protein
synthesis and cell growth. Its activity is frequently upregulated in cancers, as it
suppresses the cell cycle-inhibiting and apoptosis-promoting expression of the FoxO
genes. Akt phosphorylation of FoxO proteins induces binding of 14-3-3 or interaction
with the nuclear export protein exportin (Crm1), and subsequent nuclear exclusion, by
exporting out of the nucleus and/or sequestering FoxO in the cytoplasm, where it is not
functional and tends to be degraded149,237-239. Results of the antibody array indicate a
downregulation of Akt in the L647R PreA expressing cells, but the FoxO1 and FoxO3 do
not appear to be significantly up- or down-regulated by measuring total protein level.
Three different FoxO1 antibodies indicate downregulation at -0.33-, or -0.79-fold, or
upregulated at 0.84-fold, respectively, while the FoxO3 antibody indicates an very slight
downregulation at -0.18-fold. Antibodies directed toward peptides common to FoxO
isoforms 1, 3, and 4, demonstrate -0.46-fold regulation of total protein expression.
However, the subcellular localization of FoxO is the primary means by which it is
regulated, and this cannot be determined with the antibody array assay.
Phosphorylation, which leads to FoxO inactivation and export from the nucleus, is
significantly downregulated, indicating likely nuclear localization and activated FoxOs.
Likewise, as previously mentioned, expression of transcriptional targets of FoxO, the
cell cycle inhibitory p27 and p21, is slightly downregulated. The subcellular localization
of those is also critical to functionality and not measured by this assay.
Taken together, the results of the antibody array demonstrate changes in
expression levels of a variety of proteins that participate in regulation of the cell cycle,
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as well as altered phosphorylation of a number of activating or inhibitory sites on cell
cycle control proteins. These proteins represent several different pathways of cell cycle
control, and implicate PreA as a potential modulator of a network connecting these
pathways in cell cycle regulation.

Motif Analysis of LA Isoforms
An analysis of the peptide motifs of LA isoforms reveals insights to interaction
partners and suggests cell cycle regulatory activity related to those interactions. While
the array studies provide evidence of L647R PreA mediated changes in the expression
levels and apparent functions of many cell cycle proteins, the mechanisms by which
PreA interacts with some or all of these regulators, or with factors upstream of the
measured proteins, are not clear. Thus, we found it necessary to consider factors that
can interact directly with PreA, as potential initiator(s) in cascades of interactions
between other molecules to accomplish the expression level changes we have detected
among cell cycle regulating factors. It is well documented that LA is phosphorylated in a
cell cycle dependent manner and that modification by phosphorylation precedes the
dissociation of LA proteins from the nuclear membrane during mitosis240,241. Several
different phosphorylation sites have been reported in mature LA242. As phosphorylation
modification of proteins is a key regulatory mechanism for directing the cell cycle, we
started our motif analysis by focusing on kinase substrate motifs, then we examined
binding site motifs that require phosphorylation to activate or inactivate binding
potential, and, finally, we briefly review other binding sites or interaction partners
described in the current scientific literature.
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Kinase Substrate Motifs in PreA
To survey kinase substrate motifs to determine possible PreA binding and
interaction partners, we performed an initial motif analysis on the amino acid sequence
of full length PreA, using the using the PhosphoMotif Finder application
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on the

Human Protein Repository Database (HPRD, http://www.hprd.org/), which is a
compendium of annotated motifs for which curated literature is cross-referenced to
support the indicated interactions with the recognized motifs120. The Phosphosite
website is also a curated database of protein phosphorylation information that was
useful (www.Phosphosite.org)117-119. We also queried the Phospho.ELM Database
(http://elm.eu.org/)116, which performs analyses similar to HPRD PhophoMotif Finder but
uses homology to intuitively predict interactions (which HPRD claims, specifically, not to
do), comparing the target sequence to “incidents” (sequence matches against
previously encountered motifs) in its database. ELM does cross-reference against
annotations from literature sources by pattern hit initiated (PHI) basic local alignment
search tool (BLAST) methodology, which focuses a BLAST search on patterns that
belong to a known interaction motif[reviewed in 244]. This database introduces to the
analysis a number of filters for “SMART” exclusion of homology-based predictions
based upon the domain context of the peptide sequence, such as excluding predicted
interactions that would not be known to occur within a globular domain when the motif in
question occurs within a sequence indicating the presence of that particular structural
domain116. However, this database could also possibly return predicted motif matches
that do not have support in literature, and such computational predictions must be
interpreted more succinctly as predictions only. In the PhosphoMotif Finder analysis243,
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we found 363 motifs in Prelamin A that would be susceptible to phosphorylation by a
variety of Serine/Threonine kinases and 13 Tyrosine kinase substrate sites. As we
have particularly focused this study on deciphering functions of the Prelamin A isoform,
we narrowed the results of the motif analysis to concentrate on the section of the protein
that differs among the isoforms, the C-terminus (PreAct). The posttranslational
modifications result in the cleavage processing of the 664 amino acid residue length
protein to terminate at the site of Zmpste24 cleavage. The tyrosine residue at amino
acid position 646 becomes the C-terminus postcleavage. As the peptide sequence
actually differentiating PreA from wtLA consists of residues 647-664, we decided to
include a longer c-terminal section in our analysis, beginning with residue 598 (Figure
29). Extending the analysis to include residues 598-646 allows interrogation of any
binding sites that might overlap into the sequence 5’-to the Zmpste24 truncation site.
Also, as residue 608 is the site introducing the causative cryptic splicing-variant that
encodes Progerin, including the additional sequence allows for some comparison of
functionality to Progerin. Thus, we reasoned, interrogating residues within the 598-664
residue C-terminal fragment could help differentiate PreA isoform function from Progerin
function. We refer to this fragment herein as “the C-terminal 66 fragment.” Table 4
contains results of the Serine/Threonine kinase substrate analysis for the C-terminal 66
fragment, while a full length survey is included as Appendix C.
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Figure 29. Lamin A C-terminal 66 Amino Acid Fragment Considered In Motif Analysis.
Red text (Q/VG) indicates the G608G HGPS mutation site resulting in removal of amino
acids 607-656 from the resulting protein (Progerin); the RSY/LLG sequence is
recognized by Zmpste24 in normal Lamin A posttranslational maturation, which cleaves
the protein between the Y/L residues at amino acid positions 646-647, to yield “mature”
Lamin A; the C/SIM residues form the CaaX-box, which undergoes the initial cleavage
(–aaXing), to remove the SIM residues 662-664 in the normal maturation process,
following farnesylation of the C residue.
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Table X Page 1 of 2. Prelamin A C-terminus Serine/Threonine Kinase
Table 4. Prelamin A C-terminus Serine/Threonine Kinase Substrate Motif Analysis
Substrate Motif Analysis
Amino

AMINO

Acid

ACID

Residue #

SEQUENCE

598 - 603

ASASGS

X[pS/pT]XXX[A/P/S/T]

599 - 601

SAS

599 - 603

KINASE FOR THE INDICATED

Motif #

SUBSTRATE MOTIF

(of 363)

G protein-coupled receptor kinase 1

313

pSX[E/pS*/pT*]

Casein Kinase II

314

SASGS

pSXXX[pS/pT]

MAPKAPK2 kinase

315

599 - 603

SASGS

pSXXXpS*

GSK3 kinase

316

611 - 616

ISSGSS

X[pS/pT]XXX[A/P/S/T]

G protein-coupled receptor kinase 1

317

612 - 615

SSGS

[pS/pT]XX[S/T]

Casein Kinase I

318

Casein Kinase II

319

Casein Kinase II

320

MAPKAPK2 kinase

321

GSK3 kinase

322

SUBSTRATE MOTIF

2

612 - 615

SSGS

pSXX[E/pS*/pT*]

612 - 615

SSGS

[pS/pT]XX[E/D/pS*/pY*]

612 - 616

SSGSS

pSXXX[pS/pT]

612 - 616

SSGSS

pSXXXpS*

613 - 615

SGS

pSX[E/pS*/pT*]

Casein Kinase II

323

615 - 620

SSASSV

[pS/pT]XXX[S/T][M/L/V/I/F]

Casein Kinase I

324

616 - 618

SAS

pSX[E/pS*/pT*]

Casein Kinase II

325

616 - 619

SASS

[pS/pT]XX[S/T]

Casein Kinase I

326

616 - 619

SASS

pSXX[E/pS*/pT*]

Casein Kinase II

327

616 - 619

SASS

[pS/pT]XX[E/D/pS*/pY*]

Casein Kinase II

328

618 - 623

SSVTVT

X[pS/pT]XXX[A/P/S/T]

G protein-coupled receptor kinase 1

329

619 - 621

SVT

pSX[E/pS*/pT*]

Casein Kinase II

330

627 - 632

RSVGGS

X[pS/pT]XXX[A/P/S/T]

G protein-coupled receptor kinase 1

337

628 - 632

SVGGS

pSXXX[pS/pT]

MAPKAPK2 kinase

338

628 - 632

SVGGS

pSXXXpS*

GSK3 kinase

339

632 - 637

SGGGSF

[pS/pT]XXX[S/T][M/L/V/I/F]

Casein Kinase I

340

635 - 641

GSFGDNL

XpSXXDXX

Pyruvate dehydrogenase kinase

341

636 - 639

SFGD

pSXX[E/D]

Casein kinase II

342

636 - 639

SFGD

[pS/pT]XX[E/D]

Casein Kinase II

343

636 - 639

SFGD

[pS/pT]XX[E/D/pS*/pY*]

Casein Kinase II

344

636 - 639

SFGD

[pS/pT]XX[E/D]

Casein Kinase II

345

643 - 646

TRSY

[pS/pT]XX[E/D/pS*/pY*]

Casein Kinase II

346

1

Table continues on next page…

1

Consecutive order of the indicated motif among the 363 Serine/Threonine Kinase Substrate sites
identified within the full-length Prelamin A protein sequence.
2
*=This phosphorylation modification “primes” the site, and must occur prior to the substrate recognition
and subsequent phosphorylation of other residues within the motif.
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Table 4 (continued)
Table X Page 2 of 2 (continued from previous page).
Amino

AMINO

Acid

ACID

Residue #

SEQUENCE

650 - 653

NSSP

XXpSP

650 - 655

NSSPRT

X[pS/pT]XXX[A/P/S/T]

651 - 653

SSP

X[pS/pT]P

651 - 655

SSPRT

652 - 653
652 - 654

SUBSTRATE MOTIF

KINASE FOR THE INDICATED

Motif #

SUBSTRATE MOTIF

(of 363)

GSK-3, ERK1, ERK2, CDK5

*
G protein-coupled receptor kinase 1

347

GSK-3, ERK1, ERK2, CDK5

349

pSXXX[pS/pT]

MAPKAPK2 kinase

350

SP

pSP

ERK1, ERK2 Kinase

351

SPR

[pS/pT]P[R/K]

Growth associated histone HI

352

348

kinase
652 - 654

SPR

[pS/pT]X[R/K]

PKA kinase

353

652 - 654

SPR

[pS/pT]X[R/K]

PKC kinase

354

652 - 655

SPRT

[pS/pT]XX[S/T]

Casein Kinase I

355

652 - 655

SPRT

pSXX[E/pS*/pT*]

Casein Kinase II

356

654 - 657

RTQS

RXXpS

Calmodulin-dependent protein

357

kinase II
654 - 657

RTQS

RXXpS

654 - 657

RTQS

RXX[pS/pT]

PKA kinase

358

Calmodulin-dependent protein

359

kinase II
654 - 657

RTQS

[R/K]XX[pS/pT]

PKC kinase

655 - 658

TQSP

XXpSP

GSK-3, ERK1, ERK2, CDK5

656 - 658

QSP

X[pS/pT]P

GSK-3, ERK1, ERK2, CDK5

657 - 658

SP

pSP

360

*

ERK1, ERK2 Kinase

361
362
363

*Site also predicted by ELM as ProDK (proline directed kinase) substrate
Phosphorylation of the PreA C-Terminus
Using the PhosphoSite database117-119, we located curated data documenting
functional effects of phosphorylation of the indicated LA residues (Figure 27). In
addition, a large scale phosphoproteomics study found most of the same sites as HPRD
and Phospho.ELM, plus 2 additional sites (Thr623 and Ser625), that were found to be
phosphorylated, as well. Interestingly, this study reports LA to be 1 of 27 proteins in the
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global proteomic analysis that demonstrate a “high level of phosphorylation site
occupancy” during mitosis242. Sites indicated to have a high level of phosphorylation
during mitosis are highlighted on the Figure 27 graphic.

N-terminal Phosphorylation Sites Rod
Domain

Ig Fold and Flanking Residues

C-terminal Phosphorylation Sites

T3; S5; S12;S17; S18; T19; S22; T24;
S51; T64; S66; T81; S94; S107; T199;
S212; S277; S301; S303; S326; S390;
S392; T394; S395; S398; S403; S404;
S406

S407; T409; S414; T416; S423; T424;
S426; S428; S429; S431; S458; S463;
T480; S502; T505; T510; S525; S533;
T548

S613; S615; S616; S618; S619; 623; 625;
S628; S632; S636; S651; S652; S657
Noted as highly phosphorylated in mitosis

Figure 30. Phosphorylation Sites on Lamin A Protein (Compilation Graphic) with
Functional Indications. Phosphorylation Sites on Lamin A protein, indicated by the
curated Phosphosite database. Some cellular functions documented to be affected by
the phosphorylation modifications are indicated. Also, one of the studies referenced by
Phosphosite indicates LA is extensively hyperphosphorylated during mitosis, these
sites are circled/highlighted in blue. This figure is adapted from a Phosphosite graphic,
using additional data from Olsen, et al., Science Signaling, 2010.
Our own experiments to investigate PreA-tail phosphorylation involved Edman
Degradation-based radioisotope-labeled (32P) amino acid residue sequencing of the Cterminal fragment of PreA. In the Edman Degradation method of peptide mapping,
peptides are incubated with the radiolabeled phosphorus, then the N-terminal residues
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are “released” from the peptide one-by-one by as the free amino group reacts with
phenylisothiocyanate, and can be identified using mass spectrometry on their
phenylthiohydantoin derivatives245. As for our purposes, when the sequence and length
of a peptide are known, the assay can be used to detect which residues have the
radioactively-labeled phosphorus attached to them, indicating that residue was
phosphorylated.
Phosphorylation of Prelamin A and Progerin C-Termini
A

B
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T

Q S P Q N
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P

5

A S A S G S G
0

6

1

2

3

4

5

6 7

P
P

32P
32

32
32

Origin
origin

WT-Prelamin A
WT-Prelamin A

Progerin
Progerin

541 RKLVRSVTVV EDDEDEDGDD LLHHHHGSHC SSSGDPAEYN LRSRTVLCGT CGQPADKASA
601 SGSGAQ^VGGP ISSGSSASSV TVTRSYRSVG GSGGGSFGDN LVTRSY^LLGNSSPRTQSPQN
661 CSIM

Lamin A C-terminus: TQSPQNCSIM
Progerin C-terminus: ASASGSGAQSPQNCSIM

Figure 31. Radiolabeled Phosphorylation Peptide Mapping of the Lamin A C-Terminus.
Phospho-mapping of the C-terminal LA peptide fragments by Edman Degradation of
[32]
P-labeled wild type Lamin A (PreA, Panel A, left) and Progerin (Panel A, Right) Cterminal peptides involve separation of residues by HTLE and detection by
phosphorimaging. The cyclical release of individual N-terminal amino acids of the
peptide reveals a radioactive signal with the first [32]P-labeled residue (phosphorylated)
to be released from the peptide. Signal is cumulative when additional phosphorylated
residues “cycle off” (release, with each cycle) in subsequent reaction cycles. Panel B
graphic combines the Panel A Progerin Degradation, with an additional reaction using a
shorter terminal peptide, as the reaction in Panel A was exhausted with the 4 terminal
residues unmapped.

The peptide mapping in Figure 31 demonstrates the induced GFP -wtLA (which
accumulates primarily as FC-PreA) is phosphorylated on Ser-657. The GFP-Progerin
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C-terminus demonstrates substantial phosphorylation of Ser-601 but only a minimal
level of Ser-657 phosphorylation. The phosphorylation of LA Ser-657 is described in
only one report, a study a by Lee et al.246, investigating mechanisms of Epstein Barr
Virus (EBV) nuclear egress. During viral nuclear egress, the lamina is depolymerized,
apparently through an ability of viral kinases to mimic host endogenous kinases and
hijack of phosphosites of proteins, such as LA. The study reports EBV- and herpes
virus-mediated depolymerization of LA during nuclear egress of the virion particles, and
detection of phosphorylation on Ser-19, Ser-22, Ser-390, Ser-392, Ser-652, and Ser657 of the depolymerized LA246. HPRD reports the 657 residue to be part of a kinase
substrate site for GSK3, ERK1/2, Protein Kinase A or C (PKA/C), and/or CamK2
kinases. While we have been unable to find a study in the current scientific literature
demonstrating detection of Ser-601 phosphorylation, HPRD reports the site to be a
substrate domain for CK2. Future studies might evaluate for functional effect of this
modification and determine if it also exists in wtLA/PreA, as well, or whether the altered
sequence context of Progerin differently affects this site.

Phosphorylation-Dependent Protein Binding Motifs in PreA C-Terminus
We continued the database analysis to evaluate protein binding sites that contain
phospho-sites and demonstrate phosphorylation-mediated control of the binding.
Although 13 Tyrosine kinase substrate motifs were identified, only one of these occur
within the C-terminal 66 fragment: a JAK2 kinase substrate motif (pYXX[L/I/V] involving
residues 626-629 (YSRV). There were no Tyrosine phospho-dependent protein binding
domain sites reported within the fragment, but the sequence does contain11 binding
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sites that require Ser/Thr- kinase phosphorylation, as shown in Table 5 (there are 39,
total, indicated in the full PreA sequence, shown in Appendix D).
Table 5. Serine/Threonine Kinase-Dependent Protein Domain Binding Motifs within the
Table X.ASerine/Threonine
Kinase-Dependent Protein Domain Binding Motifs within
Prelamin
C-Terminal Fragment
Prelamin A C-terminal Fragment
Amino

AMINO

Acid

ACID

Residue #

SEQUENCE

612 - 614

SSG

S[pS/pT]X

MDC1 BRCT domain binding motif

29

612 - 614

SSG

S[pS/pT]X

Plk1 PBD domain binding motif

30

615 - 617

SSA

S[pS/pT]X

MDC1 BRCT domain binding motif

31

615 - 617

SSA

S[pS/pT]X

Plk1 PBD domain binding motif

32

618 - 620

SSV

S[pS/pT]X

MDC1 BRCT domain binding motif

33

618 - 620

SSV

S[pS/pT]X

Plk1 PBD domain binding motif

34

651 - 653

SSP

S[pS/pT]X

MDC1 BRCT domain binding motif

35

651 - 653

SSP

S[pS/pT]X

Plk1 PBD domain binding motif

36

652 - 653

SP

[pS/pT]P

WW domain binding motif

37

654 - 657

RTQS

RXXpS

14-3-3 domain binding motif

38

657 - 658

SP

[pS/pT]P

WW domain binding motif

39

DOMAIN BINDING MOTIF

BINDING MOTIF DESCRIPTION

Motif #
(of 39)

1

1

Consecutive order of the indicated motif among the 39 Serine/Threonine Kinase-Dependent protein domain
binding motif sites identified within the full-length Prelamin A protein sequence.

Three different phosphorylation-dependent binding motifs were identified by
PhosphoMotif Finder, within the C-terminal 66 fragment. First, there is a series of 4
Mediator of DNA Damage Checkpoints 1 protein (Mdc1)/Polo-like Kinase 1 (Plk1)
shared binding sites, of which the first 3 are retained following Zmpste24 proteolysis of
the PreA protein to form LA in the normal maturation processing. The second motif is
the 14-3-3 binding motif, which occurs only once in the fragment, and is lost with
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Zmpste24 cleavage. The third motif is the WW domain-binding site, found in 2 positions
that are removed in the normal maturation processing of LA. Notably, all of these
binding sites are deleted from del50/Progerin except the most 3’ WW domain-binding
site at amino acid sequence position 657-658 (graphic representation in Figure 32).
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delta50

F

606-607
PLK1
MDC1 573

LA

Q V PIN1
QNC
Δ608

CO
CH3

PLK1/MDC1 Binding Site
14-3-3 Binding Site

606-607
PLK1

Q V

MDC1 573

646-647
PLK1

PLK1

612 MDC1

MDC1

MDC1 621 646

Farnesyl Modification Site

--24 aa--

Carboxyl Methylation Site

Q V

MDC1

573

RSY L

F

606-607
PLK1

Cleavage Site

PLK1

--39aa--

PreA

WW Domain (Pin1) Binding Site

646-647
PLK1

PLK1

PLK1

612 MDC1

MDC1

MDC1 621

--39aa--

RSY LLG

PLK1

650 MDC1

PIN1

14-3-3

PIN1

QNC

CO
CH3

--29 aa--

Prelamin A

3-4 17–19
48-51 72-75
19-20
22-23

149-151

298- 331- 390- 391/ 401-404/ 423-425 455301 334 392-393 403-405/ 428-430 458
406-408

507- 533508 535

571573

612-614/ 651-653/
615-617/ 652-653
618-620 654-657
657-658

149-151

298- 331- 390- 391/ 401-404/ 423-425 455301 334 392-393 403-405/ 428-430 458
406-408

507- 533508 535

571573

612-614/ 651-653/
615-617/ 652-653
618-620 654-657
657-658

149-151

298- 331- 390- 391/ 401-404/ 423-425 455301 334 392-393 403-405/ 428-430 458
406-408

507- 533508 535

571573

612-614/ 651-653/
615-617/ 652-653
618-620 654-657
657-658

Lamin A

3-4 17–19
48-51 72-75
19-20
22-23

del 50

3-4 17–19
48-51 72-75
19-20
22-23

Figure 32. Arrangement of Phosphorylation-Dependent Protein Motif Binding Sites in
the PreA C-Terminal 66 Residue Fragment.
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Cross-Reference of Kinase Substrate Sites and
Kinase-Dependent Protein Motif Binding Sites
The cell cycle-related periodicity of the kinases controlling the phosphorylationdependent binding for the sites is an important consideration to indicate possible clues
as to cell cycle progression-related timing of activation of these binding sites. For
instance, determining conditions during which the kinases GSK3, ERK1/2, CDK4/5, and
possibly CK1/2, act on LA could provide potential information regarding the sites in LA
that are substrate-candidates for those particular kinases (Ser19-20 and Ser22-23), in
addition to the CDK1-phosphorylation activity toward Ser22 described previously.247
Similarly, Ser390-391 and 392-393 are possible substrates for ERK1/2, CK1/2,
MAPKAPK2 (Rsk90), or DNAPK (DNA dependent Protein Kinase), and Ser652-53 and
Ser657-58 are potential substrates for ERK1/2, MAPKAPK2, Growth assoc H1 Kinase,
PKA/C, CK1/2; CamK2, or GSK3. Figure 33 provides a graphic representation of the
PreA C-terminal 66 amino acid fragment kinase substrate motifs as well as the
phosphorylation-dependent binding sites.
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Figure 33. Combined Graphic of Kinase Substrate Motifs/Protein Motif Binding Sites
in PreA C-Terminus. Graphic Representation of Kinase Substrate Sites &
Phosphorylation-Dependent Binding Sites in PreA C-terminal 66-Amino Acid Fragment.

Cross-Reference of Genes/Proteins with Altered Expression vs. Motif Analysis Findings
The 14-3-3 “adapter protein” has already been discussed as an important
regulator of cell cycle, as it has demonstrated altered expression with L647R PreA
expression, on the qPCR and antibody arrays and has been previously annotated as a
Lamin A-interacting protein172. The Polo-like Kinase 1 was included in the antibody
array and demonstrates a 0.35-fold downregulation of protein expression in cells
induced to express L647R PreA. This kinase shares a phosphorylation-dependent
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binding site motif with Mdc1. In addition to ATM, ATR, and Chk1/2, 2 of the most critical
DNA damage response proteins are Plk1 and Mdc1. Mdc1 is a key regulator involved
in several cellular pathways including apoptosis induction, G2/M, and intra-S-phase cell
cycle arrest248,249. Mdc1 acts not only as a mediator of DNA damage checkpoints but
also as a mediator of DNA damage repair250. Studies suggest ATM is actually a
downstream target of Mdc1251,252, wherein Mdc1-mediated activation of ATM induces
phosphorylation/ activation of Chk2, which in turn interacts with Mdc1 and relocalizes to
the DNA damage sites, suggesting a critical role for Mdc1 in the Chk2-mediated DNA
damage response248,253. Active Chk2 is responsible for the inhibitory phosphorylation of
Cdc25C at Ser216, leading to a Cdk2-mediated G2/M arrest (we report Cdc25C Ser216
phosphorylation downregulation, with L647R PreA expression), and Chk2 also
promotes apoptosis by phosphorylation of p53 on Ser20 (also downregulated with
L647R PreA). Mdc1-ATM-activated Chk2 also negatively regulates Plk1, blocking its
ability to promote entry to mitosis, and upregulation of Mdc1 leads to downregulated
expression and activity of Plk1, along with accumulation of cells in S-phase or arrested
at the G2/M transition254,255. Mdc1 is required for assembly of the Mre11-Rad9-Nbs1
(MRN) DNA damage repair complex with ɣH2AX256 and is required for retaining p53binding protein 1(53BP1) at sites of DNA damage256,257. Thus, the major factors of DNA
damage response and repair are unable to complex and execute repair without Mdc1.
WW Domain Proteins (Pin1)
The 2 WW domain binding motifs residing in the C-terminal 66 fragment are
separated by the single 14-3-3 protein binding motif (Figure 32, Table 5). In fact, the 2
WW domain binding sites each overlap one of the other binding motifs, one with a slight
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overlap of the last Mdc1/Plk1 binding site in the sequence, and the other WW domainbinding site slightly overlaps the most c-terminal 14-3-3 site. WW domains consist of
approximately 35-40 amino acids and contain 2 Tryptophan residues (hence the
moniker “WW” domain), with β-sheets formed around the aromatic Tryptophans.
Binding motifs for WW domains require proline residues. As for binding partners
targeted to the WW domain binding motifs, HPRD identified 53 mammalian proteins
with WW domains, 17 of which are nuclear120. ProSite, a bioinformatics tool curated by
the UniProt Consortium: European Bioinformatics Institute (EMBL-EBI), Swiss Institute
of Bioinformatics (SIB) and the US’s Protein Information Resource (PIR), produced a list
of 24 human nuclear compartment proteins containing WW domains258,259 (Appendix E).
Included among these nuclear WW domain-containing proteins are several
transcriptional regulators and accessory proteins, others that participate in scaffolding of
receptor signaling complexes, ubiquitin ligase proteins (including 2 that are specific to
regulation of SMADs), an oxidoreductase involved in apoptosis, Dystrophin (the protein
mutated in Duchenne and Becker Muscular Dystrophy), Utrophin (involved in
cytoskeletal anchoring), Mlh3 (a mismatch DNA-repair protein), and the peptidyl prolyl
cis-/trans- isomerase (PPIase) Pin1. While several of these are relevant in terms of
specific cell cycle and homeostasis functions, Pin 1 has demonstrated many essential
functions in cell cycle control260 and interacts with number of cell cycle regulatory
proteins (including Akt261,262, p27263,264, FoxOs264,265, p53266,267, Plk1268, Cdc25269,270,
RNA Polymerase II271, and Smads272), see Figure 34.
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Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Molecular Cell Biology, Lu and Zhou (2007)

Figure 34. Pin1 Targets and Molecular Mechanisms. This graphic depicts the variety
among Pin1 targets, as well as among the several mechanistic activities of Pin1 273.

Importantly, there are 4 different classes of WW domains, differentiated by ligand
specificity. The binding motif repeated in the PreA sequence consists of a phosphoSerine-Proline pairing that fits the Type IV WW Domain classification, for which Pin1
appears to be unique among human nuclear proteins274. Therefore, considering the
complexity of pathways regulated by Pin1, and the equally complex effects of L647R
PreA expression upon cells (as indicated by the number of gene products
demonstrating altered expression), as well as the unique motif specifications and
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nuclear compartment localization, Pin1 was the most attractive of the candidate proteins
for further investigation. Furthermore, during the course of our study, Milbradt et al.
published a study in which they present a fascinating and elegant analysis of a Human
Cytomegalovirus (HCMV) mechanism of nuclear egress. HCMV directs viral kinase
activity toward Lamin A to induce binding of Pin1 and subsequent localized
depolarization of the nuclear lamina, similar to the depolarization involved in cytokinesis,
which appears to be dependent upon Pin1 isomerization of the Lamin A proteins. This
group used a similar bioinformatics analysis (using the ELM database, only, however) to
determine Pin1 as a candidate for binding Lamin A275. They cite a previous report
regarding HCMV viral kinase mimicry of Cdk1 in Ser22 phosphorylation of Lamin A and
subsequent nuclear membrane disruption247, which directed their attentions toward the
N-terminus of the Lamin A protein. Interestingly, Milbradt et al. arrived at the same
conclusions as have we regarding a likely fit with Pin1 for the Type IV classification of
the WW domain-binding motif in Lamin A, and the results of their work confirm Pin1
binding to Lamin A275. Therefore, we focused our attention regarding the WW-domainbinding motifs in the PreA C-terminus upon Pin1 and refer to the relevant motifs as
“Pin1binding motifs.” We find 2 individual sites and 3 sets of 2 adjacent WW/Pin1binding sites in the sequence of LA, and interestingly, the 3 2-site sets are Ser-19/20,
Ser-390/392, and Ser-652/657—the same sites identified in the Lee group study of
EBV-mediated depolymerization of LA, which supports the Milbradt work in further
implicating Pin1-mediated depolymerization of LA as a mechanism for viral nuclear
egress.
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Coimmunoprecipitation of Pin1 with L647R PreA
Binding of Pin1 by accumulated PreA could represent an extremely important
layer of cell cycle control. Pin1 is sometimes described as a “mitotic rotamase,” as most
of its regulatory action promotes mitotic progression276. In the investigation of a Pin1PreA-mediated role in cell cycle regulation, we first asked the question whether Pin1
can bind to accumulated PreA protein in vitro, as the Milbradt group had shown for
mature LA275. Immunoblotting, in Figure 35, depicts the increasing level of coimmunoprecipitated Pin1 protein detected in relation to increasing levels of accumulated
uncleavable PreA.

Ig Bands

Figure 35. Co-Immunoprecipation of Pin1 Protein with EGFP-L647R PreA. Lysates
were prepared from RheoSwitch L647R-PreA cells prior to induction (0 hours), and after
24, 48, 72 hour timepoints following induction with 500 nM GenoStat. Whole cell
lysates were quantitated and 200 µg total protein used for each immunoprecipitation, 50
µg was reserved for whole cell lysate (WCL) loading. Anti-GFP antibody was used to
precipitate expressed EGFP-L647R protein. Equal volumes of denatured precipitated
protein solution and corresponding WCLs were separated by SDS-PAGE, then blotted
using anti-Pin1 antibody. “No 1o” lane sample= Co-IP control (pooled lysate processed
as Co-IP without addition of anti-GFP antibody; Anti-tubulin loading control); MWM =
molecular weight marker. Immunoglobulins from the IP are evident on the Co-IP blot.
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These co-immunoprecipitation studies demonstrate Pin1 complexing with fulllength, uncleavable EGFP-fused PreA (in the form of the accumulated EGFP-fused
L647R PreA), from induced cells of our RheoSwitch L647R PreA cell line. Pin1 is
reported to have some increased expression stimulated by increased growth factors but
a relatively steady expression level in proliferative cells. Pin1 does show increased
nuclear localization upon increasing levels of activation dependent on the availability of
phosphorylated substrates. Pin1 expression is hardly detectable in cells that are not
proliferating and is upregulated in many cancers[as reviewed in 273 ]. In Figure 35, the WCLs
for uninduced cells and for L647R PreA-accumulating cells over the 72-hour time
course demonstrate approximately even levels of Pin1 total protein in the cells. As
L647R PreA accumulated over the 72 hours, though, an increasing amount of Pin1 is
evident in the protein complex precipitated by the GFP antibody. Although specific
binding to PreA cannot be concluded from this experiment, association of Pin1 and
EGFP-PreA in complexes is indicated. Given that the overall cellular level of Pin1
expression demonstrated very little to no change over the 72-hour course of L647R
PreA accumulation, we next asked if the increased concentration of Pin1 in complex
with the accumulating EGFP-L647R PreA was representative of an increase in nuclear
compartment subcellular localization of Pin1. To investigate, we performed
immunofluorescent imaging, using an antibody to Pin1 protein, on L647R PreAexpressing cells and uninduced L674R cells. This analysis reveals the subcellular
distribution of Pin1 in these cells, Figure 36.
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Figure 36. Immunostaining of Pin1 Protein in L647R PreA-Expressing Cells. Pin1
subcellular localization was detected by indirect immunofluorescence, using an antibody
to Pin1. Fluorescence pattern is demonstrated for Uninduced (DMSO-treated) cells of
the L647R PreA Rheoswitch model in the left panel. The cells shown in the right panel
were L647R PreA-expressing Rheoswitch 3T3 Cells, Induced 48 hours (500 nM
GenoStat).

The distribution of Pin1 in uninduced cells appears to be primarily nuclear, but
with staining evident throughout the cytoplasm. After 48 hours of L647R expression,
many cells exhibit a strongly increased pattern of Pin1 nuclear localization.
Taken together, these results indicate induction of L647R PreA-expression has
little effect on the cellular expression level of Pin1. However, the nuclear localization is
significantly enhanced, and the increased nuclear localization correlates with the
increased level of Pin1 detected in complex with GFP-L647R PreA. We suspect Pin1
complex formation with L647R PreA could represent a functional scaffolding of Pin1
upon the lamina for stabilizing and organizing its interactions, or alternatively, that PreA
sequesters Pin1 protein. PreA-mediated Pin1 sequestration could have substantial
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effects on cell cycle regulation. Future work will investigate for differential effects on
Pin1 expression and localization related to expression of different LA isoforms, whether
the Pin1-binding is influenced by mutations in the WW/Pin1-binding sites on Lamin A,
and whether the PreA C-terminal tail region has specific importance in that binding
schema. Although it is shown LA binds Pin1275, because increased expression and
accumulation of LA protein occurs in the form of PreA, “increased sequestration” related
to increased LA expression would be, in actuality, most likely associated with the
accumulated PreA protein isoform. Inhibition or deletion of PIN1 leads to mitotic entry,
chromatin condensation and mitotic catastrophe 277,278 [and reviewed in 273 ]. Considered
along with the facts (1) progerin and PreA both accumulate with cellular passaging as
well as in HGPS, and (2) highly passaged cells and HGPS cells demonstrate aberrant
mitosis, the ability of different LA isoforms to associate with Pin1, and the potential
effects of such associations, could be an important topic to follow up.

Pin1 Target Expression in L647R PreA Expressing Cells: (FoxOs/p27Kip1)
In response to low energy or lack of growth factors, as from mitogen deprivation
or treatment with cAMP, inhibition of cell proliferation partially depends on a decrease in
cyclin D1 or an increase in p27Kip1 279-282. Cyclin D1 in complex with CDK4 or CDK6
promotes proliferation by phosphorylating pRb, releasing its repressive binding to E2F
transcription factors and thus inducing genes involved in DNA replication 283. The
PI3K/PKB/Akt pathway regulates cyclin D1 levels posttranscriptionally by targeting it for
degradation284, at the translational level involving p70S6 kinase285,286 as well as
transcriptionally via regulation of forkhead box O (FoxO) transcription factors287,288. The
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FoxO family of transcription factors, include FoxO1, FoxO3, and FoxO4, which
demonstrate some differences of expression in various tissue types but seem to exhibit
significant overlap in function, and FoxO6, whose expression appears to be restricted to
the brain289. The different FoxO family members share a common DNA-binding site,
regulate overlapping sets of target genes290, and participate in diverse processes
including cell proliferation, apoptosis, stress resistance, differentiation, and
metabolism291. Consistent with their participation in a broad spectrum of processes, the
FoxO proteins are regulated by a variety of mechanisms, including phosphorylation,
acetylation, ubiquitination, and methylation 291,292. These modifications alter FoxO
intracellular localization, turnover, transactivation activity, and transcriptional
specificity293. The capacity to undergo such a variety of modifications under contextspecific situations, in addition to their ability to associate with many different cofactor
complexes to regulate context-dependent programs of gene expression294, make the
FoxOs highly versatile in gene regulation. Depending on their status of modification and
selection of binding partners, they can act as direct or indirect transcriptional activators
or repressors295. E2F1 induces FoxO1 and FoxO3 transcription296, and FoxO3
expression induces a feedback transcriptional upregulation of itself, as well as
FoxO1297.
In the absence of growth factors, active FoxOs reside in the nucleus and upregulate genes that inhibit the cell cycle (p27Kip1 and p21WAF1), promote apoptosis (Fas
ligand, Bim, and TRAIL), and decrease oxidative stress (superoxide dismutase and
catalase). A number of genes are also repressed by activated FoxOs, including Cyclin
D isoforms298. Our antibody array data suggest L647R PreA may act to stabilize
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FoxOs, for example, we see a significant downregulation of D-type cyclin proteins, and
a slight upregulation of FoxO1 protein expression (Table 5). While FoxO3a expression
levels were not significantly impacted by L647R PreA expression, this assay does not
take into account subcellular localization of the proteins and, therefore, cannot be taken
as a direct indication of FoxO3a activity. The antibody array did detect upregulation of
FoxO1, transcription of which is mediated by FoxO3, and we consider the observed
FoxO1 upregulation to be one likely indicator of FoxO3a activation and stabilization
even though detected expression level of FoxO3a is not upregulated. In addition, we
consider posttranslational FoxO modifications and examine known FoxO targets for
indication of FoxO activation. We note levels of expression of FoxO4 and FoxO6
proteins were not measured. FoxO targets, p27KIP1 and p21WAF1 offer a confusing
picture in our expression studies, as their expression at the transcript level after 24
hours of L647R PreA induction, detected by the qPCR array, indicate upregulation
(approximately 26.7-fold upregulation of p27Kip1 and more than 2.6-fold upregulation of
p21WAF1), whereas the antibody array did not detect an altered regulation of either CKI
at the protein level after 72 hours of induction. As phenotypic evidence, from observing
signs of induced cell cycle arrest, seems to argue favorably for the likelihood of
increased p27Kip1 and/or p21WAF1 activity, we chose to continue investigating these, in
part by continuing our focus on FoxO regulation.
Activity of FoxOs in transcriptional regulation is first dependent on localization to
the nucleus. A number of mechanisms exist to exclude from the nucleus and thus
inactivate FoxOs, such as phosphorylation by several kinases—including the
phosphatidyl-inosititol-3-OH kinase (PI3K) pathway activated kinase PKB/Akt299,300, the
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serum- and glucocorticoid-inducible kinase (SGK)301, casein kinase I (CK1)302, IKKβ303,
and the mitogen-activated protein kinases ERK and p38298,304,305. Phosphorylation by
these kinases induces FoxO interaction with 14-3-3, which reportedly masks the FoxO
nuclear localization signal (NLS)238,306,307 or enhances binding affinity for nuclear export
molecules302, wihich shuttles FoxO to the cytoplasm. On the other hand, FoxO
phosphorylation at some sites can lead to its activation. Two examples are:
phosphorylation by c-Jun N-terminal kinase (JNK) kinases upon cell stress activates
FoxOs308 and Cdk1 phosphorylation activates FoxO transcription by preventing Akt
phosphorylation and consequent 14-3-3 binding-induced nuclear exclusion309.
Phosphorylation can also induce the proteosomal degradation of FoxO factors. Erkmediated FoxO phosphorylation results in FoxO polyubiquitination, carried out by
MDM2, the same E3 ligase as is implicated in p53 regulation. As it does for p53, this
polyubiquitination results in proteosomal degradation of the FoxO protein304. Another
affect of phosphorylation could be positive or negative regulation of FoxO ability to bind
to DNA290. The 4 FoxO phosphorylation sites assayed by the antibody array are Akt
sites, and the profile of these indicate a significant decrease in phosphorylation status
when L647R PreA is expressed. The hypophosphorylated status of FoxO transcription
factors in L647R PreA-expressing cells indicates a substantial stabilization of nuclear
FoxO proteins. The phosphorylation sites assayed and found to have decreased Akt
phosphorylation include sites common to FoxO1, FoxO3, and FoxO4, these are Ser256, Ser-319, Thr-24/32, and Ser-322/325 (Table 5). Also, on our antibody array,
expression of Akt, itself, is downregulated by expression of L647R PreA and
demonstrates significant hypophosphorylation on the sites most commonly associated
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with Akt activation (Table 5)239,310. FoxO transcriptional activity is further regulated by
acetylation in the nucleus290. Interaction with the transcriptional coactivator p300 has
been demonstrated to negatively regulate FoxO transcriptional activity311 in part by
enhancing Akt-mediated phosphorylation and subsequent translocation to the
cytoplasm312 as well as by decreasing its ability to bind and act on target DNA313. Our
antibody array demonstrates a marked decrease of p300 expression as an effect of
L647R PreA expression (-1.34-fold, Table 5), logically making it less available to act on
FoxO proteins, with effects possibly demonstrated by the obvious lack of enhanced Akt
phosphorylation of the FoxOs as well as indications of FoxO regulation of several
targets.
Another mode of FoxO regulation, ubiquitination, can have different effects on
FoxO stability: monoubiquitination can occur in response to oxidative stress and result
in increased nuclear localization and stabilization of FoxOs, while polyubiquitination
leads to proteasomal degradation264,314-316. Pin1 inhibits ubiquitination of FoxOs, and
while this can lead to decreased degradation, it also inhibits the nuclear translocation,
and has been demonstrated to inhibit p27 Kip1 transcription mediated by FoxOs264. As
we have demonstrated an increased accumulation of Pin1 in complex with L647R PreA
in induced cells, we sought to determine if this accumulation had an effect on FoxO
localization and FoxO-mediated p27 Kip1 expression in L647R PreA expressing cells.

Nuclear Localization of FoxO3a and p27 Kip1 with L647R PreA Expression
Immunofluorescence imaging (Figure 37) reveals an increased level of FoxO3a
localization in the L647R PreA expressing nuclei as compared to the uninduced control.
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Figure 37. Immunstaining of FoxO3a Protein in EGFP-L647R PreA-Expressing
Cells and Colocalization with GFP. Immunofluorescence microscopy detected FoxO3a
antibody (top panels, red), and Anti-GFP antibody (middle panels, green), in uninduced
(DMSO-treated) Rheoswitch L647R PreA cells (left panels) and the L647R-expressing
cells (right panels). Induced cells were incubated 48 hours with 500 nM GenoStat.

The staining with anti-FoxO3a antibody, in Figure 37, demonstrates diffuse
expression throughout the uninduced cells, while the cells induced to express L647R
PreA for 48 hours demonstrate a marked increase in expression of nuclear FoxO3a.
Anti-GFP demonstrates GFP-tagged L647R PreA in the nuclei of the induced cells,
which is absent from uninduced cells. Colocalization of L647R PreA and FoxO3a
proteins is seen in the nuclei of induced cells. Correspondingly, the L647R PreAinduced cells demonstrated increased p27Kip1 expression and nuclear translocation
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compared to the uninduced cells. Immunoblotting of equal concentrations of whole cell
lysate and corresponding separated cellular compartment fractions (Figure 38)
demonstrates the altered expression of FoxO3a and p27Kip1 in induced L647R PreA-
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The immunblotting of the whole cell lysates of cells induced 48 hours to express
L647R PreA, in Figure 38, demonstrates a small increase in total FoxO3a expression in
the induced cells, while comparison of the cytoplasmic and nuclear fractions reveal a
significant increase in nuclear translocation of expressed FoxO3a in induced cells,
compared to the uninduced cells. The whole cell lysates demonstrate a marked
increase in p27 Kip1 expression in the induced cells expressing L647R PreA compared to
the uninduced cells, while the proportion of p27 Kip1 in the cytoplasm of L647R PreAexpressing was not significantly different from uninduced cells. The nuclear fractions,
however, demonstrate the dramatic increase in expression seen in the L647Rexpressing induced cells is almost exclusively confined to the nuclei of those cells.
These data demonstrate that L647R PreA expression enhances FoxO3a
expression and increases the nuclear translocation of the protein, thus indicating a
higher level of FoxO3a activation[as reviewed in 295]. The accompanying enhanced
expression level and nuclear translocation of the CKI, p27Kip1, a FoxO target for
transcriptional activation, offers support for an L647R PreA-induced effect on FoxO
activation and suggests a potential mechanism of PreA-mediated cell cycle arrest.

Pin1 Inhibition Mimics L647R PreA Effect on FoxOs and p27Kip1 in Uninduced Cells
Given that Pin1 functions to suppress FoxO proteins, one might expect the
increased presence of PreA-complexed-Pin1 protein in these nuclei to correlate to
decreased FoxO activity. On the contrary, taken together, these data suggest Pin1mediated suppression of FoxO nuclear translocation is inhibited in L647R PreA cells.
To test this, we examined the effects of treatment with Juglone, a Pin1 inhibitor, on
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FoxO nuclear translocation (Figure 39), and on p27Kip1 expression and localization

Changes in FoxO3a subcellular distribution in response to
L647R prelamin A expression and Pin1 inhibitor Juglone

(Figure 40), in these cells.
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Figure 39. Pin1 Inhibition by Juglone Treatment Mimics L647R PreA Effects in
Uninduced Cells, Leads to FoxO3a Nuclear Localization. Juglone treatment leads to
Pin1 inhibition and FoxO3a nuclear localization in uninduced cells, while prominent
nuclear localization of FoxO3a in L647R PreA cells remains unaltered. Immunoblotting
of equal concentrations of total protein [50 µg] from whole cell lysates (W), cytoplasmic
(C) and nuclear (N) fractions, with anti-FoxO3a antibody after 72 hour Juglone
treatment (at concentrations of [5 µM] and [15 µM], with “0” µM representing no Juglone
treatment) of uninduced cells (upper blot), and L647R PreA-expressing induced cells.
Densitometry of pixilation of blots, left panels, provides semiquantitative comparison
using arbitrary units. MW=Molecular Weight marker.
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Changes in expression and subcellular distribution of p27Kip (FoxO
proteins regulated molecule) in response to L647R expression and
pin1 inhibitor Juglone
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Figure 40. Pin1 Inhibition By Juglone Treatment Mimics L647R PreA Effects in
Uninduced Cells, Results in Increased P27kip1 Expression and Nuclear Localization.
Pin1 inhibition by Juglone treatment results in an increased expression level of p27Kip1
in uninduced cells, with the majority of the protein demonstrating nuclear localization.
Meanwhile, the upregulated p27Kip1 in L647R PreA-expressing induced cells is not
significantly altered. Immunoblotting of equal concentrations of total protein [50 µg]
from whole cell lysates (W), cytoplasmic (C) and nuclear (N) fractions, with anti-FoxO3a
antibody after 72 hour Juglone treatment (at concentrations of [5 µM] and [15 µM], with
“0” µM representing no Juglone treatment) of uninduced cells (upper blot), and L647R
PreA-expressing induced cells. Densitometry of pixilation of blots, panels left, provides
semiquantitative comparison using arbitrary units. MW=Molecular Weight marker.
Pin1 inhibition by Juglone treatment leads to an increase of p27Kip1 expression in
uninduced cells, with the majority of the protein demonstrating nuclear localization. As
the Juglone-untreated L647R PreA-expressing cells already demonstrate a large
increase in p27Kip1 expression compared to uninduced cells without Juglone treatment,
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little significant change is induced by Pin1 inhibition in these cells. A small p27Kip1
expression increase is detected in the cytoplasmic fraction, with an unexplainable
downshift in the intensity of the band representing the p27Kip1 expression in the nuclear
fraction of cells treated with 5 µM Juglone. This fluctuation is not present in the cells
treated with the 15 µM Juglone, rather, a level consistent with that in induced cells in the
absence of Juglone treatment is seen, representing an almost total nuclear localization
of p27Kip1 expression in these cells.
Taken together, the data from analyses of FoxO3a and p27 Kip1 expression and
subcellular localization in uninduced cells and induced cells expressing L647R PreA
indicate a positive effect of PreA on FoxO3a and p27Kip1 expression and activity in
arresting the cell cycle progression. Furthermore, the data also suggest a similar effect
on FoxO3a and p27Kip1 expression and activity can be achieved in uninduced cells by
inhibiting Pin1. In the context of the demonstrated increase in Pin1 complexing with
accumulating L647R PreA without a change in the Pin1 expression levels or subcellular
localization, these findings appear to indicate accumulating levels of PreA likely function
to sequester, and thus inhibit, Pin1 in the nucleus.

Pin1 Overexpression Reverses L647R PreA Effect on FoxOs & p27 Kip1
If Pin1 inhibition is occurring with L647R PreA expression, with the consequent
increased nuclear expression of FoxO3a and p27 Kip1, we reasoned that overexpressing
Pin1 protein in those same L647R PreA-expressing cells should reverse the observed
effect. To test this, we cotransfected cells from the Rheoswitch L647R PreA cell line
with a GST-Pin1 fusion protein-expressing plasmid.
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Figure 41. Overexpression of GST-Pin1 in Induced L647R PreA-Expressing Cells
Reverses L647R PreA-Mediated Nuclear Localization of FoxO3. Cells were transfected
with 0, 5, and 15 µg of GST-Pin1 plasmid DNA. Cells were then induced with 1 µM
GenoStat and incubated 48 h, prior to collection and preparation of cell fractions. Cell
fractions (C=Cytoplasmic, N=Nuclear, W=Whole Cell Lysate) and WCLs were
immunoblotted with GFP and FoxO3 antibodies. Presence or absence of the GFP-PreA
band indicate integrity of Nuclear, or Cytoplasmic fractions, respectively.

In Figure 41, a significant reversal of FoxO3a nuclear expression is
demonstrated, in the induced L647R PreA-expressing cells, in a GST-Pin1-dosagedependent manner. The higher level of Pin1 expression results in a more dramatic
export of FoxO3a protein from the nucleus. The level of protein exported is indicated by
the enrichment of the cytoplasmic fraction, with a proportionate depletion of the protein
from the nucleus. The functional consequences of FoxO3a inhibition are indicated by
effects on p27 Kip1 expression (Figure 42).
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Figure 42. Diminished p27Kip1 Expression is Evident upon Overexpression of GST-Pin1.
Cells from the Rheoswitch L647R PreA-expressing 3T3 cell line were transfected with
varying concentrations of GST-Pin1 expression plasmid (in µg, X-axis). Cells were
then induced with 1 µM GenoStat and incubated 48 hours, prior to collection and
preparation of cell fractions. Nuclear fractions were subjected to immunoblot using an
antibody to Pin1, to detect GST-Pin1, an Anti-p27 Kip1 antibody detected p27 Kip1 protein
present in the nuclei, and Anti-Histone protein (H2A, nuclear) serves as a loading
control.

Senescence Develops in L647R PreA-Expressing Cells
Taken together, the results of the array studies indicate L647R PreA expression
alters gene expression to induce conditions of cell cycle arrest. Supporting this
regulatory effect, proliferation and cell cycle distribution analyses reflect decreased
levels of proliferation in these cells. Furthermore, increased nuclear localization of
FoxO and the cell cycle arrest-inducing p27Kip1 in L647R PreA-expressing cells is
consistent with induction of a program of cellular quiescence. However, as PreA
expression is related to both quiescence and senescence conditions, and several of the
gene expression patterns are implicated in either condition, we sought to evaluate if the
arresting conditions are indicative of quiescence or senescence. In order to assay the
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cells for senescence activity, we performed a β-galactosidase staining assay (Figure
43).

Figure 43. Senescence Assay of L647R PreA-Expressing Cells (β-galactosidase
Assay). Senescence develops in L647R PreA-expressing cells with successive cell
divisions, as indicated by this β-galactosidase staining assay. L647R PreA Rheoswitch
cells, induced for expression (500nM GenoStat, red bars) or Uninduced (DMSOVehicle, blue bars) were split every other day in 1:3 ratio. At the indicated passage
number, 104 cells were plated onto 1.8 cm2 chambered cover glass and incubated for
16h. Senescence was then measured with a β-galactosidase staining kit. A) Overlay of
DIC and bright field images of a representative 40x field at passage 14. B) Percentage
of cells positive for β-galactosidase by manual count under microscope.
The β-galactosidase assay detects hydrolase enzyme activity at a pH of 6, which
is found only in senescent cells, not in quiescent, presenescent, or immortal cells 317.
The results of this assay indicate accumulation of PreA protein induces senescence,
although only after several successive passages have occurred.
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Results Summary
Through multiple assays of cell cycle related gene expression in cells expressing
L647R PreA, we have demonstrated a significant impact on the cell cycle gene
expression profile in those cells as compared to control cells not expressing the PreA.
At the protein level, as well, significant changes were demonstrated in the expression
levels and/or the phosphorylation modifications of components of cell cycle regulation in
cells induced to express the L647R PreA. The overall expression pattern is indicative of
a negative regulation of cell cycle progression by accumulated PreA. Analysis of the
peptide sequence differentiating PreA from LA, the C-terminal fragment, reveals
potential interacting partners that could mediate cell cycle effects related to expression
of PreA. Our studies of such a potential interaction partner, Pin1, demonstrate
compelling evidence for a PreA-mediated sequestration of Pin1 to have a major impact
on cell cycle regulation.
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CHAPTER 4
DISCUSSION
Cell Cycle-Related Expression of PreA
PreA Expression is Cell Cycle Stage-Specific, Related to Arrest
A reason for the existence of a precursor protein for Lamin A does has not been
readily apparent. Lamin B remains associated with the nuclear membrane even
through mitosis and offers a redundancy in much of the structural function of A type
lamins, and it does not have an immature isoform. Also, existence of the Lamin C
splicing variant provides an additional level of redundancy in structural function in a
protein form that is not obligatorily bound tightly to the nuclear membrane. Thus, even
without expression of PreA or LA proteins, lamin filaments are available at the nuclear
envelope as well as throughout the nucleoplasm in the form of B-type lamins and Lamin
C, respectively. The maturation processing of PreA to form Lamin A is executed in a
quick and efficient manner, and as cells progress through mitosis, mature LA is
phosphorylated, disassembled, and then reassembled in daughter cells, in an
apparently conservative process13,32,33,97,98. Consequently, with a continuous production
rate and no obvious harmful effects from an “excess” of mature, normal LA, it seems
unlikely that there is such a great need for holding a reserve of this intermediate
filament protein in an “inactive” progenitor state, yet the energy-expending processing
pathway is highly conserved in vertebrates[as reviewed in 88]. The cell cycle dependent
pattern of PreA accumulation must surely offer insight to the purpose for the precursor
protein. It seems likely that a threshold level of expression of PreA is integral to a
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program of initiation of exit from the cell cycle. Whether the accumulation of the PreA
has a direct effect on the cells’ exit from the cell cycle has yet to be determined.
Accumulated PreA is Related to Decreased Zmpste24 Activity
While FTI treated cells demonstrate marked PreA accumulation and are
rendered quiescent, other normally prenylated proteins are also affected by the
inhibition of farnesyl transferase. However, it is clear in untreated cells, that the
accumulation of PreA prior to or during periods of cell cycle arrest occurs despite an
intact program of normal posttranslational modifiers, up to the point in the processing
pathway at which the protein would normally undergo proteolytic cleavage by
Zmpste24. The logical conclusions would be that PreA accumulation must depend
upon some direct modification that hinders access of Zmpste24 to the cleavage site or a
modification to Zmpste24 resulting in the inhibition of proteolytic activity. Observance of
a sharp decrease in Zmpste24 activity level much earlier than a demonstrable decrease
in the level of expression of mRNA transcript or protein would seem to suggest
Zmpste24 is regulated posttranslationally, likely by phosphorylation. Furthermore, when
observing culture behavior of cells transiently transfected with a Zmpste24 expression
construct, we found the overexpressing cells appear to proliferate at a rapid rate
compared to cultured cells not expressing the recombinant protease, and we have
demonstrated the overexpression of Zmpste24 leads to an apparent bypass of entry to
quiescence when exposed to conditions that would normally cause cells to enter
“resting phase.” While ongoing studies are exploring the specifics of Zmpste24
expression and cell cycle, as they relate to effects of preventing PreA accumulation, our
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current studies have focused in the other direction, with overexpression of PreA to
investigate cell cycle related effects.

Overexpression Of PreA Inhibits Cell Cycle Progression
We have demonstrated that, despite availability of growth factors and prevention
of cell-cell contact, L647R PreA-expressing cells demonstrate a decreased S-phase
population compared to passage-matched cells not induced to express the mutant
lamin, with a tendency to accumulate in G0/G1-phase. Induced cells containing the
EGFP-only expression construct do not exhibit the impaired proliferation effects of
L647R PreA. Furthermore, when these cells are arrested by serum-deprivation or
contact-inhibition, those induced to express L647R PreA demonstrate an impaired
ability to re-enter the cell cycle once the arresting agent is removed (serum-return, or
trypsinization and replating at lowered density), compared to uninduced cells or those
induced to express EGFP only. We conclude, therefore, PreA expression is a cause,
rather than an effect, of cell cycle arrest, and its cell cycle-related expression (by
accumulation due to lack of maturation processing) is a likely mechanism used by
proliferating cells to coordinate the processes of exiting from the cell cycle.
Motif Analysis Suggests Potential Modes of PreA Interaction with Cell Cycle Regulators
As we considered PreA as a protein isoform with activities that might differ from
other isoforms, we determined a critical step in the investigation would be analysis of
the sequence of the portion of the isoform that differentiates it from the other isoforms,
the C-terminus. As our study was focused, specifically, upon a cell cycle-related role—
a process so heavily controlled by differential phosphorylation of proteins, and a
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process that has already been demonstrated to modify LA in a cell cycle-dependent
manner—we elected to investigate the C-terminus in terms of relationships that might
be influenced by phosphorylation. We considered, in the analysis, the c-terminal 66
amino acid residues in the sequence in order to encompass motifs that also differentiate
the delta50/Progerin isoform from normal, mature LA. The substantial number of
phosphorylation motifs within the C-terminal sequence of PreA present a large project
for further research: considering the different kinases involved, the implications of the
cellular contexts during which those particular kinases are active and under which
conditions these act upon the C-terminus as a substrate (or even if they can actually be
demonstrated to do so), and if effects upon the lamin protein can be detected as a result
of these potential modifications. Such an investigation is far beyond the scope of this
study, however, although it is noteworthy that the C-terminus, as the differentiating
sequence between the LA isoforms is rich with sites for potential activity.
We also examined the C-terminus for phosphorylation-dependent binding motifs,
as this more directly addresses the pertinent question that led us to analyze the
sequence: What molecules might directly interact with the PreA C-terminus, in a cell
cycle-dependent fashion, that could regulate gene expression changes to affect cell
cycle regulation? Our analysis produced 3 primary motifs in the C-terminus for
consideration, a binding site for the cell cycle regulatory adapter protein,14-3-3, four
binding sites that could be occupied either by the kinase Plk1 (which, interestingly, was
not identified among the kinases for which this site could be a substrate ) or the by the
DNA damage repair complex-assembly-required and checkpoint-mediating protein,
MDC1, and finally, 2 WW-domain-binding motifs. We have described our evaluation of

183

WW domain-containing proteins, and our arrival at Pin1 as the likely candidate as a
Type IV WW domain-containing protein with nuclear activity.
Pin1 as a Lamin-Binding Protein. The serendipitous timing of the publication by
Milbradt and associates of their study on mechanisms of viral egress in CMV-infection,
and their work revealing Pin1-mediated isomerization of Lamin A in this capacity, of
their study on mechanisms of viral egress in CMV-infection, and their work revealing
Pin1-mediated isomerization of Lamin A in this capacity275, reinforced our hypothesis
that Pin1 binds LA in a phosphorylation-dependent manner. In fact, as the early stages
of the work of this group, in characterizing Pin1 as a Lamin A-binding protein, closely
paralleled the work we had done on the characterization. Their progress then surpassed
ours when they analyzed crystal structures and demonstrated the binding. Therefore,
we determined this work to preclude any need, on our behalf, to investigate further in
considering WW-domain-containing proteins that might interact with LA. We therefore
refer to the WW domain-binding motifs in LA as “Pin1-binding motifs.”
The Pin1protein has 2 domains connected by a flexible linker, with the WW
domain located N-terminal to the catalytic PPIase domain. Interestingly, both domains
recognize the phosphorylated Serine-Proline residue of the Type IV WW domain
binding motif.318,319 While some proteins have demonstrated PPIase-independent
effects from binding of the WW domain alone, the binding of both is required for high
affinity Pin1 binding and execution of the rotamase/PPIase cis/trans isomerization
effect, which essentially “twists” the substrate protein to introduce conformational
changes that result in altered protein function, localization, or stability320,321. In order to
bind both domains simultaneously, 2 (or more) WW domain binding motifs, situated
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closely within the binding peptide sequence, are required322,323[Reviewed in273,324 ]. The
grouping of the WW domain binding sites at 3 sites within Lamin A appear to have fit the
pattern required for dual WW domain-binding and isomerization by Pin1, at the Nterminus: sites 19-20/22-23. This site was determined by the Milbradt group to bind
Pin1 HCMV viral kinase mediated-Pin1 isomerization of Lamin A in nuclear egress of
the virus275. Binding sites in the approximate center of the protein sequence are sites
390-391/392-393, and in the C-terminus of the full length PreA sequence: at sites 652653/657-658. As noted, each of the 3 sets of 2 adjacent binding sites were referenced
as phosphorylated during viral manipulation of LA polymerization for viral nuclear
egress246, the mechanism of which Milbradt et al. attribute to Pin1-mediated binding and
action on LA. The del50/Progerin truncated mutant protein does retain the final WW
domain-binding site (residues 657-658). However, functionality would be questionable
for that site in the mutant protein, considering the apparent requirement for two closely
situated binding sites to accommodate Pin1 binding and isomerization activity, if that
phenomenon, indeed, is shown to be an operative mechanism in PreA metabolism or
function. The other 2 WW domain/Pin1 binding sites found within the LA sequence (at
amino acid residues 3-4, and 507-508) occur singly and thus would not meet the
criterion of likely sites at which Pin1 isomerization could occur, although the ability to
bind Pin1 is not precluded at those sites by the lack of another, closely situated, Pin1
site. While binding sites for MDC1/Plk1, 14-3-3, and WW domains occur scattered
periodically throughout the full Prelamin A length, the clustering and overlap of these
sites within the C-terminus presents a pattern not found elsewhere in the sequence, and
this unique arrangement could have significant impact on protein interactions. Possibly,
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Pin1 isomerization of sites overlapping an Mdc1 and 14-3-3 binding motif could affect
some regulation of these sites as well as polymerization or other characteristics of the
actual lamin filaments themselves. Therefore, we suggest the potential functional
implications of the particular arrangement of the phosphorylation-dependent binding
motifs in the PreA C-terminus warrants further investigation. Importantly, sequestration
of transcription factors by components of the nuclear envelope has been demonstrated
as a mechanism of controlling gene expression325. PreA, specifically, has been shown
participate in such a regulatory role by sequestering SREBP1326. Likewise, a PreArelated sequestration of Pin1 could have a substantial effect on gene expression levels
affecting cell cycle progression, potentially such as the effects demonstrated in the gene
expression analyses in L647R PreA expressing cells.
One caveat to the correlation of our work with that of Milbradt and coworkers, is
that the other group focused their attentions on Pin1 binding to LA that was
phosphorylated on Ser22, yet they found Lamin C to interact with Pin 1 with a very low
affinity compared to Lamin A275. As LA and Lamin C both contain Ser22, we suggest
the discrepancy in the binding affinities between Lamins A and C could suggest a
potential importance of the C-terminus in the high-affinity binding demonstrated by
Lamin A. However, while they used recombinant proteins Lamin A and Lamin C to
clearly demonstrate Pin1 binding differences between those 2 isoforms275, the Lamin
A/C antibody used is directed to an epitope common to Lamin C, LA, and PreA
isoforms, and thus, PreA might have been indistinguishable from mature LA as the
moiety they describe to possess high Pin1 binding affinity. We suggest this is a
possibility worth consideration and further evaluation. Nonetheless, we suggest Pin1 as
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a primary mediator in PreA regulation of the cell cycle, as Pin1 has been described to
directly bind LA in a phosphorylation dependent manner, it has binding sites in the PreA
C-terminus, and it has been implicated in the control of a multitude of cell cycle
regulators.

PreA Expression Alters the Cellular Gene Expression Profile

Investigation of Gene Expression Effects Using Uncleavable PreA Expression Construct
To determine effects of accumulation of PreA protein, we transiently transfected
NIH 3T3 cells with a pEGFP-C3 expression vector containing the Lamin A cDNA, which
had been subjected to site-directed mutagenesis of the Lysine 647 residue, converting it
to Arginine. This mutation disrupts the recognition/cleavage site for the Zmpste24mediated second proteolytic maturation processing step. The resulting EGFP-tagged
uncleavable PreA protein, L647R-PreA, undergoes irreversible farnesylation and
carboxymethylation modifications. A GeneChip Whole Transcript Mouse Exon Gene
Array (Affymetrix, Santa Clara, CA) was performed on RNA from NIH3T3 cells
transiently transfected (48 hours) with the construct, along with RNA from a parallel
control of NIH 3T3 cells transfected with the empty pEGFP-C3 expression vector.
Subsequently, we created a set of stable lines harboring inducible constructs for
expression of L647R PreA, del50 LA, and wtLA, each tagged N-terminally with EGFP.
An additional control line expressing EGFP only was also created. We then began
gene expression array analysis on these cell lines using cell cycle gene pathwayspecific RT-qPCR analysis. Due, however, to unresolved normalization of gene
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expression levels between the uninduced cell lines, most likely owing to the discordant
number of culture passages to which each cell line had been subjected at the time of
analysis, we elected to focus on the L647R PreA-expressing cell line only for these
studies. Future studies should involve careful passage-matching of the cell lines used
for comparison of gene expression profiles. Additionally, to eliminate the variable of
slight clonal differences in gene expression, systematic comparisons should be
performed on a number of reference genes to generate a reliable algorithm to more
succinctly normalize comparative analysis of genes of interest between the cell lines.
Gene expression analyses of the cells induced to express L647R PreA,
compared to uninduced cells, were conducted by comparing the levels of transcript
expression of cell cycle-specific genes, using RT-qPCR array methodology.
Additionally, using an array comprising a panel of 82 different antibodies specific to cell
cycle regulatory proteins, expression at the protein level (including status of
phosphorylation modifications) was measured and compared between L647R PreAexpressing induced cells and uninduced cells. These analyses revealed altered
expression of various genes when L647R PreA is expressed. The whole genome
microarray indicates L647R PreA affects a range of cellular functions but especially cell
cycle control and several pathways with functions that overlap cell cycle control. The
cell cycle pathway specific analyses of transcript and protein levels confirm altered
expression of numerous cell cycle regulators upon L647R PreA accumulation. These
regulators are members of several different regulatory pathways and point to a role for
PreA in the coordination of the pathways that control the cell cycle.
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Among the key pathways affected by L647R PreA are the AHR pathway, the RBE2F pathway, and the p53 pathway. Overlapping with these, L647R PreA effects were
noted for p300-CyclinE and FoxO-p27Kip1 regulation. Acting as a potential common
thread in modulating some, if not all, of the observed effects of PreA expression on the
cell cycle, is the Pin1 prolyl isomerase. A Pin1-PreA interaction could ultimately prove
to be a keystone relationship in control of cell cycle.
Cell Cycle-Control-Related Pathways Demonstrating
Effects from L647R PreA Expression
Aryl Hydrocarbon Receptor (AHR) Pathway Regulation
Of the several pathways indicated by microarray analysis and Ingenuity
Pathways™ Analysis, the AHR pathway is, surprisingly, indicated to be the most
significantly regulated, when L647R PreA is expressed in 3T3 cells. The AHR is a
member of the bHLH (basic Helix–Loop–Helix)- PAS (Per-ARNT-Sim) family of
transcriptional regulators that control a variety of developmental and physiological
events, including neurogenesis, formation of secretory ducts, circadian rhythms,
response to hypoxia, hormone receptor function, and toxin metabolism, the latter being,
perhaps, the best known role for AHR134. Known as the Dioxin receptor, AHR is the
mediator for most toxic responses to Polycyclic Aromatic Hydrocarbons (PAH), Dioxins
(such as TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin)), and Polychlorinated Biphenyls.
In addition to the toxic chemicals known to be AHR ligands, other ligands include dietary
compounds, natural and synthetic flavonoids, and pharmaceuticals 135. Upon activation
by ligand binding, the AHR translocates to the nucleus, and dimerizes with another
basic helix-loop-helix protein, ARNT, also known as Hypoxia Inducible Factor β (HIF1β), which, in complex with HIF1-α, has its own transcriptional activity independent of
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AHR in response to hypoxia and, perhaps, some normoxic conditions327. The activated
AHR/ARNT heterodimer complex interacts with AH-responsive elements and activates
the expression of AHR target genes328. AHR binding results in recruiting of CBP/p300,
a Histone Acetyltransferase (HAT) Complex coactivator and facilitates binding of the
transcription factor SP1, resulting in enhanced expression from the target gene329, as in
case of the Cytochrome P450 xenobiotic metabolism genes330. AHR can affect cellular
signaling through interactions with various other regulatory and signaling proteins,
including chaperone and immunophilin-like proteins (such as heat shock proteins), the
Aryl Hydrocarbon Receptor-Interacting Protein (AIP), as well as protein kinases and
phosphatases (including tyrosine kinases, Casein Kinase-2 (CK2), Protein Kinase-C
(PKC)). In addition, AHR is also known to interact with cell cycle-relevant signaling
pathways that are mediated by hormone receptors (including Estrogen Receptor),
Hypoxia, NF-KappaB (Nuclear Factor-Kappa-B) and Rb (Retinoblastoma) protein134,135
and SUMO1-modification331,332. AHR association with coactivators can lead to histone
acetylation, Pol II (RNA Polymerase-II) recruitment and subsequent gene transcription,
or, in contrast, activation of the AHR results in transcriptional inhibition of some target
genes, such as those encoding the Immunoglobulin heavy-chain and Estrogen-inducible
p27Kip1. Inhibitors of PKC and Tyrosine Kinase block the induction of AHR target genes,
indicating a likelihood they are also involved in AHR signal transduction 333,334. AHR also
interacts with NF-KappaB signaling pathways. Direct interactions between AHR and
RelA (a NF-KappaB subunit) induce transactivation of c-Myc protein135,335,336.
Functional cross talk between AHR and NF-KappaB occurs through interactions with
common coactivators SRC1 and p300/CBP. AHR and NF-KappaB RelA form an
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inactive complex, thereby causing mutual repression. The association between the
AHR and RelA provides a physical basis for the functional antagonism 337. AHR may
also be involved in cell-cycle regulation through growth factor signaling, cell-cycle
arrest, and apoptosis134,337,338. In fact, Puga and coworkers presented a comprehensive
review of AHR roles in cell cycle339 in which they discuss a wide range of AHR-ligand
activation induced cell cycle perturbations, including G0/G1 and G2/M arrest,
diminished capacity for DNA replication, and inhibition of cell proliferation. AHRmediated functions are often accomplished in the absence of an exogenous ligand, but
the underlying molecular mechanisms governing these processes are poorly
understood, partly because no endogenous ligands have been definitively identified.
More than a decade of research points to a role for the AHR in cell cycle control, yet the
precise mechanism remains ill-defined. Reports suggest that in the absence of an
exogenous ligand, the AHR promotes progression through the cell cycle [reviewed in 340]. In
contrast, evidence spanning more than 20 years has shown that TCDD, the prototypical
AHR ligand, can inhibit cell proliferation339. Marlowe and associates show that the
repressor activity of the AHR is fully independent of its transcriptional activity, not
requiring its transactivation or DNA binding domains or interaction with ARNT,
delineating a dual activity of AHR in mediating promotion or inhibition of cell
proliferation, dependent upon the cellular environment or ligand exposure 341. AHR is
shown to contribute to p300-mediated induction of DNA synthesis during S-phase342,
and in fact was shown to competitively displace p300 from E2F-dependent
promoters341,343. Studies also found AHR contributes to the inhibition of cell cycle
progression by directly interacting with the RB/E2F complex to block its phosphorylation
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in G1136,137. This interaction constitutes a major G1 checkpoint in cells exposed to AHR
ligands138. AHR and RB have demonstrated a synergistic relationship to reinforce the
repression of E2F-dependent gene expression, thus slowing down the progression of
cells from G1 into S-phase137. In addition, AHR is recruited to RB-regulated promoters,
where it functions as a corepressor for RB. Through the formation of specific proteinprotein interactions and the exclusion of coactivator proteins from RB-regulated
promoters, the interaction with AHR results in repression of transcription of RB target
genes such as CDK2 and cyclin A to cause cell cycle arrest341,344,345. It is suggested the
AHR tandem effects of RB-corepression and blocking of recruitment of p300 to E2Fregulated genes are interrelated and that inhibition of p300 binding is one of the
molecular events responsible for the persistence of active gene repression by AHR-RB
complexes341. Pin1 is reported to bind, and potentially stabilize p300 expression, as
well as increase its affinity for binding its targets346. In this way, sequestration of Pin1,
rendering it unavailable to act on p300, presents a potential mechanism by which
L647R PreA could contribute to AHR-RB-mediated gene repression. As RB regulation
by Lamin A is well-documented102,347, the indication of highly significant regulation of
this pathway in our microarray analysis of cells exogenously expressing L647R PreA
could represent an important mechanism, heretofore apparently unexplored, by which
PreA protein accumulation drives cells toward cell cycle arrest.

RB-E2F Pathway Regulation
Three pRB family members, termed pocket proteins, are expressed in
mammalian cells: pRB/p105 (herein, “pRB” will refer to the protein, “RB” to the gene),
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pRbl1/p107, and pRbl2/p130 (proteins referred to herein as “p107” and “p130,”
respectively, and “p107 gene,” or “p130 gene,” respectively, for reference to the genes).
In their hypophosphorylated state, these proteins bind to members of the E2F-family of
transcriptional regulators and inhibit transcription. This inhibition is relieved when the
pocket proteins are released from E2F complexes following their phosphorylation by
cyclin/CDK activity348, freeing the E2F proteins to influence the transcription of genes
whose protein products are necessary for cell cycle progression. The phosphorylation
status of each of the RB- family members varies throughout the cell cycle. Several
cyclin dependent kinases are implicated in this process349. As their functions and
structures differ, members of the E2F- and RB-families exhibit differential interactions
with each other in a temporally regulated manner through the cell cycle. E2Fs 1-3 are
transcriptional activators and interact only with pRB350. E2F4 and -5 are transcriptional
repressors and preferentially bind p130 and p107351. The p130/E2F4 complex is
thought to possess the primary function of helping maintain a state of transcriptional
silence352,353 and is the complex most abundant in quiescent cells, although p107/ E2F4
and pRB/E2F4 complexes also accumulate in G1 phase353. As the cells start to re-enter
the cell cycle, in early G1, E2F4 is still found primarily in association with p130, but p130
is replaced in mid to late G1 by p107, and then by pRB in late G1 and S phases 353-356.
p130 also regulates the expression of the RB and p107 genes, which contain E2F sites
in their promoters357,358. In addition, while both p130 and p107 are bound to a number
of promoters in asynchronously growing cells, only p130 is recruited to promoters in
quiescent or serum-restimulated human cells. Repression of promoters in quiescent
cells has been shown to be specifically associated with recruitment of E2F4 and p130
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as well as with histone hypoacetylation359. While 9 members of the E2F family have
been identified (including 2 isoforms of E2F-3), only E2Fs1-5 interact with the pocket
proteins[reviewed in 360]. E2Fs 6-8, the functions of which are somewhat less well
characterized than the other 6 family members, lack the N-terminal sequences of
E2Fs1–3 as well as the C-terminal domain common to all the other E2F proteins361-365.
They do not have activation domains or pocket protein interaction domains and, thus,
exhibit RB-independent transcriptional-repression activity364-367. E2F6, specifically, has
been shown to interact with Polycomb proteins to repress transcription 363. E2F1 has
well documented target genes that are proapoptotic, such as Caspase 3, 7, 9 and
Apaf1368. Furthermore, E2F1 directly induces expression of p19ARF (for which
expression of the transcript was upregulated after 48 hours of L647R PreA expression,
according to our initial microarray data but is not assayed at the protein level after 72
hours of L647R expression). p19ARF, in turn, activates p53 by binding and inhibiting
MDM2 function369. Implications of that relationship are further explored in the p53
pathway discussion section.
In additional paradox to the well-known growth-promoting function of E2F1, its
expression is suggested to be counterbalanced by multiple self-imposed safeguard
mechanisms, one of which is activation of the promoter of the cyclin dependent kinase
inhibitor (CKI) p27 Kip1 gene, for which E2F1 expression has actually been shown to be
necessary for maintaining basal level p27 expression370. In this negative feedback
mechanism, expression of p27 Kip1 cooperates with pRb to suppress E2F1 activity, and
this association of p27 Kip1 with pRb has demonstrated ability to activate cellular
senescence371. Interestingly, E2F1 protein levels are reduced in a dosage-dependent
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manner with expression of p130, which, as mentioned, is a transcriptional target of
E2F1. The resulting E2F1 reduction leads to inhibition of cyclin A expression and
subsequent reduction in cyclin A-associated kinase activity. Furthermore, induction of
p130 expression has also been shown to lead to a substantial induction in the protein
levels of p27Kip1, 372-374. To further complicate this E2F1-negative feedback process,
because p27Kip1 levels are mainly regulated by ubiquitin-mediated proteasomal
degradation that is targeted by cyclin E-Cdk2 phosphorylation of p27Kip1 on Thr187375,376, p130-mediated inhibition of cyclin E-associated kinase activity may induce
p27Kip1 levels by decreasing or inhibiting targeted proteolysis of p27, extending the
feedback loop by stabilizing p27Kip1 at expression levels that can propagate further
inhibition of CDK activity. In that loop, p130 and other RB-family members are
protected from the inactivation-inducing phosphorylation of CDKs377. p27Kip1 is
discussed again in the FoxO discussion section, involving its FOXO-mediated
transcription.
While our data from the RT-qPCR array indicate significant mRNA expression
level upregulation of the pRB-interacting, transcription-activating E2Fs1-3, as well as
the repressor E2F4, after 24 hours of L647R PreA expression, E2Fs 5-8 were not
included in the RT-qPCR assay. Consistent with the increased E2F-1-3 transcript
expression, several targets do exhibit increased expression, such as cell cycle
regulating genes cyclin A, CDK2, the RB and p107 genes, as well as E2F2 and E2F3
(which are E2F targets, themselves), the DNA replication associated Mcm2 gene, and
the DNA repair and checkpoint control regulating genes, PCNA, Rad51, Msh2, Chk1,
and MAD2L153.
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E2Fs are regulated not only at the level of transcription, but also significantly by
posttranslational modifications, subcellular localization, association of cofactors, and
degradation378,379. Our protein microarray results do not indicate significant changes in
the levels of expressed E2Fs after 72 hours of induced L647R PreA expression, except
in the case of E2F-6, which demonstrates downregulated levels with L647R PreA
expression. Interestingly, though E2F-6 is a transcriptional repressor, repressing the
E2F-mediated transcription of genes responsible for the G1/S transition, it is expressed
only during S-phase, and exogenous expression of E2F-6 has been shown to result in
accumulation of cells in S-phase367. Repression of the G1/S transition-inducing genes
by E2F-6 could, therefore, potentially have a role in maintaining a unidirectional
progression forward of the cell cycle. Nonetheless, the decreased level of expression
represented by our antibody array could be a reflection of the proportional decrease in
the number of cells in S-phase among the cells expressing L647R PreA as compared to
control cells that were not induced to express the mutant lamin protein. Likewise, the
measured levels of pRB expression do not indicate differences between cells
expressing L647R PreA compared to uninduced cells on the antibody array. However,
phosphorylation of pRB Ser-795 is indicated to be significantly downregulated with
L647R PreA expression. Phosphorylation of the Ser-795 residue is mediated by CDK4
and requires the activity of MEK-ERK pathway. Moreover, this phosphorylation is
functionally significant in that it occurs rapidly and directly correlates with dissociation of
E2F-1 from pRB and initiation of E2F-mediated transcription380. Therefore,
hypophophosphorylation of this site is consistent with RB-mediated transcriptional
repression in the L647R PreA-expressing cells. It has been suggested that Pin1 binds
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pRB to stabilize its hyperphosphorylated, inactive conformation, thus inhibiting RBmediated transcriptional repression and cell cycle arrest381. In addition to the potential
role of Pin1 inhibition in promoting AHR-RB-mediated transcriptional repression,
preventing a direct Pin1 conformational inhibitory regulation of pRB presents another
mechanism in which PreA sequestration of Pin1 could contribute to cell cycle arrest.
Unfortunately, the antibody array does not feature p107 or p130 to confirm results of the
qPCR array, which indicated increased mRNA transcript levels for those 2 RB family
members, and the qPCR array did not assay for the RB transcript. Considering our
data in the context of RB-E2F-related transcriptional control of the cell cycle, the results
suggest L647R PreA protein expression has significant effects on this pathway, which is
not completely surprising, given several studies have previously revealed a role for Atype lamins in stabilization and regulation of the pRB protein102,347. Taken together,
data from the qPCR array and the antibody array strongly suggest the PreA isoform has
a role of its own, which appears to be separate from that of mature LA, in regulating
expression and interactions of members of the RB-family of pocket proteins with E2F
transcriptional regulators in a program regulating cell cycle control.

p300 and Cyclin E Pathway
Pin1 has been shown to facilitate p300 binding to its targets346. Given the Pin1
propensity to stabilize many of its binding partners, it could raise the question of
whether PreA sequestration of Pin1 could contribute to destabilization and our observed
decrease in the expression level of p300 protein in PreA-expressing cells (decreased
nearly 2-fold, according to antibody-detection in our protein microarray). p300,
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described as both a transcription cofactor and a HAT, is considered to be a master
regulatory protein and molecular switch, integrating transcriptional control of cell cycle
progression, DNA repair382, and tumorigenesis[reviewed in 228,234,383-385] and may be
required to maintain tissue homeostasis386. It is required for cell and tissue function
during embryonic development, cell differentiation in vitro233, and in fact, even a 25%
decrease in p300/CBP proteins is detrimental for normal development234,235, while p300
nullizygous (p300_/_) embryos die between days 9 and 11.5[reviewed in 385]. p300 is
targeted by viral oncoproteins, mutated in certain forms of cancer, and phosphorylated
in a cell cycle-dependent manner[reviewed in 228]. In addition, p300 interacts with numerous
transcription factors including p53, E2F, micropthalmia transcription factor (MITF), and
RB387. p300 can stimulate either transactivation or repressor functions of several
different transcription factors, suggesting that the interacting proteins, promoter, and
cellular context are critical determinants of p300 function[reviewed in385,388]. A reduction in
p300 levels results in an apparently directly proportionate level of transcriptional
repression, from competition between transcription factors for limited amounts p300 in
the nucleus385, and has direct negative effects on cellular proliferation, as it does for
development234,235. The involvement of p300 in maintaining the proliferative state of
cells is supported by studies using p300-deficient fibroblasts, including fibroblasts from
p300-nullizygous animals, which show slow proliferation and rapid replicative
senescence in culture235,389.
Importantly, p300 binds integrally to the cyclin E-CDK2 complex390, of which it
controls the activity, and has been determined to be required for the G1-S transition,
with a decrease in cyclin E-CDK2 activity directly resulting in inhibition of the G1- to S-
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phase transition389. Cyclin E, in its complex with CDK2, controls 3 major S-phase
events: DNA replication, centrosome duplication, and histone gene expression [reviewed in
391]

. Overexpression of cyclin E promotes S-phase entry increases the frequency of

centrosome duplication and genetic instability391 and induces escape from Ras-induced
senescence in mouse embryonic fibroblasts392. p300 is a critical regulator of cyclin E
transcription in vivo, and p300 depletion directly results in cyclin E down-regulation,
causing growth arrest and expression of a senescent-like phenotype393. Access to DNA
by transcriptional regulatory proteins is determined by chromatin organization, which
regulates activation or repression of transcription. Chromatin structure is primarily
controlled by ATP-dependent reorganization of nucleosomal positioning and
posttranslational modifications to the histone tails by acetylases or deacetylases, which
introduce localized perturbations to the chromatin, either allowing or preventing the
binding of transcriptional machinery394. Loss of acetylation may shift the balance toward
repressive heterochromatin, causing silencing of genes associated with cell cycle
progression. Errors in the maintenance of repressive heterochromatin domains have
been proposed to accumulate during the proliferative life span of normal human cells,
ultimately triggering a senescence checkpoint and leading to irreversible cell cycle
exit.395 It has been suggested, a progressive decline in HAT levels (such as with
decreased levels of p300), with further cell divisions, leads to increased HDAC activity
and chromatin modifications that cause altered gene regulation and permanent
relocation of genes into the heterochromatin compartment, thereby triggering a
senescence checkpoint that ultimately results in activation of cellular senescence 393.
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Our antibody array study indicates expression of L647R PreA results in significantly
decreased protein levels of both p300 and Cyclin E protein levels compared to the
uninduced control. These findings strongly suggest a role for PreA in induction of cell
cycle arrest and inhibition of cellular proliferation. The association of Cyclin E downregulation by reduced p300 levels with senescence, and the fact cells expressing
L647R PreA demonstrate that particular expression pattern is a potential indicator that
PreA protein accumulation has a role in senescence induction. Recruitment of p300
and HDACs to promoters may be a cyclic event in proliferating cells, while a decrease in
p300 levels favors recruitment of other repressor proteins396-399 to cyclin E and other cell
cycle-regulatory gene promoters393. We reason, therefore, that a transiently cyclic
pattern of p300-cyclin E repression might be related to the equally transient
accumulation of PreA protein in cycling cells, resulting in quiescence, while it is
conceivable that sustained accumulation of the protein could result in senescence,
potentially implicating PreA in regulation of cell fate.
FoxO Pathway
A decreased expression level of p300 represents another potential means of
PreA-mediated positive regulation of FoxOs. As p300 acetylation of FoxO inhibits its
ability to bind DNA, FoxO transcriptional activity is ablated by p300 expression 313.
Therefore, the observed significant decrease in p300 expression in L647R PreAexpressing cells is consistent with FoxO activation. Likewise, as modulation of the
subcellular localization is the primary means by which FoxOs are regulated, Akt
downregulation is a highly positive indicator of FoxO activity. Because Akt is the major
inducing kinase of FoxO phosphorylation-dependent, 14-3-3-mediated export from the
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nucleus, the downregulation of expression and activity-inducing phosphorylation of Akt
that we observe in our protein microarray is consistent with nuclear localization and an
active status of FoxO transcriptional regulation. Importantly, Pin1 has been shown to be
a primary mediator of Akt stability. Inhibition of Pin1 results in destabilization and
proteasomal degradation of Akt. Our proposed mechanism of accumulated PreA
binding, and thus sequestering, Pin1, should be able to induce the observed
downregulation in Akt. A downstream effect would be stable FoxO nuclear localization
and active transcription of targets such as p27, such as we see in the immunoblots and
immunfluorescence imaging of the L647R PreA expressing cells. Interestingly, while we
show that Juglone treatment increased nuclear translocation of FoxO3a and p27KIP in
uninduced cells, the already increased nuclear pool of FoxO3a and p27 Kip1 proteins
were not significantly altered in L647R PreA expressing cells. This suggests expression
of PreA inhibits Pin1 negative effects upon FoxO3a nuclear translocation and
consequent p27Kip1 expression, with at least as much effectiveness as treatment with a
chemical Pin1 inhibitor. Also, Pin1 inhibition does not decrease the nuclear
translocation of FoxO3a, nor p27Kip1 expression in L647R PreA cells, thus confirming
the increased Pin1 in complex with PreA does not have a negative regulatory effect on
FoxO3a or p27Kip1 expression. These data, taken together, suggest a heretofore
undescribed mechanism of PreA cell cycle regulation through sequestration of Pin1,
thus limiting its nuclear availability and preventing its binding to targets. This
mechanism could have many consequences for cell cycle regulation, considering the
plethora of cell cycle targets of Pin1 activity.
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In line with their ability to block cell growth and to induce senescence or
apoptosis, FoxO genes act as tumor suppressors. Deletion of all FoxO1, FoxO3, and
FoxO4 alleles in adult mice induces a cancer prone condition characterized by
hemangiomas and thymic lymphomas400. In human cancers, several chromosomal
translocations disrupt FoxO genes, producing hybrid proteins in which the forkhead
DNA-binding domain and the Akt phosphorylation sites are lost401, and in fact, much of
the oncogenic activity of the Ras-Erk pathway depends on inactivation of FoxO
transcription factors400. It has been suggested that nuclear FoxO and Myc might
compete for the promoter site of the p27Kip1 gene, where, in character with its
oncogenesis-promoting functions, Myc acts in direct opposition to the function of FoxO
transcriptional activation of p27Kip1, acting rather to repress transcription of p27Kip1 402.
In addition, Oncogene-Induced Senescence (OIS), as from BRAF, for example, is
mediated by JNK phosphorylation of FoxOs but does not activate p27Kip1 or p16ARF1.
Rather, JNK-mediated FoxO phosphorylation specifically induces p21WAF1 expression to
induce senescence. PKB/Akt phosphorylation FoxO sites are not affected by JNKmediated OIS FoxO activation, and ERK phosphorylation does not play a role in this
FoxO activation403. Importantly, although a mechanism of tumor suppression, it is
argued that induction of cellular senescence is also causative to organismal aging 404,405.
FoxO response to OIS may therefore represent a trade-off between tumor suppression
and lifespan.
Cellular signaling induced by growth factors is propagated, at least in part, by
Reactive Oxygen Species (ROS), which are thereby necessary to regulate a variety of
cellular processes including proliferation406,407. However, accumulation of ROS above a
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certain threshold level causes damage to the cellular interior, referred to as oxidative
stress. Toxic levels of ROS can induce cellular senescence408, so they are also
considered to accelerate aging and age-related pathologies409,410. In response to
accumulation of ROS, a poorly understood induction of senescence occurs. FoxOs are
known to be mediators of oxidative stress repression308, increasing resistance to
oxidative stress through transcription of such enzymes as MnSOD310 and Catalase411,
through a negative feedback loop, which appears to ultimately result in senescence
whenever high levels of ROS are encountered, likely as a measure to avoid cell death,
or ensuing tumorigenesis caused by ROS-induced DNA damage. Paradoxically,
increased FoxO activity is associated with longevity in model organisms 412 and
humans413, but at the same time, in managing response to ROS accumulation, FoxOs
are responsible for inducing senescence, lending credit to the hypothesis that excessive
ROS accelerate aging. It is interesting that both lack of growth factor signaling and
increased OIS/ROS result in FoxO activation. However, there is a cost differential to
the organism between the 2 programs in which the absence of growth factor signaling
can impose a reversible FoxO-p27kip1-mediated G1 cell cycle arrest and/or quiescence,
which may, perhaps, be used for cellular maintenance and to repair cellular damage310,
wherein FoxO proteins may positively affect lifespan with little cost to the organism. In
contrast, FoxOs’ response to OIS and ROS, while protecting against immediate cell
death or tumorigenesis, does so at a significant cost to the organism, as this service is
accomplished through induction of senescence—thus defining a limited lifespan. These
concepts underline the pivotal role that FoxOs play in minimizing the damage of ROS
from normal cellular signaling and in neutralizing intercepted oncogenic signaling, as
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well mediating the aging that results from overexposure to ROS or OIS. Thus, while our
current study does not assay the sites of JNK-mediated phosphorylation on FoxOs and
does not test effects of oxidative stress or OIS upon cells expressing L647R PreA
compared to controls, as FoxOs are regulated by ROS and oncogenic signaling, in
addition to signals related to growth factors and cell metabolism, and play a role in both
tumor suppression and aging, regulation of these effects provide an important paradigm
to understanding the relationships between aging and disease such as cancer. Our
study does, however, demonstrate a capacity for FoxO regulation by PreA, with the
strong indication of a PreA-mediated role for regulation of Pin1 in that mechanism. As
PreA has been demonstrated to accumulate with progressive aging and in
senescence35,43,66,74,146, and A-type lamins have been associated with cell cycle
regulation102,103,347, while both FoxO and Pin1 dysregulation have been implicated in cell
cycle dysfunction and numerous cancers (FoxOs and cancer review414, Pin1 and cancer
review415 ), we suggest this PreA-Pin1-FoxO regulatory relationship warrants further
investigation in the roles of tumor suppression and senescence induction, and thus, on
the role of these relationships in cancer and in aging.
p53 Pathway
The pocket proteins can induce expression of both p21Waf1 and p27Kip1 and are
essential for both quiescence and senescence416. p53, on the other hand, has been
thought to play a key role primarily in senescence, mainly by inducing p21Waf1, which
permanently blocks cell cycle progression417. The p53 pathway was indicated by our
genomic expression microarray pathway analysis to be highly affected by PreA L647R
expression. This pathway controls the expression of hundreds of genes in response to
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signaling stimuli from sources of genotoxic insult, as well as from sources of
nongenotoxic metabolic stresses and is the subject of many reviews[217,418-424 and a multitude
of others]

. The activity of p53 has been shown to be essential to arrest the cell cycle in

response to irradiation or DNA-damaging chemical agents (examples of genotoxic
stressors)170,425, as well as in response to virus infection-related interferon production,
and cytokine signaling in metabolic stresses such as hypoxia (nongenotoxic
stressors)426. As a consequence of its large number of downstream effectors, activated
p53 can elicit a number of responses, including activation of several kinase-mediated
signaling pathways or transcriptional induction or repression of several hundred genes.
Results of this signaling are either arrest of cell cycle progression in late G1-, S-, or G2phases or the induction of apoptosis. Many p53-downstream effectors function in a
feedback mechanism with p53, signaling in cooperation to promote cell and tissue
homeostasis by directing many repair processes, including transient inhibition of nucleic
acid synthesis, DNA repair, control of the cell division cycle, elimination of damaged
proteins, autophagy, ATP generation via oxidative phosphorylation, affecting function of
the mitochondria, and directing programmed cell death 426.
The binding to DNA for transcriptional regulation by p53 involves alteration of the
protein conformation and occurs in a DNA sequence-specific manner. Mutations in p53,
or in the target genes, that alter the binding specificity or the ability to achieve proper
conformation result in suppression of p53 function and are associated with the loss of
genomic stability found in a wide range of human cancers418,427,428. In fact, studies have
shown that more than 50% of human cancers involve mutations that dysregulate
p53420,429. Regulation of p53 is accomplished by posttranslational modifications,

205

including phosphorylation, acetylation, methylation, and ubiquitination, as well as by
interactions with other factor molecules that enhance or diminish activity by altering p53
binding to partner molecules, determining its cellular localization, or affecting its rate of
degradation[426,430,431, and as reviewed in 217,418-420]. Stabilization of p53 is primarily controlled
by Mdm2432-435. These proteins act as E3-ubiquitin ligases, binding to and targeting p53
for degradation by the 26S proteasome. Mdm2, a ring-finger protein, is generally
considered to be the major regulator of p53 in response to genotoxic stress436 and is
amplified in several types of cancers437. Mdm2-binding simultaneously conceals the
p53 transcription activation domain and facilitates p53 export out of the nucleus into the
cytoplasm, in addition to its targeting the p53 protein for degradation438. Interestingly,
expression of Mdm2 is transcriptionally activated by p53 in a negative feedback loop
that controls the level, extent, and duration of p53 protein activation439. Upon stress
signaling, p53 phosphorylation promotes the dissociation of MDM2 from the MDM2/p53
complex, allowing activation of a stable p53424,425,427,440. Our data show the transcript
expression of Mdm2 is upregulated after 24 hours of induced expression of L647R
PreA, but the cells demonstrate no significant changes in the protein expression level of
Mdm2 after 72 hours of expressing L647R PreA. Importantly, though, the Ser-166
residue of Mdm2 protein in the L647R PreA-expressing cells is hypo-phosphorylated.
Phosphorylation of Mdm2 at Ser-166 is accomplished by Akt following growth factor
stimulation, and results in increased half-life of Mdm2 protein, enhanced Mdm2mediated p53 degradation, and nuclear translocation that allows it to inhibit p-53mediated transcription. Additionally, the p53-inducible phosphatase Wip1/Ppm1d is
able to dephosphorylate Mdm2, thereby inactivating its repressive and degradation-
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targeting effects on p53. The transcript level of Wip1 in the L647R PreA expressing
cells, by RT-qPCR assay, was found to be upregulated, but Wip1 is not assayed by the
antibody array. In contrast, Akt is not assayed on the RT-qPCR array. The antibody
array, however, demonstrates a significant downregulation of Akt protein expression in
L647R PreA-expressing cells. Additionally, the phosphorylation profile of Akt in L647R
PreA-expressing cells indicates it is considerably hypoactive. As for p53, itself, the
transcript shows a very modest upregulation after 24 hours of L647R PreA expression,
and actually a slight downregulation at the protein level, after 72 hours of induced
L647R PreA expression, with a phosphorylation profile consistent with response to
oxidative damage, microtubule disruption, or replicative senescence.

p53 and mTOR Pathway
The paradigm for the p53 pathway has recently shifted. For many years, p53
was considered, primarily, as the driver of a program of apoptosis, and after several
years of work it has been proven to have an equally significant role in cell cycle arrest,
most recently, extraordinary revelations have been made about p53 roles in the
decision between the pathways quiescence441 or senescence[as reviewed in 418,421,424,427].
Notably, p27Kip1 is the primary CKI involved in inducing quiescence and is not a target of
p53442, and thus p53 is considered dispensable in quiescence induction, although, it has
also been shown that p53-activation of p21Waf1 can trigger pRB-mediated quiescence,
possibly by triggering p27Kip1 expression443. The recent work of Leontieva, Demidenko,
Blagosklonny, and colleagues, have challenged the long-held notion that p53 is
primarily an inducer of senescence but propose, rather, that p53 is actually a
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suppressor of the senescent phenotype444. Additionally, several groups have
contributed to the realization that the mammalian Target of Rapamycin (mTOR)
signaling pathway and the p53 pathway converge to determine cellular quiescence
versus senescence445-449. In fact, p53 has been demonstrated to inhibit mTOR445,447,450.
mTOR is a PI3Kinase-like-kinase (PIKK) family kinase, and the mTOR pathway
mediates protein synthesis as part of cellular growth when adequate nutrients, energy,
and mitogens are supplied in the cell[as reviewed in 445 ]. PI3K-activated Akt activates
mTOR, when cellular conditions are favorable, while PTEN, AMPK, and TSC1/2 inhibit
the pathway when conditions are not favorable, as in serum-starvation or high-density
contact, in cell culture. The p53-inhibition of mTOR occurs via p53 activation of
AMPK445. In the crosstalk between these pathways, activated p53 activates AMPK,
which inhibits Akt, and thus mTOR, and p53 is able to induce quiescence. In conditions
where the mTOR pathway is active, p53 activates a senescence response to stress
signaling. Furthermore, weak induction of p53 is unable to inhibit the mTOR pathway,
and thus weakly increased p53 expression is associated with irreversible induction of
senescence. Paradoxically, high levels of p53 expression/activation, such as would
occur acutely in response to a DNA-damaging event, potently inhibit mTOR signaling,
initiating quiescence, conceivably to allow the cell to execute repair processes451-455. If
cellular stressors such as hypoxia or DNA damage occur during the conditions in which
mTOR is inhibited, p53 would not induce senescence but, rather, would continue to
participate in mediating the mTOR inhibition and maintenance of quiescence. If p53
signaling is resolved prior to restimulation of mTOR, then the cells re-enter the cell
cycle. However, if serum is returned while p53 signaling is still increased, and high
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levels of mitogen-signaling overrides the p53-AMPK inhibition of mTOR, senescence
will be induced.
If one considers the cell cycle related expression pattern we have described for
PreA, it is seen in conditions of serum starvation or high-density plating, where
quiescence is induced (wherein, mTOR would be inhibited), but it is also expressed in
replicative senescence (wherein, plating conditions could be spacious and plenty of
serum provided in the medium, and mTOR would not be inhibited), according to this
work and that of others35, 121,122. This phenomenon is inconsistent with our theory that
PreA-mediated inhibition of Akt and the mTOR pathway could play a role in the recently
described function of the p53-mTOR pathway in selecting for quiescence in conditions
inhibiting the mTOR pathway444,451,452,455. In that model, senescence activation occurs
only in conditions of p53 activation without mTOR inhibition. Therefore, in the normal
physiological circumstances of its accumulation, PreA would likely participate in the
mTOR-inhibited induction of quiescence, where p53 induction would be related to the
cellular stressors of the conditions of starvation or crowding. The cells are able to reenter the cell cycle upon mitogen restimulation or replating, as this simultaneously
relieves the p53-inducing stress and releases inhibition of mTOR. As we are
expressing PreA exogenously in the cells of our current study, in conditions of plentiful
mitogens and low- to medium-plating densities, it seems that mTOR inhibition should
not be in effect, and yet, we see the downregulated Akt that must indicate mTOR
repression, as would the increased transcription of the Camk2s and Sestrin 2 that we
see in these cells. We also see the nuclear localization of FoxOs and p27Kip1 that would
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indicate quiescence, and the p300 and Cyclin E downregulation that signify either
quiescence or senescence.
In the absence of serum starvation or contact-inhibition induced stress, we also
do not see strong activation of p53. Our observed low p53 expression level in the cells
expressing L647R PreA, seems congruent with a the noted senescence induction by
continued low-level p53 expression, or with a p53-independent mode of quiescence
initiation, and is consistent with previous findings related to a relative lack of p53
induction by PreA103. We presume the low p53 levels observed are because the cells
are not being serum starved, crowded, or treated with stressing agents in order to
induce the PreA accumulation. However, the phosphorylation signature (indicative of
hypoxic stress, microtubule dysfunction, or replicative senescence), and the fact that
PreA is found in senescent cells as well, leads us to the question of how cells are able
to enter senescence despite accumulation of PreA, when PreA accumulation apparently
downregulates Akt and would presumably lead to mTOR inhibition?
A possible answer for this question comes in the form of Pin1. Pin1
phosphorylation-dependent binding to p53 is required for the DNA damage-induced
response of p53. The specific sites reportedly requiring phosphorylation to bind Pin1
are Ser-33, Thr-81, and Ser-315 (notably, Ser-33 and Thr-81 are somewhat
hypophosphorylated, with L647R PreA expression, while Ser-315 phosphorylation is
upregulated)267,456.

We hypothesize PreA accumulation, in the absence of mitogen

deprivation or cell crowding, would not typically be present at the initiation of DNA
damage signaling related to substantial genotoxic insult to the cell, or at the induction of
telomere-uncapping-mediated DNA damage signaling as cells reach the replicative limit.
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Therefore, our proposed PreA-Pin1 sequestration-related inhibition of Akt and the
mTOR pathway would not be in effect at the initiation of that mode of p53-activation.
Also, Pin1 sequestration by PreA would not be a factor, and thus Pin1 could freely
interact with p53 to promote its DNA damage response cell cycle arrest activities. On
the other hand, it has been recently demonstrated that Pin1 must be inhibited to allow
induction of replicative senescence457. It is possible, then, that PreA-mediated Pin1
inhibition could be the key to directing cells with p53 activated by shortened telomeres
to senescence. Future studies will demonstrate if PreA accumulation occurs
subsequent to p53-mediated cell cycle arrest in cells that enter senescence due to DNA
damage signaling, including that which occurs from uncapped telomeres as the
replicative limit is reached. Successive passaging of cells expressing L647R PreA
results in progressive PreA accumulation to levels that have been shown to
demonstrate perturbations of cell cycle function, defective mitosis, altered chromatin
organization, and telomere stability. For this reason, we suggest use of this exogenous
PreA-expressing model could make it difficult to determine if normal pathways leading
to senescence involve PreA accumulation after p53-activation has already occurred.
Activation of p53 by telomere-uncapping-induced DNA damage signaling could induce
senescence directly, before the effects of PreA-mediated mTOR-inhibition-related
quiescence induction could occur. However, the effects of DNA damage signaling upon
the proposed PreA-Pin1 sequestration must be evaluated. Given the overlap of putative
Pin1- and MDC1-binding sites in the PreA c-terminal tail, the possibility exists for DNA
damage signaling to alter the ability of accumulated PreA to bind Pin1. Such
interference could neutralize the proposed sequestration effect and consequences such
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as Akt-mTOR inhibition. This latter phenomenon could reconcile the contradictions of
PreA-mediated inhibition of Akt/mTOR (and implied p53-mediated direction to a
quiescent state), and the known expression of PreA in replicatively senescent cells.
The ability of L647R PreA-expressing cells to enter senescence after successive
passaging, as demonstrated in the β-galactosidase assay for the L647R PreAexpressing cells, could be attributed to the ability of “prolonged” cell cycle
arrest/quiescence to convert to senescence. Some researchers have demonstrated
depletion of mTOR pathway inhibitors, such as TSC2, can allow reactivation of the
mTOR pathway despite continued stress conditions. This reactivation initiates
conversion of prolonged quiescence into senescence.455 Perhaps a conversion to
replicative senescence is allowed after p53-mediated quiescence is induced in
response to telomere-uncapping DNA damage signaling, once PreA accumulation
occurs to a level at which it is able to adequately sequester and inhibit Pin1. Future
work should examine this relationship in the absence of exogenously expressed PreA,
in the context of DNA damage induction in young, proliferating cells, in highly passaged
cells, and in disease cells such as RD, HGPS, and WS (typical/ atypical). The diagram
in Figure 44 represents the mTOR signaling pathway and proposed regulatory effects of
PreA expression and sequestration of Pin1.
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Conclusions
Cellular senescence is considered to be a tumor-suppressive mechanism and to
contribute to cellular aging. Senescent cells exhibit multiple changes in gene
expression of cell cycle-regulatory and stress response genes as well as matrixremodeling proteins458, involving some combination of up-regulation of one or more of
the CKIs p16INK4a, p21Waf-1 and p27Kip1, down-regulation of cyclin E, down-regulation of
CDK4 and CDK2 activities, and hypophosphorylation of the RB protein [reviewed in459 ]. Our
data suggest that PreA complexes with Pin1 in a matter such that Pin1 is rendered
largely inactive. We hypothesize PreA-mediated Pin1 inhibition could have dramatic
effects on a broad range of cell cycle regulators, and thus, it could be a central
mechanism in determining lifespan and healthspan of organisms ranging from fruit flies,
to mice, to humans. High order changes in chromatin structure may be involved in the
generation of the senescence, considering the complexity of the phenotype. The
senescence induced prematurely in HGPS cells58 and the altered chromatin
organization460 could be related, at least in part, to the phenomenon of PreA
accumulation reported in HGPS cells. In fact, Pin1 has been reported to control the
ability of cells to condense and organize chromatin461 462, to control major channels of
transcription271,463,464, and to mediate protein translation, most likely due at least in part
to its control of the mTOR pathway261. Key factors in support of suggesting the PreAmediated Pin1 sequestration/inhibition would have major cell cycle and cell fatedecision impact include the Akt regulatory function of Pin1 and our observed
downregulation of Akt expression and activity levels. Modulation of FoxO-p27Kip1
expression and the mTOR pathway are among Akt-related mechanisms of cell cycle

214

and cell fate determination, and together with the direct effects of Pin1 on critical
regulators including pRB, p53, p300, Cyclin D, and Cyclin E, it is clear that control of
Pin1 function is a fundamental cell cycle and cell fate-controlling mechanism.
Successive passaging of cells expressing PreA result in its progressive accumulation to
levels that demonstrate cell cycle perturbation, and senescence ensues. Researchers
have previously demonstrated overexpression of PreA results in rapid progression to
senescence with telomeres that are shortened to critical levels that induce DNA damage
signaling43,66,69,71,99,121. A primary pathology of HGPS is early, or premature,
senescence (some researchers refer to “early” senescence as entry to senescence with
long telomeres that would appear capable of many further divisions, while “premature”
senescence refers to an accelerated progression toward the normal replicative limit of
cells). Examples of stimuli to enter early senescence would be OIS, ROS, or other
signaling factors that communicate high levels of stress or risk to the cell. On the other
hand, the normal process of aging and repeated cellular replication is the most common
example of entering senescence due to shortened telomeres. It has been
demonstrated that the rate of alternative splicing increases with aging, and potentially
as a result, progerin accumulation increases with age-related cell passaging75,92.
Furthermore, progerin has been shown to elicit recruitment of PreA expression 65,71,208,
and it is interesting to consider the potential role of exponential effects of Pin1-related
alternative splicing, progerin accumulation and further PreA accumulation, possibly
leading to acceleration of telomere erosion via effects of Pin1-sequestration on TRF1,
ultimately controlling the rate of the cell’s progression to its fate of replicative
senescence.
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The findings of this project suggest many interesting, and potentially highly
impactful, avenues of research that could be followed. Among the most interesting are
those involving the tantalizing clues to help us understand our own mortality.
Modulation of quiescence and senescence is critical to maintain genomic integrity, to
allow cells to grow, repair, and organize between cell cycles, or to navigate checkpoints
to assure fidelity of genomic replication, and to avoid the need for cells to undergo
apoptosis with each insult to its systems, or decide to initiate apoptosis when sacrifice of
the cell is beneficial to the organism. A PreA-specific role in organizing the interactions
between several important cell cycle regulatory pathways, including those we have
described, place a potentially tremendous importance on the PreA isoform in the
functions of LA as a master regulator of cellular proliferation, genomic integrity, lifespan,
disease, and aging.
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APPENDICES
Appendix 1 Full SABioscences RTqPCR Gene List/Results (Page 1 of 4)
Appendix A. Full SABiosciences RT-qPCR Gene List/Array Data
PCR Array Catalog:
Test Group:
Control Group:

PAMM-020 (Mouse Cell Cyle)

24 hr/500 nM Induced L647R PreA-expressing Rheoswitch 3T3 cells
Uninduced L647R (Not Induced "NI"DMSO-treated) Rheoswitch 3T3 cells

Fold Difference Cutoff:
p-value Cutoff:

2
0.05

Arrays included in Test Group:
Arrays included in Control Group:

L647R PLATE1, L647R PLATE2, L647R PLATE3
L647R NI-PLATE1, L647R NI-PLATE2, L647R NI-PLATE3

RT2
Catalog

Fold

Position Symbol Regulation Status p-value Unigene
OKAY
OKAY
A
OKAY
OKAY

A01
A02
A03
A04
A05

Abl1
Ak1
Apbb1
Atm
Brca1

1.324
7.917
40.928
4.033
19.360

A06
A07
A08

Brca2
Camk2a
Camk2b

14.107 OKAY
13.817 A
15.190 A

A09
A10

Casp3
Ccna1

4.537 OKAY
6.226 A

0.00706 Mm.34405
0.04367 Mm.4815

NM_009810
NM_007628

A11

Ccna2

4.464 OKAY

0.00007 Mm.4189

NM_009828

A12
B01
B02

Ccnb1
Ccnb2
Ccnc

1.989 OKAY
-2.097 OKAY
10.045 OKAY

0.00734 Mm.260114 NM_172301
0.03536 Mm.22592 NM_007630
0.00249 Mm.278584 NM_016746

B03
B04
B05
B06
B07
B08
B09

Ccnd1
Ccne1
Ccnf
Cdc25a
Cdk2
Cdk4
Cdk5rap1

5.836
18.443
1.106
1.083
2.107
37.315
8.990

0.00365
0.00277
0.32047
0.24310
0.00062
0.00103
0.00064

B10

Cdkn1a

6.313 OKAY

B11

Cdkn1b

23.237 OKAY

0.00010 Mm.2958

NM_009875

B12
C01

Cdkn2a
Chek1

-2.471 C
22.136 OKAY

0.00095 Mm.4733
0.00070 Mm.16753

NM_009877
NM_007691

OKAY
OKAY
OKAY
OKAY
OKAY
OKAY
OKAY

0.04650
0.00729
0.02435
0.00036
0.00109

Mm.1318
Mm.480325
Mm.38469
Mm.5088
Mm.244975

Refseq
NM_009594
NM_021515
NM_009685
NM_007499
NM_009764

0.00032 Mm.236256 NM_009765
0.00348 Mm.131530 NM_177407
0.00010 Mm.439733 NM_007595

Mm.273049
Mm.16110
Mm.77695
Mm.307103
Mm.111326
Mm.6839
Mm.289427

NM_007631
NM_007633
NM_007634
NM_007658
NM_016756
NM_009870
NM_025876

0.00194 Mm.195663 NM_007669

Gene Name
AI325092/Abl/E430008G22Rik/
MGC117749/c-Abl
Ak-1/B430205N08Rik
Fe65/Rir
AI256621/C030026E19Rik
AI256696/AW045498/Fancd1/R
AB163
CaMKII/R74975/mKIAA0968
Camk2d/MGC90738
A830040C14Rik/AC3/Apopain/CC3/CPP32/Caspas
e-3/Lice/Yama/mldy
MGC159139
AA408589/Ccn1/Ccn1/Ccna/CycA2/Cyca
Ccnb1-rs1/Ccnb1rs13/CycB1/Cycb-4/Cycb5/Cycb1rs1/MGC18763/MGC90915
CycB2
AI451004/AU020987/CG1C
AI327039/Cyl-1/PRAD1/bcl1/cD1
AW538188/CycE1
CycF/Fbxo1
D9Ertd393e
A630093N05Rik
Crk3
2310066P17Rik
CAP20/CDKI/CIP1/Cdkn1/P21/
SDI1/Waf1/mda6/p21Cip1/p21
WAF
AA408329/AI843786/Kip1/p27/
p27Kip1
ARF-INK4a/Arf/INK4aARF/Ink4a/Arf/MTS1/Pctr1/p16/
p16(INK4a)/p16INK4a/p19<AR
F>/p19ARF
C85740/Chk1/rad27

PPM03439B
PPM27482E
PPM28549A
PPM03454B
PPM03442A
PPM03704E
PPM31219A
PPM04592A

PPM02922E
PPM03258B
PPM02913C

PPM02894E
PPM03259E
PPM02905B
PPM02903E
PPM02891B
PPM03260B
PPM03246E
PPM02902E
PPM02911C
PPM37671E

PPM02901A
PPM02909B

PPM02906E
PPM03253A

Continued next page
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Fold
Position Symbol Regulation Status p-value Unigene

C02

Cks1b

1.638 OKAY

0.32036 Mm.3049

C03
C04

Ddit3
Dnajc2

4.579 OKAY
-1.564 OKAY

C05
C06
C07
C08
C09
C10
C11
C12
D01

Dst
E2f1
E2f2
E2f3
E2f4
Gadd45a
Gpr132
Hus1
Inha

25.369
6.357
3.494
2.825
9.613
-1.158
-1.916
3.754
7.021

D02

Itgb1

9.613 OKAY

0.00003 Mm.263396

D03

Macf1

9.770 OKAY

0.00121 Mm.402299

D04

Mad2l1

2.704 OKAY

0.00231 Mm.485053

D05

Mcm2

17.651 OKAY

0.00351 Mm.16711

D06

Mcm3

-1.264 OKAY

0.06021 Mm.4502

D07

Mcm4

1.380 OKAY

0.03367 Mm.1500

D08
D09
D10
D11
D12

Mdm2
Mki67
Mre11a
Msh2
Mtbp

2.097
1.279
6.269
-1.044
17.529

E01
E02

Myb
Nek2

-2.471 C
15.581 OKAY

0.00095 Mm.52109
0.00051 Mm.33773

E03
E04
E05
E06
E07

Nfatc1
Notch2
Npm2
Pcna
Pes1

5.534
10.691
16.545
-1.352
-1.191

0.00079
0.00009
0.00051
0.06326
0.03433

E08

Pkd1

E09
E10

Pmp22
Ppm1d

-1.838 OKAY
4.302 OKAY

0.01359 Mm.1237
0.00394 Mm.45609

E11

Ppp2r3a

20.464 A

0.00137 Mm.271249

E12
F01
F02

Ppp3ca
Prm1
Rad17

0.00076 Mm.110220
0.01399 Mm.266312

OKAY <0.00001 Mm.478284
OKAY 0.00158 Mm.18036
OKAY 0.23644 Mm.307932
OKAY 0.00083 Mm.268356
OKAY 0.00157 Mm.34554
OKAY 0.35949 Mm.72235
OKAY 0.00644 Mm.20455
OKAY 0.00366 Mm.42201
OKAY 0.00137 Mm.1100

OKAY
OKAY
OKAY
OKAY
OKAY

OKAY
OKAY
A
OKAY
OKAY

4.590 OKAY

2.838 OKAY
2.660 B
1.137 OKAY

0.00418
0.00944
0.00068
0.30323
0.00147

Mm.22670
Mm.4078
Mm.149071
Mm.4619
Mm.390829

Mm.329560
Mm.254017
Mm.347749
Mm.7141
Mm.28659

0.00007 Mm.290442

0.02059 Mm.331389
0.59979 Mm.42733
0.26549 Mm.248489

Refseq

Gene Name

2410005G18Rik/2610005D0
3Rik/AA407784/Cks1/sid133
NM_016904 4
CHOPNM_007837 10/CHOP10/chop/gadd153
NM_009584 AU020218/MIDA1/Zrf1/Zrf2
2310001O04Rik/A830042E1
9Rik/AW554249/BP230/BPA
G1n/Bpag/Bpag1/Macf2/ah/athet
oid/dt/mKIAA0728/nmf203/n
NM_134448 mf339
NM_007891 E2F-1/KIAA4009/mKIAA4009
NM_177733 9230110J10/E130207A07
NM_010093 E2F3b/E2f3a/mKIAA0075
NM_148952 2010111M04Rik/AI427446
NM_007836 AA545191/Ddit1/GADD45
NM_019925 G2a
NM_008316 mHus1
NM_010564 AW555078
4633401G24Rik/AA409975/A
A960159/CD29/ENSMUSG00
000051907/Fnrb/Gm9863/gpI
NM_010578 Ia
ABP620/Acf7/Aclp7/MACF/R7
NM_001199136
4989/mACF7/mKIAA0465
AA673185/MAD2/MGC11376
NM_019499 3
AA959861/AW476101/BM28/
NM_008564 CDCL1/Mcmd2/mKIAA0030
AL033361/C80350/Mcmd/P1/
NM_008563 p1.m
19G/AI325074/AU045576/Cd
c21/KIAA4003/Mcmd4/mKIAA
NM_008565 4003/mcdc21
1700007J15Rik/AA415488/M
NM_010786 dm-2
NM_001081117
D630048A14Rik/Ki-67/Ki67
NM_018736 Mre11/Mre11b
NM_008628 AI788990
NM_134092 AI429604/MDM2BP
AI550390/M16449/MGC1853
NM_010848 1/c-myb
NM_010892 AA617254/C77054
2210017P03Rik/AI449492/AV
076380/NFNM_016791 ATc/NFAT2/NFATc/Nfatcb
NM_010928 AI853703/N2
NM_181345 MGC123506/MGC123507
NM_011045 NM_022889 FLJ00285/MGC118471/PC1/
NM_013630 mFLJ00285
22kDa/GasNM_008885 3/HNPP/Tr/trembler
NM_016910 AV338790/Wip1
3222402P14Rik/A730042E0
NM_001161362
7/MGC29057
2900074D19Rik/AI841391/A
W413465/CN/Caln/Calna/Cn
NM_008913 A/MGC106804
NM_013637 Prm-1
NM_011233 9430035O09Rik/MmRad24

Continued next page
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RT2
Catalog
PPM03255B
PPM03736A
PPM36067E

PPM05185F
PPM02892E
PPM03463A
PPM03263B
PPM03464A
PPM02927B
PPM04846E
PPM03266B
PPM04412E

PPM03668B
PPM24961A
PPM03267A
PPM03268B
PPM03269E

PPM03270A
PPM02929B
PPM03457A
PPM03445B
PPM04993E
PPM05073B
PPM05270C
PPM28098A

PPM04560F
PPM05137B
PPM41992B
PPM03456E
PPM27335E
PPM37759E
PPM05053E
PPM04992A
PPM36321E

PPM05007B
PPM28989D
PPM03276E
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Fold
Regulation Status p-value
OKAY
OKAY
OKAY
OKAY
OKAY
OKAY

0.00060
0.53383
0.00248
0.00684
0.00075
0.01196

Unigene

Refseq

Gene Name

Mm.182628
Mm.471596
Mm.277629
Mm.297440
Mm.244671
Mm.235580

NM_009009
NM_011234
NM_011237
NM_009391
NM_011249
NM_011250

MGC150311/MGC150312/SCC
1/mKIAA0078
AV304093/Rad51a/Reca
Rad9a
AW547426/PRB1/p107
Rb2/p130

F03
F04
F05
F06
F07
F08

Rad21
Rad51
Rad9
Ran
Rbl1
Rbl2

2.381
-1.539
5.420
-1.894
11.458
2.517

F09
F10
F11

Sesn2
Sfn
Shc1

5.496 OKAY
25.252 A
5.959 OKAY

0.00070 Mm.23608
0.00053 Mm.44482
0.00036 Mm.86595

NM_144907 HI95/MGC11758/SEST2/Ses2
NM_018754 Er/Mme1/Ywhas
NM_011368 Shc/ShcA/p66/p66shc

F12
G01

Skp2
Slfn1

3.968 OKAY
1.851 B

0.00511 Mm.35584
0.38371 Mm.10948

NM_013787 68
NM_011407 AV316259

RT2
Catalog
PPM32537B
PPM03278B
PPM03279E
PPM05257E
PPM02898B
PPM02896B
PPM26463A
PPM03467A
PPM04024B

FBXL1/MGC102075/MGC1166

G02
G03

Smc1a
Stag1

19.540 OKAY
2.359 OKAY

0.00074 Mm.482095 NM_019710
0.00140 Mm.42135 NM_009282

G04

Sumo1

1.008 OKAY

0.89002 Mm.362118 NM_009460

G05
G06
G07

Taf10
Terf1
Tfdp1

2.540 OKAY
3.360 OKAY
2.806 OKAY

0.00455 Mm.285771 NM_020024
0.00019 Mm.4306
NM_009352
0.00137 Mm.925
NM_009361

G08
G09

Psmg2
Trp53

3.007 OKAY
2.806 OKAY

0.00115 Mm.150701 NM_134138
0.00060 Mm.222
NM_011640

G10
G11
G12

Trp63
Tsg101
Wee1

1.321 B
1.247 OKAY
24.905 OKAY

H01

Gusb

PPM02915B
PPM25636A

5830426I24Rik/KIAA0178/SMC1A/Sb1.8/Smc1/Smc1alpha/Sm
c1l1/Smcb/mKIAA0178
PPM26876A
AU045003/SA-1/Scc3
PPM28956E
GMP1/MGC103203/PIC1/SENT
RIN/SMT3/SMT3H3/SMTP3/SU
MO-1/Smt3C/Ubl1
PPM03281E
30kDa/AU041226/TAFII30/Taf2
h
PPM37466A
Pin2/Trbf1/Trf1
PPM04758A
Dp1/Drtf1
PPM03468E
1700017I17Rik/AW545363/Cla
st3/Tnfsf5ip1
PPM31670A
Tp53/bbl/bfy/bhy/p44/p53
PPM02931B
AI462811/Ket/MGC115972/P51

0.87605 Mm.20894 NM_011641 /P63/P63/P73l/Tp63/Trp53rp1
0.10884 Mm.241334 NM_021884 AI255943/CC2
0.00016 Mm.287173 NM_009516 Wee1A

PPM03458A
PPM34493F
PPM04998E

AI747421/Gur/Gus/Gus-r/Gus-

H02

Hprt

1.908 OKAY
-1.034 OKAY

H03

Hsp90ab1

1.034 OKAY

H04

Gapdh

17.570 OKAY

H05
H06
H07
H08
H09
H10
H11

Actb
MGDC
RTC
RTC
RTC
PPC
PPC

14.843
-2.471
-2.925
-3.099
-2.832
-2.618
-2.540

OKAY
C
OKAY
OKAY
OKAY
OKAY
OKAY

0.02722 Mm.3317

NM_010368 s/Gus-t/Gus-u/Gut/asd/g

C81579/HPGRT/Hprt1/MGC10
0.59453 Mm.299381 NM_013556 3149

PPM05490B
PPM03559E

90kDa/AL022974/C81438/Hsp8
4/Hsp840.55713 Mm.2180
NM_008302 1/Hsp90/Hspcb/MGC115780
PPM04803E
Gapd/MGC102544/MGC10254
6/MGC103190/MGC103191/M
0.00004 Mm.343110 NM_008084 GC105239
PPM02946E
Actx/E430023M04Rik/beta0.00183 Mm.328431 NM_007393 actin
PPM02945A
0.00095 N/A
SA_00106 MIGX1B
0.08167 N/A
SA_00104 RTC
0.08341 N/A
SA_00104 RTC
0.15561 N/A
SA_00104 RTC
0.00107 N/A
SA_00103 PPC
0.00068 N/A
SA_00103 PPC

Set as reference (“housekeeping”) gene
p-value >0.05, not considered as highly statistically relevant for the purposes of this
study.
Less than 2-fold expression change, not considered as highly statistically relevant
for the purposes of this study.
RT-qPCR assay specific controls, data are relatively meaningless on this
“expression fold change” scale, controls met comparison standards in relevant
statistical evaluations.
Continued next page
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Comments:
A: This gene’s average threshold cycle is relatively high (> 30) in either the control or the test sample, and
is reasonably low in the other sample (< 30).
These data mean that the gene’s expression is relatively low in one sample and reasonably detected in
the other sample suggesting that the actual fold-change value is at least as large as the calculated and
reported fold-change result.
This fold-change result may also have greater variations if p value > 0.05; therefore, it is important to
have a sufficient number of biological replicates to validate the result for this gene.
B: This gene’s average threshold cycle is relatively high (> 30), meaning that its relative expression level
is low, in both control and test samples, and the p-value for the fold-change is either unavailable or
relatively high (p > 0.05).
This fold-change result may also have greater variations; therefore, it is important to have a sufficient
number of biological replicates to validate the result for this gene.
C: This gene’s average threshold cycle is either not determined or greater than the defined cut-off value
(default 35), in both samples meaning that its expression was undetected, making this fold-change result
erroneous and un-interpretable.

Fold Change & Fold Regulation:
Fold-Change (2^(- Delta Delta Ct)) is the normalized gene expression (2^(- Delta Ct)) in the Test Sample
divided the normalized gene expression (2^(- Delta Ct)) in the Control Sample.
Fold-Regulation represents fold-change results in a biologically meaningful way. Fold-change values
greater than one indicate a positive- or an up-regulation, and the fold-regulation is equal to the foldchange.
Fold-change values less than one indicate a negative or down-regulation, and the fold-regulation is the
negative inverse of the fold-change.

p-value:
The p values are calculated based on a Student’s t-test of the replicate 2^(- Delta Ct) values for each
gene in the control group and treatment groups, and p values less than 0.05 are indicated in red.
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Appendix B. Volcano Plot of RT-qPCR Data (Corresponding to Genes in Appendix A)
L647R PreA Induced vs. Uninduced (Control)

Log 2 (Fold Change of L647R PreA Induced/ Uninduced (Control))
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Appendix C.
C. Supplemental
Supplemental Motif
Motif Analysis
Analysis Data
Data
Appendix
HPRD
Survey
of
Kinase
Substrate
Sites
in
Lamin
A
Peptide
Sequence
HPRD Survey of Kinase Substrate Sites in Lamin A Peptide Sequence

#

Position
in
Sequence in
Query
Query
Protein
Protein

1

2-4

ETP

2

2-5

ETPS

3

2-6

ETPSQ

4

4-6

PSQ

5

4-6

PSQ

6

4-9

PSQRRA

7

5-6

SQ

8

5-7

SQR

9

5-7

SQR

10

7 - 10

RRAT

11

7 - 10

RRAT

12

7 - 10

RRAT

13

7 - 10

RRAT

14

8 - 10

RAT

15

8 - 10

RAT

16

11 - 16

RSGAQA

17

17 - 19

SST

18

17 - 22

SSTPLS

19

18 - 20

STP

20

18 - 22

STPLS

21

18 - 22

STPLS

22

19 - 22

TPLS

23

19 - 22

TPLS

24

20 - 23

PLSP

25

20 - 23

PLSP

26

20 - 23

PLSP

27

20 - 25

PLSPTR

28

21 - 23

LSP

29

22 - 23

SP

30

22 - 24

SPT

31

22 - 25

SPTR

32

22 - 25

SPTR

33

22 - 25
22 - 26

SPTR
SPTRI

Corresponding Motif
Described in the Literature
(Phosphorylated Residues In Red)

X[pS/pT]P
[E/D]XX[pS/pT]
[E/D][pS/pT]XXX
XpSQ
P[pS/pT]X
X[pS/pT]XXX[A/P/S/T]
pSQ
[pS/pT]X[R/K]
[pS/pT]X[R/K]
RXX[pS/pT]
[R/K]XX[pS/pT]
[R/K][R/K]X[pS/pT]
[R/K][R/X]X[pS/pT]
[R/K]X[pS/pT]
[R/K]X[pS/pT]
X[pS/pT]XXX[A/P/S/T]
pSX[E/pS*/pT*]
X[pS/pT]XXX[A/P/S/T]
X[pS/pT]P
pSXXX[pS/pT]
pSXXXpS*
[pS/pT]XX[S/T]
[pS/pT]XX[E/D/pS*/pY*]
PXpSP
XXpSP
PX[pS/pT]P
PL[pS/pT]PX[R/K/H]
X[pS/pT]P
pSP
pSX[E/pS*/pT*]
[pS/pT]PX[R/K]
[pS/pT]PX[R/K]
[pS/pT]PX[R/K]
pSPX[R/K]X

34
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Features of Motif Described in the Literature
GSK-3, ERK1, ERK2, CDK5 substrate motif
Casein Kinase I substrate motif
b-Adrenergic Receptor kinase substrate motif
DNA dependent Protein kinase substrate motif
DNA dependent Protein kinase substrate motif
G protein-coupled receptor kinase 1 substrate motif
ATM kinase substrate motif
PKA kinase substrate motif
PKC kinase substrate motif
Calmodulin-dependent protein kinase II substrate motif
PKC kinase substrate motif
PKA kinase substrate motif
PAK2 kinase substrate motif
PKA kinase substrate motif
PKC kinase substrate motif
G protein-coupled receptor kinase 1 substrate motif
Casein Kinase II substrate motif
G protein-coupled receptor kinase 1 substrate motif
GSK-3, ERK1, ERK2, CDK5 substrate motif
MAPKAPK2 kinase substrate motif
GSK3 kinase substrate motif
Casein Kinase I substrate motif
Casein Kinase II substrate motif
GSK-3, ERK1, ERK2, CDK5 substrate motif
GSK-3, ERK1, ERK2, CDK5 substrate motif
ERK1, ERK2 Kinase substrate motif
CDK4 kinase substrate motif
GSK-3, ERK1, ERK2, CDK5 substrate motif
ERK1, ERK2 Kinase substrate motif
Casein Kinase II substrate motif
CDK1, 2, 4, 6 kinase substrate motif
Growth associated histone HI kinase substrate motif
Cdc2 kinase substrate motif
CDK kinase substrate motif

Appendix C (Continued)
Appendix C (Continued)

#

Position
in
Sequence in
Query
Query
Protein
Protein

35

23 - 25

PTR

36

24 - 27

TRIT

37

25 - 27

RIT

38

25 - 27

RIT

39

46 - 51

IDRVRS

40

46 - 51

41

46 - 52

42

46 - 53

43

48 - 51

44

48 - 51

45

48 - 51

46

48 - 51

47

51 - 53

48

51 - 54

49

51 - 54

50

52 - 55

51

53 - 57

52

61 - 70

53

62 - 64

54

62 - 64

55

62 - 65

56

64 - 67

57

64 - 67

58

64 - 67

59

65 - 69

60

66 - 68

61

68 - 71

62

70 - 75

63

70 - 75

64

70 - 75

VSREVS

65

70 - 77

VSREVSGI

66

71 - 73

SRE

Corresponding Motif
Described in the Literature

Features of Motif Described in the Literature

(Phosphorylated Residues in Red)

P[pS/pT]X
[pS/pT]XX[S/T]
[R/K]X[pS/pT]
[R/K]X[pS/pT]
[M/I/L/V]X[R/K]XX[pS/pT]

DNA dependent Protein kinase substrate motif
Casein Kinase I substrate motif
PKA kinase substrate motif
PKC kinase substrate motif
Chk1 kinase substrate motif

Calmodulin-dependent protein kinase IV substrate
motif
Calmodulin-dependent protein kinase II alpha
IDRVRSL[M/I/L/V/F/Y]XRXX[pS/pT][M/I/L/V/F/Y]
substrate motif
IDRVRS

[M/I/L/V/F/Y]XRXX[pS/pT]

[M/V/L/I/F]X[R/K]XX[pS/pT]XX Calmodulin-dependent protein kinase II substrate motif
Calmodulin-dependent protein kinase II substrate motif
RXXpS
RVRS
PKA kinase substrate motif
RXXpS
RVRS
Calmodulin-dependent protein kinase II substrate motif
RXX[pS/pT]
RVRS
PKC kinase substrate motif
[R/K]XX[pS/pT]
SLE
Casein Kinase II substrate motif
pSX[E/pS*/pT*]
SLET
Casein Kinase I substrate motif
[pS/pT]XX[S/T]
SLET
Casein Kinase II substrate motif
pSXX[E/pS*/pT*]
LETE
G protein-coupled receptor kinase 1 substrate motif
XX[pS/pT]E
ETENA
b-Adrenergic Receptor kinase substrate motif
[E/D][pS/pT]XXX
[M/V/L/I/F][R/K/H]XXX[pS/pT]XXX[M/V
LRITESEEVV
AMP-activated protein kinase substrate motif
/L/I/F]
RIT
PKA kinase substrate motif
[R/K]X[pS/pT]
RIT
PKC kinase substrate motif
[R/K]X[pS/pT]
RITE
G protein-coupled receptor kinase 1 substrate motif
XX[pS/pT]E
TESE
Casein Kinase II substrate motif
[pS/pT]XX[E/D]
TESE
Casein Kinase II substrate motif
[pS/pT]XX[E/D/pS*/pY*]
TESE
Casein Kinase II substrate motif
[pS/pT]XX[E/D]
ESEEV
b-Adrenergic Receptor kinase substrate motif
[E/D][pS/pT]XXX
SEE
Casein Kinase II substrate motif
pSX[E/pS*/pT*]
EVVS
Casein Kinase I substrate motif
[E/D]XX[pS/pT]
VSREVS
Chk1 kinase substrate motif
[M/I/L/V]X[R/K]XX[pS/pT]
VSREVS
G protein-coupled receptor kinase 1 substrate motif
X[pS/pT]XXX[A/P/S/T]
IDRVRSLE
RVRS

67

71 - 75

SREVS

68

71 - 75

SREVS

69

72 - 75

REVS

70

72 - 75

REVS

71

72 - 75

REVS

72

72 - 75

REVS

[M/I/L/V/F/Y]XRXX[pS/pT]

Calmodulin-dependent protein kinase IV substrate
motif

[M/V/L/I/F]X[R/K]XX[pS/pT]XX Calmodulin-dependent protein kinase II substrate motif
Casein Kinase II substrate motif
pSX[E/pS*/pT*]
MAPKAPK2 kinase substrate motif
pSXXX[pS/pT]
GSK3 kinase substrate motif
pSXXXpS*
Calmodulin-dependent protein kinase II substrate motif
RXXpS
PKA kinase substrate motif
RXXpS
Calmodulin-dependent protein kinase II substrate motif
RXX[pS/pT]
PKC kinase substrate motif
[R/K]XX[pS/pT]
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Position Sequence
in
in
Query
Query
Protein
Protein
73

72 - 75

REVS

74

89 - 91

RKT

75

89 - 91

RKT

76

90 - 94

KTLDS

77

91 - 94

TLDS

78

91 - 94

TLDS

79

93 - 97

DSVAK

80

117 - 121

KARNT

81

119 - 121

RNT

82

119 - 121

RNT

83

119 - 123

RNTKK

84

121 - 123

TKK

85

121 - 123

TKK

86

121 - 124

TKKE

87

121 - 124

TKKE

88

121 - 124

TKKE

89

142 - 147

NSKEAA

90

143 - 145

SKE

91

148 - 153

LSTALS

92

149 - 153

STALS

93

149 - 153

STALS

94

150 - 153

TALS

95

150 - 153

TALS

96

151 - 154

ALSE

97

153 - 155

SEK

98

153 - 155

SEK

99

153 - 158

SEKRTL

100

154 - 157

EKRT

101

155 - 157

KRT

102

155 - 157

KRT

103

196 - 199

RLQT

104

196 - 199

RLQT

105

196 - 201

RLQTMK

106

199 - 201

TMK

107

199 - 201

TMK

108

199 - 202

TMKE

109

199 - 202

TMKE

110

199 - 202

TMKE

111

208 - 212

KNIYS

112

210 - 213

IYSE

Corresponding Motif
Described in the Literature

Features of Motif Described in the Literature

(Phosphorylated Residues in Red)

R[K/E/R]XpS
[R/K]X[pS/pT]
[R/K]X[pS/pT]
KXXX[pS/pT]
[pS/pT]XX[S/T]
[pS/pT]XX[E/D/pS*/pY*]
[E/D][pS/pT]XXX
KXXX[pS/pT]
[R/K]X[pS/pT]
[R/K]X[pS/pT]
[R/K]X[pS/pT]X[R/K]
[pS/pT]X[R/K]
[pS/pT]X[R/K]
[pS/pT]XX[E/D]
[pS/pT]XX[E/D/pS*/pY*]
[pS/pT]XX[E/D]
X[pS/pT]XXX[A/P/S/T]
pSX[E/pS*/pT*]
X[pS/pT]XXX[A/P/S/T]
pSXXX[pS/pT]
pSXXXpS*
[pS/pT]XX[S/T]
[pS/pT]XX[E/D/pS*/pY*]
XX[pS/pT]E
[pS/pT]X[R/K]
[pS/pT]X[R/K]
[pS/pT]XXX[S/T][M/L/V/I/F]
[E/D]XX[pS/pT]
[R/K]X[pS/pT]
[R/K]X[pS/pT]
RXX[pS/pT]
[R/K]XX[pS/pT]
[R/K]XX[pS/pT]X[R/K]
[pS/pT]X[R/K]
[pS/pT]X[R/K]
[pS/pT]XX[E/D]
[pS/pT]XX[E/D/pS*/pY*]
[pS/pT]XX[E/D]
KXXX[pS/pT]
XX[pS/pT]E

270

PKC epsilon kinase substrate motif
PKA kinase substrate motif
PKC kinase substrate motif
PKA kinase substrate motif
Casein Kinase I substrate motif
Casein Kinase II substrate motif
b-Adrenergic Receptor kinase substrate motif
PKA kinase substrate motif
PKA kinase substrate motif
PKC kinase substrate motif
PKC kinase substrate motif
PKA kinase substrate motif
PKC kinase substrate motif
Casein Kinase II substrate motif
Casein Kinase II substrate motif
Casein Kinase II substrate motif
G protein-coupled receptor kinase 1 substrate motif
Casein Kinase II substrate motif
G protein-coupled receptor kinase 1 substrate motif
MAPKAPK2 kinase substrate motif
GSK3 kinase substrate motif
Casein Kinase I substrate motif
Casein Kinase II substrate motif
G protein-coupled receptor kinase 1 substrate motif
PKA kinase substrate motif
PKC kinase substrate motif
Casein Kinase I substrate motif
Casein Kinase I substrate motif
PKA kinase substrate motif
PKC kinase substrate motif
Calmodulin-dependent protein kinase II substrate motif
PKC kinase substrate motif
PKC kinase substrate motif
PKA kinase substrate motif
PKC kinase substrate motif
Casein Kinase II substrate motif
Casein Kinase II substrate motif
Casein Kinase II substrate motif
PKA kinase substrate motif
G protein-coupled receptor kinase 1 substrate motif
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Position Sequence
in
in
Query
Query
Protein
Protein
113

212 - 214

SEE

114

216 - 218

RET

115

216 - 218

RET

116

216 - 220

RETKR

117

217 - 221

ETKRR

118

218 - 220

TKR

119

218 - 220

TKR

120

221 - 224

RHET

121

221 - 224

122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141

145
146
147
148
149

Corresponding Motif
Described in the Literature

Features of Motif Described in the Literature

(Phosphorylated Residues in Red)

pSX[E/pS*/pT*]
[R/K]X[pS/pT]
[R/K]X[pS/pT]
[R/K]X[pS/pT]X[R/K]
[E/D][pS/pT]XXX
[pS/pT]X[R/K]
[pS/pT]X[R/K]

Casein Kinase II substrate motif
PKA kinase substrate motif
PKC kinase substrate motif
PKC kinase substrate motif
b-Adrenergic Receptor kinase substrate motif
PKA kinase substrate motif
PKC kinase substrate motif

RXX[pS/pT]

Calmodulin-dependent protein kinase II substrate motif

PKC kinase substrate motif
[R/K]XX[pS/pT]
223 - 227
ETRLV
b-Adrenergic Receptor kinase substrate motif
[E/D][pS/pT]XXX
236 - 239
EFES
Casein Kinase I substrate motif
[E/D]XX[pS/pT]
238 - 242
ESRLA
b-Adrenergic Receptor kinase substrate motif
[E/D][pS/pT]XXX
263 - 268
LEKTYS
Chk1 kinase substrate motif
[M/I/L/V]X[R/K]XX[pS/pT]
263 - 270 LEKTYSAK [M/V/L/I/F]X[R/K]XX[pS/pT]XX Calmodulin-dependent protein kinase II substrate motif
265 - 268
KTYS
PKA kinase substrate motif
KXX[pS/pT]
265 - 268
KTYS
PKC kinase substrate motif
[R/K]XX[pS/pT]
265 - 270 KTYSAK
PKC kinase substrate motif
[R/K]XX[pS/pT]X[R/K]
268 - 270
SAK
PKA kinase substrate motif
[pS/pT]X[R/K]
268 - 270
SAK
PKC kinase substrate motif
[pS/pT]X[R/K]
275 - 277
RQS
PKA kinase substrate motif
RXpS
275 - 277
RQS
PKA kinase substrate motif
[R/K]X[pS/pT]
275 - 277
RQS
PKC kinase substrate motif
[R/K]X[pS/pT]
277 - 279
SAE
Casein Kinase II substrate motif
pSX[E/pS*/pT*]
279 - 282
ERNS
Casein Kinase I substrate motif
[E/D]XX[pS/pT]
280 - 282
RNS
PKA kinase substrate motif
RXpS
280 - 282
RNS
PKA kinase substrate motif
[R/K]X[pS/pT]
280 - 282
RNS
PKC kinase substrate motif
[R/K]X[pS/pT]
296 - 301
RIRIDS
Akt kinase substrate motif
RXRXX[pS/pT]
296 - 301
RIRIDS
MAPKAPK1 kinase substrate motif
[R/K]XRXXpS
296 - 302 RIRIDSL
p70 Ribosomal S6 kinase substrate motif
[R/K]XRXX[pS/pT][M/L/V/I]
296 - 302 RIRIDSL
Akt kinase substrate motif
RXRXX[pS/pT][F/L]
298 - 301
RIDS
Calmodulin-dependent protein kinase II substrate motif
RXXpS
298 - 301
RIDS
PKA kinase substrate motif
RXXpS
298 - 301
RIDS
Calmodulin-dependent protein kinase II substrate motif
RXX[pS/pT]
298 - 301
RIDS
PKC kinase substrate motif
[R/K]XX[pS/pT]
300 - 303
DSLS
Casein Kinase I substrate motif
[E/D]XX[pS/pT]
300 - 304
DSLSA
b-Adrenergic Receptor kinase substrate motif
[E/D][pS/pT]XXX
301 - 303
SLS
Casein Kinase II substrate motif
pSX[E/pS*/pT*]
302 - 307
LSAQLS
G protein-coupled receptor kinase 1 substrate motif
X[pS/pT]XXX[A/P/S/T]
RHET
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Appendix C (Continued)
Appendix C (Continued)
Position
in
Query
Protein

Sequence
in
Query
Protein

150

303 - 307

SAQLS

151

303 - 307

SAQLS

152

306 - 308

LSQ

153

307 - 308

SQ

154

325 - 329

DSLAR

155

329 - 334

RERDTS

156

329 - 334

RERDTS

157

330 - 333

ERDT

158

330 - 337 ERDTSRRL

159

331 - 333

RDT

160

331 - 333

RDT

161

331 - 334

RDTS

162

331 - 334

RDTS

163

331 - 334

RDTS

164

331 - 334

RDTS

165

331 - 335

RDTSR

331 - 336

RDTSRR

332 - 336

DTSRR

169

333 - 335

TSR

#

333 - 335

TSR

170

388 - 390

RLS

171

388 - 390

RLS

172

388 - 390

RLS

173

388 - 391

RLSP

174

389 - 391

LSP

175

389 - 394

LSPSPT

176

390 - 391

SP

177

390 - 392

SPS

178

390 - 394

SPSPT

179

390 - 394

SPSPT

180

391 - 393

PSP

181

392 - 393

SP

182

392 - 395

SPTS

183

392 - 395

SPTS

184

392 - 395

SPTS

185

394 - 396

TSQ

186

395 - 396

SQ

187

395 - 397

SQR

188

395 - 397

SQR

189

397 - 402

RSRGRA

Corresponding Motif
Described in the Literature

Features of Motif Described in the Literature

(Phosphorylated Residues in Red)

pSXXX[pS/pT]
pSXXXpS*
XpSQ
pSQ
[E/D][pS/pT]XXX
RXRXX[pS/pT]
[R/K]XRXXpS
[E/D]XX[pS/pT]
XRXX[pS/pT]XRX
[R/K]X[pS/pT]
[R/K]X[pS/pT]
RXXpS
RXXpS
RXX[pS/pT]
[R/K]XX[pS/pT]
[R/K]X[pS/pT]X[R/K]
[R/K]XX[pS/pT]X[R/K]
[E/D][pS/pT]XXX
[pS/pT]X[R/K]
[pS/pT]X[R/K]
RXpS
[R/K]X[pS/pT]
[R/K]X[pS/pT]
XXpSP
X[pS/pT]P
X[pS/pT]XXX[A/P/S/T]
pSP
pSX[E/pS*/pT*]
pSXXX[pS/pT]
pSPXX[pS*/pT*]
P[pS/pT]X
pSP
[pS/pT]XX[S/T]
pSXX[E/pS*/pT*]
[pS/pT]XX[E/D/pS*/pY*]
XpSQ
pSQ
[pS/pT]X[R/K]
[pS/pT]X[R/K]
X[pS/pT]XXX[A/P/S/T]
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MAPKAPK2 kinase substrate motif
GSK3 kinase substrate motif
DNA dependent Protein kinase substrate motif
ATM kinase substrate motif
b-Adrenergic Receptor kinase substrate motif
Akt kinase substrate motif
MAPKAPK1 kinase substrate motif
Casein Kinase I substrate motif
PKC kinase substrate motif
PKA kinase substrate motif
PKC kinase substrate motif
Calmodulin-dependent protein kinase II substrate motif
PKA kinase substrate motif
Calmodulin-dependent protein kinase II substrate motif
PKC kinase substrate motif
PKC kinase substrate motif
PKC kinase substrate motif
b-Adrenergic Receptor kinase substrate motif
PKA kinase substrate motif
PKC kinase substrate motif
PKA kinase substrate motif
PKA kinase substrate motif
PKC kinase substrate motif
GSK-3, ERK1, ERK2, CDK5 substrate motif
GSK-3, ERK1, ERK2, CDK5 substrate motif
G protein-coupled receptor kinase 1 substrate motif
ERK1, ERK2 Kinase substrate motif
Casein Kinase II substrate motif
MAPKAPK2 kinase substrate motif
Casein Kinase I substrate motif
DNA dependent Protein kinase substrate motif
ERK1, ERK2 Kinase substrate motif
Casein Kinase I substrate motif
Casein Kinase II substrate motif
Casein Kinase II substrate motif
DNA dependent Protein kinase substrate motif
ATM kinase substrate motif
PKA kinase substrate motif
PKC kinase substrate motif
G protein-coupled receptor kinase 1 substrate motif

Appendix C (Continued)
Appendix C (Continued)
Position
in
Query
Protein

Sequence
in
Query
Protein

190

399 - 404

RGRASS

191

399 - 404

RGRASS

192

401 - 403

RAS

194

401 - 403

RAS

401 - 403

RAS

195

401 - 404

RASS

196

401 - 404

RASS

197

401 - 404

RASS

198

401 - 404

RASS

199

403 - 406

SSHS

200

403 - 406

SSHS

201

403 - 406

SSHS

202

403 - 407

SSHSS

203

403 - 407

SSHSS

204

404 - 406

SHS

205

406 - 408

SSQ

206

407 - 408

SQ

207

407 - 409

SQT

208

414 - 416

SVT

209

416 - 418

TKK

210

416 - 418

TKK

211

420 - 423

KLES

212

420 - 423

KLES

213

420 - 424

KLEST

215

422 - 426

ESTES

216

423 - 425

STE

217

423 - 426

STES

219

423 - 426

STES

423 - 426

STES

220

423 - 428

STESRS

221

425 - 428

ESRS

222

426 - 428

SRS

223

427 - 429

RSS

224

427 - 429

RSS

225

427 - 429

RSS

226

428 - 431

SSFS

227

428 - 431

SSFS

228

428 - 431

SSFS

229

429 - 431

SFS

230

430 - 432

FSQ

Corresponding Motif
Described in the Literature

Features of Motif Described in the Literature

(Phosphorylated Residues in Red)

RXRXX[pS/pT]
[R/K]XRXXpS
RXpS
[R/K]X[pS/pT]
[R/K]X[pS/pT]
RXXpS
RXXpS
RXX[pS/pT]
[R/K]XX[pS/pT]
[pS/pT]XX[S/T]
pSXX[E/pS*/pT*]
[pS/pT]XX[E/D/pS*/pY*]
pSXXX[pS/pT]
pSXXXpS*
pSX[E/pS*/pT*]
XpSQ
pSQ
pSX[E/pS*/pT*]
pSX[E/pS*/pT*]
[pS/pT]X[R/K]
[pS/pT]X[R/K]
KXX[pS/pT]
[R/K]XX[pS/pT]
KXXX[pS/pT]
[E/D][pS/pT]XXX
pSX[E/pS*/pT*]
[pS/pT]XX[S/T]
pSXX[E/pS*/pT*]
[pS/pT]XX[E/D/pS*/pY*]
X[pS/pT]XXX[A/P/S/T]
[E/D]XX[pS/pT]
pSX[E/pS*/pT*]
RXpS
[R/K]X[pS/pT]
[R/K]X[pS/pT]
[pS/pT]XX[S/T]
pSXX[E/pS*/pT*]
[pS/pT]XX[E/D/pS*/pY*]
pSX[E/pS*/pT*]
XpSQ
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Akt kinase substrate motif
MAPKAPK1 kinase substrate motif
PKA kinase substrate motif
PKA kinase substrate motif
PKC kinase substrate motif
Calmodulin-dependent protein kinase II substrate motif
PKA kinase substrate motif
Calmodulin-dependent protein kinase II substrate motif
PKC kinase substrate motif
Casein Kinase I substrate motif
Casein Kinase II substrate motif
Casein Kinase II substrate motif
MAPKAPK2 kinase substrate motif
GSK3 kinase substrate motif
Casein Kinase II substrate motif
DNA dependent Protein kinase substrate motif
ATM kinase substrate motif
Casein Kinase II substrate motif
Casein Kinase II substrate motif
PKA kinase substrate motif
PKC kinase substrate motif
PKA kinase substrate motif
PKC kinase substrate motif
PKA kinase substrate motif
b-Adrenergic Receptor kinase substrate motif
Casein Kinase II substrate motif
Casein Kinase I substrate motif
Casein Kinase II substrate motif
Casein Kinase II substrate motif
G protein-coupled receptor kinase 1 substrate motif
Casein Kinase I substrate motif
Casein Kinase II substrate motif
PKA kinase substrate motif
PKA kinase substrate motif
PKC kinase substrate motif
Casein Kinase I substrate motif
Casein Kinase II substrate motif
Casein Kinase II substrate motif
Casein Kinase II substrate motif
DNA dependent Protein kinase substrate motif

Appendix C (Continued)
Appendix C (Continued)
Position
in
Query
Protein

Sequence
in
Query
Protein

231

431 - 432

SQ

232

435 - 437

RTS

233

435 - 437

RTS

234

435 - 437

RTS

235

435 - 439

RTSGR

236

436 - 441

TSGRVA

237

437 - 439

SGR

238

437 - 439

SGR

239

453 - 458

RLRNKS

240

453 - 458

RLRNKS

241

455 - 458

RNKS

242

455 - 458

RNKS

244

455 - 458

RNKS

455 - 458

RNKS

245

457 - 463

KSNEDQS

246

458 - 460

SNE

247

458 - 461

SNED

248

458 - 461

SNED

249

458 - 461

SNED

250

458 - 461

SNED

251

460 - 463

EDQS

252

479 - 484

LTYRFP

253

480 - 482

TYR

254

480 - 482

TYR

255

486 - 488

KFT

256

486 - 488

KFT

257

486 - 490

KFTLK

258

488 - 490

TLK

259

488 - 490

TLK

260

495 - 500

VTIWAA

261

504 - 509

ATHSPP

262

505 - 508

THSP

263

506 - 508

HSP

264

507 - 508

SP

265

507 - 510

SPPT

266

507 - 510

SPPT

267

509 - 511

PTD

269

515 - 519

KAQNT

524 - 529

NSLRTA

525 - 527

SLR

270

Corresponding Motif
Described in the Literature

Features of Motif Described in the Literature

(Phosphorylated Residues in Red)

pSQ
RXpS
[R/K]X[pS/pT]
[R/K]X[pS/pT]
[R/K]X[pS/pT]X[R/K]
X[pS/pT]XXX[A/P/S/T]
[pS/pT]X[R/K]
[pS/pT]X[R/K]
RXRXX[pS/pT]
[R/K]XRXXpS
RXXpS
RXXpS
RXX[pS/pT]
[R/K]XX[pS/pT]
XpSXXDXX
pSX[E/pS*/pT*]
pSXX[E/D]
[pS/pT]XX[E/D]
[pS/pT]XX[E/D/pS*/pY*]
[pS/pT]XX[E/D]
[E/D]XX[pS/pT]
X[pS/pT]XXX[A/P/S/T]
[pS/pT]X[R/K]
[pS/pT]X[R/K]
[R/K]X[pS/pT]
[R/K]X[pS/pT]
[R/K]X[pS/pT]X[R/K]
[pS/pT]X[R/K]
[pS/pT]X[R/K]
X[pS/pT]XXX[A/P/S/T]
X[pS/pT]XXX[A/P/S/T]
XXpSP
X[pS/pT]P
pSP
[pS/pT]XX[S/T]
pSXX[E/pS*/pT*]
P[pS/pT]X
KXXX[pS/pT]
X[pS/pT]XXX[A/P/S/T]
[pS/pT]X[R/K]
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ATM kinase substrate motif
PKA kinase substrate motif
PKA kinase substrate motif
PKC kinase substrate motif
PKC kinase substrate motif
G protein-coupled receptor kinase 1 substrate motif
PKA kinase substrate motif
PKC kinase substrate motif
Akt kinase substrate motif
MAPKAPK1 kinase substrate motif
Calmodulin-dependent protein kinase II substrate motif
PKA kinase substrate motif
Calmodulin-dependent protein kinase II substrate motif
PKC kinase substrate motif
Pyruvate dehydrogenase kinase substrate motif
Casein Kinase II substrate motif
Casein kinase II substrate motif
Casein Kinase II substrate motif
Casein Kinase II substrate motif
Casein Kinase II substrate motif
Casein Kinase I substrate motif
G protein-coupled receptor kinase 1 substrate motif
PKA kinase substrate motif
PKC kinase substrate motif
PKA kinase substrate motif
PKC kinase substrate motif
PKC kinase substrate motif
PKA kinase substrate motif
PKC kinase substrate motif
G protein-coupled receptor kinase 1 substrate motif
G protein-coupled receptor kinase 1 substrate motif
GSK-3, ERK1, ERK2, CDK5 substrate motif
GSK-3, ERK1, ERK2, CDK5 substrate motif
ERK1, ERK2 Kinase substrate motif
Casein Kinase I substrate motif
Casein Kinase II substrate motif
DNA dependent Protein kinase substrate motif
PKA kinase substrate motif
G protein-coupled receptor kinase 1 substrate motif
PKA kinase substrate motif

Appendix C (Continued)
Appendix C (Continued)
Position
in
Query
Protein

Sequence
in
Query
Protein

271

525 - 527

SLR

272

525 - 528

SLRT

273

525 - 528

SLRT

274

526 - 528

LRT

275

533 - 536

STGE

276

533 - 536

STGE

277

533 - 536

STGE

278

533 - 536

STGE

279

533 - 536

STGE

280

542 - 546

KLVRS

281

543 - 548

LVRSVT

[pS/pT]X[R/K]
[pS/pT]XX[S/T]
pSXX[E/pS*/pT*]
LRpT
pSXX[E/D]
pSXX[E/pS*/pT*]
[pS/pT]XX[E/D]
[pS/pT]XX[E/D/pS*/pY*]
[pS/pT]XX[E/D]
KXXX[pS/pT]
[M/I/L/V]X[R/K]XX[pS/pT]

282

543 - 548

LVRSVT

[M/I/L/V/F/Y]XRXX[pS/pT]

283

543 - 549

284

543 - 550

285

545 - 548

286

545 - 548

287

546 - 548

288

548 - 551

289

548 - 551

290

548 - 551

291

567 - 572

292

568 - 571

294

568 - 571
568 - 571

295

568 - 572

296

568 - 572

297

571 - 573

298

571 - 577

299

572 - 575

300

572 - 575

301

572 - 575

302

572 - 575

303

582 - 585

304

582 - 585

305

583 - 585

306

589 - 594

307

596 - 599

308

597 - 599

Corresponding Motif
Described in the Literature

Features of Motif Described in the Literature

(Phosphorylated Residues in Red)

PKC kinase substrate motif
Casein Kinase I substrate motif
Casein Kinase II substrate motif
LKB1 Kinase substrate motif
Casein kinase II substrate motif
Casein Kinase II substrate motif
Casein Kinase II substrate motif
Casein Kinase II substrate motif
Casein Kinase II substrate motif
PKA kinase substrate motif
Chk1 kinase substrate motif
Calmodulin-dependent protein kinase IV substrate
motif

[M/I/L/V/F/Y]XRXX[pS/pT][M/I/L/V/F/ Calmodulin-dependent protein kinase II alpha
substrate motif
Y]
LVRSVTVV [M/V/L/I/F]X[R/K]XX[pS/pT]XX Calmodulin-dependent protein kinase II substrate motif
RSVT
Calmodulin-dependent protein kinase II substrate motif
RXX[pS/pT]
RSVT
PKC kinase substrate motif
[R/K]XX[pS/pT]
SVT
Casein Kinase II substrate motif
pSX[E/pS*/pT*]
TVVE
Casein Kinase II substrate motif
[pS/pT]XX[E/D]
TVVE
Casein Kinase II substrate motif
[pS/pT]XX[E/D/pS*/pY*]
TVVE
Casein Kinase II substrate motif
[pS/pT]XX[E/D]
GSHCSS
G protein-coupled receptor kinase 1 substrate motif
X[pS/pT]XXX[A/P/S/T]
SHCS
Casein Kinase I substrate motif
[pS/pT]XX[S/T]
SHCS
Casein Kinase II substrate motif
pSXX[E/pS*/pT*]
SHCS
Casein Kinase II substrate motif
[pS/pT]XX[E/D/pS*/pY*]
SHCSS
MAPKAPK2 kinase substrate motif
pSXXX[pS/pT]
SHCSS
GSK3 kinase substrate motif
pSXXXpS*
SSS
Casein Kinase II substrate motif
pSX[E/pS*/pT*]
SSSGDPA
Pyruvate dehydrogenase kinase substrate motif
XpSXXDXX
SSGD
Casein kinase II substrate motif
pSXX[E/D]
SSGD
Casein Kinase II substrate motif
[pS/pT]XX[E/D]
SSGD
Casein Kinase II substrate motif
[pS/pT]XX[E/D/pS*/pY*]
SSGD
Casein Kinase II substrate motif
[pS/pT]XX[E/D]
RSRT
Calmodulin-dependent protein kinase II substrate motif
RXX[pS/pT]
RSRT
PKC kinase substrate motif
[R/K]XX[pS/pT]
SRT
Casein Kinase II substrate motif
pSX[E/pS*/pT*]
GTCGQP
G protein-coupled receptor kinase 1 substrate motif
X[pS/pT]XXX[A/P/S/T]
DKAS
Casein Kinase I substrate motif
[E/D]XX[pS/pT]
KAS
PKA kinase substrate motif
[R/K]X[pS/pT]
LVRSVTV
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Appendix C (Continued)
Appendix C (Continued)
Position
in
Query
Protein

Sequence
in
Query
Protein

309

597 - 599

KAS

310

597 - 601

KASAS

311

598 - 603

ASASGS

312

599 - 601

SAS

313

599 - 603

SASGS

314

599 - 603

SASGS

315

611 - 616

ISSGSS

316

612 - 615

SSGS

317

612 - 615

SSGS

319

612 - 615

SSGS

612 - 616

SSGSS

320

612 - 616

SSGSS

321

613 - 615

SGS

322

615 - 620

SSASSV

323

616 - 618

SAS

324

616 - 619

SASS

325

616 - 619

SASS

326

616 - 619

SASS

327

618 - 623

SSVTVT

328

619 - 621

SVT

329

619 - 623

SVTVT

330

623 - 626

TRSY

331

625 - 627

SYR

332

625 - 627

SYR

333

625 - 628

SYRS

334

625 - 628

SYRS

335

627 - 632

RSVGGS

336

628 - 632

SVGGS

337

628 - 632

SVGGS

338

632 - 637

SGGGSF

339

635 - 641

GSFGDNL

340

636 - 639

SFGD

341

636 - 639

SFGD

342

636 - 639

SFGD

344

636 - 639

SFGD

643 - 646

TRSY

345

650 - 653

NSSP

346

650 - 655

NSSPRT

347

651 - 653

SSP

348

651 - 655

SSPRT

Corresponding Motif
Described in the Literature

Features of Motif Described in the Literature

(Phosphorylated Residues in Red)

[R/K]X[pS/pT]
KXXX[pS/pT]
X[pS/pT]XXX[A/P/S/T]
pSX[E/pS*/pT*]
pSXXX[pS/pT]
pSXXXpS*
X[pS/pT]XXX[A/P/S/T]
[pS/pT]XX[S/T]
pSXX[E/pS*/pT*]
[pS/pT]XX[E/D/pS*/pY*]
pSXXX[pS/pT]
pSXXXpS*
pSX[E/pS*/pT*]
[pS/pT]XXX[S/T][M/L/V/I/F]
pSX[E/pS*/pT*]
[pS/pT]XX[S/T]
pSXX[E/pS*/pT*]
[pS/pT]XX[E/D/pS*/pY*]
X[pS/pT]XXX[A/P/S/T]
pSX[E/pS*/pT*]
pSXXX[pS/pT]
[pS/pT]XX[E/D/pS*/pY*]
[pS/pT]X[R/K]
[pS/pT]X[R/K]
[pS/pT]XX[S/T]
pSXX[E/pS*/pT*]
X[pS/pT]XXX[A/P/S/T]
pSXXX[pS/pT]
pSXXXpS*
[pS/pT]XXX[S/T][M/L/V/I/F]
XpSXXDXX
pSXX[E/D]
[pS/pT]XX[E/D]
[pS/pT]XX[E/D/pS*/pY*]
[pS/pT]XX[E/D]
[pS/pT]XX[E/D/pS*/pY*]
XXpSP
X[pS/pT]XXX[A/P/S/T]
X[pS/pT]P
pSXXX[pS/pT]
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PKC kinase substrate motif
PKA kinase substrate motif
G protein-coupled receptor kinase 1 substrate motif
Casein Kinase II substrate motif
MAPKAPK2 kinase substrate motif
GSK3 kinase substrate motif
G protein-coupled receptor kinase 1 substrate motif
Casein Kinase I substrate motif
Casein Kinase II substrate motif
Casein Kinase II substrate motif
MAPKAPK2 kinase substrate motif
GSK3 kinase substrate motif
Casein Kinase II substrate motif
Casein Kinase I substrate motif
Casein Kinase II substrate motif
Casein Kinase I substrate motif
Casein Kinase II substrate motif
Casein Kinase II substrate motif
G protein-coupled receptor kinase 1 substrate motif
Casein Kinase II substrate motif
MAPKAPK2 kinase substrate motif
Casein Kinase II substrate motif
PKA kinase substrate motif
PKC kinase substrate motif
Casein Kinase I substrate motif
Casein Kinase II substrate motif
G protein-coupled receptor kinase 1 substrate motif
MAPKAPK2 kinase substrate motif
GSK3 kinase substrate motif
Casein Kinase I substrate motif
Pyruvate dehydrogenase kinase substrate motif
Casein kinase II substrate motif
Casein Kinase II substrate motif
Casein Kinase II substrate motif
Casein Kinase II substrate motif
Casein Kinase II substrate motif
GSK-3, ERK1, ERK2, CDK5 substrate motif
G protein-coupled receptor kinase 1 substrate motif
GSK-3, ERK1, ERK2, CDK5 substrate motif
MAPKAPK2 kinase substrate motif

Appendix C (Continued)
Appendix C (Continued)
Position
in
Query
Protein

Sequence
in
Query
Protein

349

652 - 653

SP

350

652 - 654

SPR

351

652 - 654

SPR

352

652 - 654

SPR

353

652 - 655

SPRT

354

652 - 655

SPRT

355

654 - 657

RTQS

356

654 - 657

RTQS

357

654 - 657

RTQS

358

654 - 657

RTQS

359

655 - 658

TQSP

360

656 - 658

QSP

361

657 - 658

SP

otif
Corresponding Motif
Described in the Literature

Features of Motif Described in the Literature

(Phosphorylated Residues in Red)

pSP
[pS/pT]P[R/K]
[pS/pT]X[R/K]
[pS/pT]X[R/K]
[pS/pT]XX[S/T]
pSXX[E/pS*/pT*]
RXXpS
RXXpS
RXX[pS/pT]
[R/K]XX[pS/pT]
XXpSP
X[pS/pT]P
pSP

ERK1, ERK2 Kinase substrate motif
Growth associated histone HI kinase substrate motif
PKA kinase substrate motif
PKC kinase substrate motif
Casein Kinase I substrate motif
Casein Kinase II substrate motif
Calmodulin-dependent protein kinase II substrate motif
PKA kinase substrate motif
Calmodulin-dependent protein kinase II substrate motif
PKC kinase substrate motif
GSK-3, ERK1, ERK2, CDK5 substrate motif
GSK-3, ERK1, ERK2, CDK5 substrate motif
ERK1, ERK2 Kinase substrate motif

Absent in mature LA; Absent in del50/Progerin (in addition to all sequence absent from LA,
except residues 657-661, which are absent from mature LA but present in del50/Progerin)
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Appendix D. Supplemental Motif Analysis Data: HPRD Survey of Kinase-Dependent Protein
Motif-Binding Sites in Lamin A Peptide Sequence

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39

Position in Sequence in
Corresponding Motif
Query
Query
Described in the Literature
Protein
Protein
(Phosphorylated Residues in
Red)
3-4
TP
[pS/pT]P
17 - 19
SST
S[pS/pT]X
17 - 19
SST
S[pS/pT]X
19 - 20
TP
[pS/pT]P
22 - 23
SP
[pS/pT]P
48 - 51
RVRS
RXXpS
72 - 75
REVS
RXXpS
149 - 151
STA
S[pS/pT]X
149 - 151
STA
S[pS/pT]X
298 - 301
RIDS
RXXpS
331 - 334
RDTS
RXXpS
390 - 391
SP
[pS/pT]P
392 - 393
SP
[pS/pT]P
401 - 404
RASS
RXXpS
403 - 405
SSH
S[pS/pT]X
403 - 405
SSH
S[pS/pT]X
406 - 408
SSQ
S[pS/pT]X
406 - 408
SSQ
S[pS/pT]X
423 - 425
STE
S[pS/pT]X
423 - 425
STE
S[pS/pT]X
428 - 430
SSF
S[pS/pT]X
428 - 430
SSF
S[pS/pT]X
455 - 458
RNKS
RXXpS
507 - 508
SP
[pS/pT]P
533 - 535
STG
S[pS/pT]X
533 - 535
STG
S[pS/pT]X
571 - 573
SSS
S[pS/pT]X
571 - 573
SSS
S[pS/pT]X
612 - 614
SSG
S[pS/pT]X
612 - 614
SSG
S[pS/pT]X
615 - 617
SSA
S[pS/pT]X
615 - 617
SSA
S[pS/pT]X
618 - 620
SSV
S[pS/pT]X
618 - 620
SSV
S[pS/pT]X
651 - 653
651 - 653
652 - 653
654 - 657
657 - 658

SSP
SSP
SP
RTQS
SP

S[pS/pT]X
S[pS/pT]X
[pS/pT]P
[pS/pT]P

Features of Motif Described in the
Literature

WW domain binding motif
MDC1 BRCT domain binding motif
Plk1 PBD domain binding motif
WW domain binding motif
WW domain binding motif
14-3-3 domain binding motif
14-3-3 domain binding motif
MDC1 BRCT domain binding motif
Plk1 PBD domain binding motif
14-3-3 domain binding motif
14-3-3 domain binding motif
WW domain binding motif
WW domain binding motif
14-3-3 domain binding motif
MDC1 BRCT domain binding motif
Plk1 PBD domain binding motif
MDC1 BRCT domain binding motif
Plk1 PBD domain binding motif
MDC1 BRCT domain binding motif
Plk1 PBD domain binding motif
MDC1 BRCT domain binding motif
Plk1 PBD domain binding motif
14-3-3 domain binding motif
WW domain binding motif
MDC1 BRCT domain binding motif
Plk1 PBD domain binding motif
MDC1 BRCT domain binding motif
Plk1 PBD domain binding motif
MDC1 BRCT domain binding motif
Plk1 PBD domain binding motif
MDC1 BRCT domain binding motif
Plk1 PBD domain binding motif
MDC1 BRCT domain binding motif
Plk1 PBD domain binding motif
MDC1 BRCT domain binding motif
Plk1 PBD domain binding motif
WW domain binding motif
14-3-3 domain binding motif
WW domain binding motif

Absent in mature LA; Absent in del50/Progerin (in addition to all sequence absent from LA,
except residues 657-661, which are absent from mature LA but present in del50/Progerin)

278

Appendix E. WW Domain-Containing Nuclear Proteins (HPRD)
1

Name : WW domain containing protein, 45KD

Molecule Function : Transcription regulator activity

Number of Interactions : 3

2

Name : NEDD4

Molecule Function : Ubiquitin-specific protease activity

Number of Interactions : 37

3

Name : Amyloid beta A4 precursor protein binding, Molecule Function : Receptor signaling complex scaffold
family B, member 1
activity

Number of Interactions : 16

4

Name : Amyloid beta (A4) precursor protein
binding family B member 3
Number of Interactions : 3

Molecule Function : Receptor signaling complex scaffold
activity

5

Name : Pin1

Molecule Function : Isomerase activity

Number of Interactions : 55
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6

Name : WW domain containing oxidoreductase

Molecule Function : Oxidoreductase activity

Number of Interactions : 7

7

Name : Polyglutamine binding protein 1

Molecule Function : Transcription regulator activity

Number of Interactions : 12

8

Name : Transcription elongation regulator 1

Molecule Function : Transcription factor activity

Number of Interactions : 25

9

Name : FNBP4

Molecule Function : Molecular function unknown

Number of Interactions : 6

10 Name : MAGI-3

Molecule Function : Molecular function unknown

Number of Interactions : 12
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11

Name : Smad ubiquitination regulatory factor 2

Molecule Function : Ubiquitin-specific protease activity

Number of Interactions : 66

12 Name : SMAD specific E3 ubiquitin protein ligase

Molecule Function : Ubiquitin-specific protease activity

1

Number of Interactions : 76

13 Name : DNA mismatch repair protein Mlh3

Molecule Function : Protein binding

Number of Interactions : 3

14 Name : Utrophin

Molecule Function : Cytoskeletal anchoring activity

Number of Interactions : 14

15 Name : WW domain containing protein 1

Molecule Function : Ubiquitin-specific protease activity

Number of Interactions : 20
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16 Name : PEPP2

Molecule Function : Receptor signaling complex scaffold
activity

Number of Interactions : 2

Name : DiGeorge syndrome critical region gene 8

Molecule Function : Molecular function unknown

17

Number of Interactions : 1
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